AP900419-0001 <DOCNO>
The <NA>
new <NA>
drug <NA>
was <NA>
developed <NA>
at <NA>
Scripps_Clinic_and_Research_Foundation <ORGANIZATION>
in <NA>
La_Jolla <LOCATION>
, <NA>
Calif. <LOCATION>
, <NA>
where <NA>
doctors <NA>
tested <NA>
it <NA>
on <NA>
patients <NA>
with <NA>
hairy <NA>
cell <NA>
leukemia. <NA>
The <NA>
Scripps <ORGANIZATION>
doctors <NA>
concluded <NA>
that <NA>
the <NA>
medicine, <NA>
called <NA>
2-chlorodeoxyadenosine, <NA>
or <NA>
2-CdA, <NA>
``may <NA>
well <NA>
be <NA>
the <NA>
drug <NA>
of <NA>
choice <NA>
in <NA>
the <NA>
treatment <NA>
of <NA>
hairy <NA>
cell <NA>
leukemia. <NA>
Lawrence <NA>
D. <NA>
Piro <NA>
and_published_in_the_<ORGANIZATION>New_England_Journal_of_Medicine </PERSON>
. <NA>
The <NA>
Scripps_Clinic <ORGANIZATION>
reached <NA>
an <NA>
agreement <NA>
recently <NA>
with <NA>
Johnson_&amp;_Johnson <ORGANIZATION>
's <NA>
Ortho_Pharmaceuticals <ORGANIZATION>
to <NA>
produce <NA>
the <NA>
drug, <NA>
which <NA>
is <NA>
not <NA>
yet <NA>
approved <NA>
for <NA>
routine <NA>
use. <NA>
AP900418-0106 <DOCNO>
The <NA>
latest <NA>
study, <NA>
published <NA>
in <NA>
Thursday <DATE>
's <NA>
New <NA>
England <NA>
Journal <NA>
of <NA>
Medicine, <NA>
was <NA>
directed <NA>
by <NA>
Lawrence <NA>
D. <NA>
Piro <NA>
of_the_<ORGANIZATION>Scripps_Clinic_and_Research_Foundation </PERSON>
in <NA>
La_Jolla <LOCATION>
, <NA>
Calif <LOCATION>
. <NA>
Scripps <NA>
recently <NA>
made <NA>
an <NA>
agreement <NA>
with <NA>
Johnson_&amp;_Johnson <ORGANIZATION>
's <NA>
Ortho_Pharmaceuticals <ORGANIZATION>
to <NA>
produce <NA>
and <NA>
distribute <NA>
the <NA>
drug <NA>
once <NA>
it's <NA>
approved <NA>
by <NA>
the <NA>
In <NA>
all, <NA>
the <NA>
Scripps <ORGANIZATION>
doctors <NA>
have <NA>
treated <NA>
24 <NA>
patients <NA>
with <NA>
almost <NA>
complete <NA>
success. <NA>
WSJ900419-0016 <DOCNO>
"There <NA>
aren't <NA>
many <NA>
{drugs} <NA>
where <NA>
you <NA>
can <NA>
administer <NA>
one <NA>
course <NA>
of <NA>
treatment <NA>
and <NA>
have <NA>
the <NA>
disease <NA>
go <NA>
away <NA>
and <NA>
stay <NA>
away <NA>
for <NA>
as <NA>
long <NA>
as <NA>
four <NA>
years," <NA>
says <NA>
Lawrence_Piro <PERSON>
, <NA>
chief <NA>
of <NA>
cancer <NA>
research <NA>
at <NA>
Scripps_Clinic_&amp;_Research_Foundation <ORGANIZATION>
, <NA>
La_Jolla <LOCATION>
, <NA>
Calif. <LOCATION>
, <NA>
where <NA>
the <NA>
drug <NA>
was <NA>
developed. <NA>
"It <NA>
is <NA>
without <NA>
doubt <NA>
the <NA>
most <NA>
effective <NA>
treatment <NA>
for <NA>
hairy-cell <NA>
leukemia, <NA>
in <NA>
terms <NA>
of <NA>
rapidity <NA>
of <NA>
response," <NA>
adds <NA>
Elihu_H._Estey <PERSON>
, <NA>
a <NA>
cancer <NA>
researcher <NA>
at <NA>
the <NA>
Anderson <NA>
Cancer <NA>
Center <NA>
,_<LOCATION>Houston </ORGANIZATION>
. <NA>
" <NA>
Hairy-cell <NA>
leukemia, <NA>
so-called <NA>
because <NA>
of <NA>
the <NA>
appearance <NA>
of <NA>
the <NA>
cancerous <NA>
cells <NA>
under <NA>
the <NA>
microscope, <NA>
affects <NA>
about <NA>
6,000 <NA>
people <NA>
in <NA>
the <NA>
U.S. <LOCATION>
, <NA>
with <NA>
600 <NA>
new <NA>
cases <NA>
a <NA>
year. <NA>
Since <NA>
then, <NA>
alpha <NA>
interferon, <NA>
a <NA>
drug <NA>
sold <NA>
by <NA>
Hoffmann-La_Roche_Inc. <ORGANIZATION>
and <NA>
Schering-Plough_Corp. <ORGANIZATION>
and <NA>
an <NA>
experimental <NA>
drug <NA>
called <NA>
deoxycoformycin <NA>
have <NA>
significantly <NA>
reduced <NA>
death <NA>
rates <NA>
from <NA>
hairy-cell <NA>
leukemia. <NA>
Hoffmann-La_Roche <PERSON>
is <NA>
the <NA>
U.S. <LOCATION>
subsidiary <NA>
of <NA>
Hoffmann-La <NA>
Roche <NA>
&amp; <NA>
Co. <NA>
of_<LOCATION>Switzerland </ORGANIZATION>
. <NA>
"With <NA>
the <NA>
lack <NA>
of <NA>
toxicity <NA>
and <NA>
the <NA>
ease <NA>
with <NA>
which <NA>
people <NA>
go <NA>
into <NA>
remission <NA>
{with <NA>
2-CdA}, <NA>
I <NA>
think <NA>
there's <NA>
something <NA>
really <NA>
going <NA>
on <NA>
here," <NA>
says <NA>
Ellin_Berman <PERSON>
, <NA>
a <NA>
staff <NA>
leukemia <NA>
doctor <NA>
at <NA>
Memorial_Sloan_Kettering_Cancer_Center <ORGANIZATION>
, <NA>
New_York <LOCATION>
. <NA>
Scripps <ORGANIZATION>
said <NA>
it <NA>
negotiated <NA>
an <NA>
agreement <NA>
with <NA>
a <NA>
subsidiary <NA>
of <NA>
Johnson_&amp;_Johnson <ORGANIZATION>
, <NA>
New_Brunswick <LOCATION>
, <NA>
N.J. <LOCATION>
, <NA>
to <NA>
produce <NA>
and <NA>
distribute <NA>
2-CdA <NA>
to <NA>
other <NA>
centers <NA>
for <NA>
broader <NA>
clinical <NA>
trials. <NA>
The <NA>
drug <NA>
was <NA>
first <NA>
made <NA>
about <NA>
10 <NA>
years <NA>
ago <NA>
at <NA>
Scripps <ORGANIZATION>
by <NA>
Dennis_A._Carson <PERSON>
, <NA>
who <NA>
studied <NA>
severe <NA>
combined <NA>
immunodeficiency <NA>
disease, <NA>
made <NA>
famous <NA>
a <NA>
few <NA>
years <NA>
ago <NA>
by <NA>
the <NA>
Texas <LOCATION>
boy <NA>
that <NA>
lived <NA>
in <NA>
a <NA>
bubble. <NA>
Since <NA>
cancer <NA>
patients <NA>
have <NA>
the <NA>
enzyme, <NA>
Scripps <ORGANIZATION>
scientists <NA>
developed <NA>
a <NA>
compound <NA>
that <NA>
mimics <NA>
deoxyadenosine, <NA>
but <NA>
tricks <NA>
the <NA>
enzyme <NA>
so <NA>
it <NA>
can't <NA>
be <NA>
processed. <NA>
About <NA>
50% <PERCENT>
to <NA>
60% <PERCENT>
of <NA>
patients <NA>
-- <NA>
most <NA>
of <NA>
whom <NA>
had <NA>
failed <NA>
other <NA>
treatments <NA>
-- <NA>
responded <NA>
to <NA>
the <NA>
drug, <NA>
some <NA>
with <NA>
complete <NA>
remission, <NA>
he <NA>
said. <NA>
Meanwhile, <NA>
researchers <NA>
at <NA>
University_of_California <ORGANIZATION>
at <NA>
San_Francisco <LOCATION>
are <NA>
testing <NA>
2-CdA <NA>
on <NA>
AIDS-related <NA>
lymphoma. <NA>
AP901211-0040 <DOCNO>
Paul_K._Mills <PERSON>
, <NA>
a <NA>
professor <NA>
at <NA>
Loma_Linda_University <ORGANIZATION>
and <NA>
the <NA>
principal <NA>
author <NA>
of <NA>
the <NA>
study, <NA>
said <NA>
research <NA>
suggests <NA>
that <NA>
even <NA>
former <NA>
smokers <NA>
are <NA>
at <NA>
high <NA>
risk. <NA>
``It's <NA>
very <NA>
discouraging,'' <NA>
Mills <PERSON>
said <NA>
Monday <DATE>
. <NA>
'' <NA>
The <NA>
study's <NA>
results <NA>
are <NA>
being <NA>
published <NA>
this <NA>
month <NA>
in <NA>
the <NA>
Journal <NA>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
. <NA>
The <NA>
study <NA>
is <NA>
part <NA>
of <NA>
the <NA>
Adventist_Health_Study <ORGANIZATION>
, <NA>
a <NA>
major <NA>
epidemiological <NA>
investigation <NA>
of <NA>
the <NA>
causes <NA>
of <NA>
various <NA>
cancers <NA>
among <NA>
California <LOCATION>
members <NA>
of <NA>
the <NA>
Seventh-day <NA>
Adventist_Church <ORGANIZATION>
. <NA>
The <NA>
disease <NA>
kills <NA>
18,000 <NA>
people <NA>
a <NA>
year <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
Clark <NA>
Heath <NA>
Jr. <NA>
of_the_<ORGANIZATION>American_Cancer_Society </PERSON>
said <NA>
the <NA>
causes <NA>
of <NA>
leukemia <NA>
are <NA>
largely <NA>
unknown. <NA>
But <NA>
several <NA>
studies <NA>
in <NA>
recent <NA>
years, <NA>
including <NA>
a <NA>
large <NA>
study <NA>
of <NA>
U.S. <LOCATION>
military <NA>
veterans, <NA>
have <NA>
suggested <NA>
smoking <NA>
as <NA>
a <NA>
cause, <NA>
he <NA>
said. <NA>
The <NA>
Loma_Linda <LOCATION>
study <NA>
estimates <NA>
that <NA>
about <NA>
20_percent <PERCENT>
of <NA>
leukemia <NA>
cases <NA>
were <NA>
linked <NA>
to <NA>
smoking. <NA>
WSJ880909-0170 <DOCNO>
Men <NA>
who <NA>
smoke <NA>
heavily <NA>
are <NA>
nearly <NA>
twice <NA>
as <NA>
likely <NA>
as <NA>
nonsmokers <NA>
to <NA>
die <NA>
from <NA>
a <NA>
common <NA>
form <NA>
of <NA>
leukemia, <NA>
concludes <NA>
a <NA>
report <NA>
by <NA>
the <NA>
University_of_Edinburgh <ORGANIZATION>
. <NA>
The <NA>
analysis, <NA>
based <NA>
on <NA>
a <NA>
previous <NA>
study <NA>
of <NA>
248,046 <NA>
U.S. <LOCATION>
veterans, <NA>
offers <NA>
the <NA>
firmest <NA>
link <NA>
yet <NA>
between <NA>
cigarette <NA>
consumption <NA>
and <NA>
the <NA>
disease. <NA>
The <NA>
report <NA>
in <NA>
tomorrow's <NA>
British <NA>
Medical <NA>
Journal <NA>
"may <NA>
well <NA>
have <NA>
an <NA>
emotional <NA>
impact <NA>
on <NA>
some <NA>
people <NA>
who <NA>
are <NA>
vacillating" <NA>
about <NA>
quitting <NA>
smoking <NA>
"and <NA>
for <NA>
one <NA>
reason <NA>
or <NA>
another <NA>
have <NA>
a <NA>
fear <NA>
of <NA>
leukemia," <NA>
suggested <NA>
Nicholas_Wald <PERSON>
, <NA>
an <NA>
epidemiologist <NA>
at <NA>
the <NA>
Medical_College_of_St._Bartholomew's_Hospital <ORGANIZATION>
here. <NA>
Wald <NA>
wrote_in_an_accompanying_commentary_on_the_analysis,_which_was_conducted_by_<ORGANIZATION>University_of_Edinburgh </PERSON>
epidemiologist <NA>
Leo_Kinlen <PERSON>
. <NA>
Kinlen <NA>
,_who_directs_the_university's_Cancer_Epidemiology_Unit,_examined_leukemia_deaths_from_a_<LOCATION>U.S. </PERSON>
study <NA>
that <NA>
had <NA>
tracked <NA>
veterans' <NA>
smoking <NA>
between <NA>
1954 <DATE>
and <NA>
1969 <DATE>
. <NA>
These <NA>
heavy <NA>
smokers <NA>
had <NA>
a <NA>
93% <PERCENT>
greater <NA>
chance <NA>
of <NA>
developing <NA>
fatal <NA>
leukemia <NA>
than <NA>
the <NA>
veterans <NA>
who <NA>
never <NA>
had <NA>
smoked. <NA>
For <NA>
those <NA>
smoking <NA>
between <NA>
10 <NA>
and <NA>
20 <NA>
cigarettes <NA>
a <NA>
day, <NA>
the <NA>
increased <NA>
risk <NA>
was <NA>
75% <PERCENT>
. <NA>
And <NA>
men <NA>
using <NA>
fewer <NA>
than <NA>
10 <NA>
cigarettes <NA>
daily <NA>
were <NA>
31% <PERCENT>
more <NA>
likely <NA>
to <NA>
die <NA>
from <NA>
leukemia <NA>
than <NA>
nonsmokers, <NA>
according <NA>
to <NA>
the <NA>
report. <NA>
But <NA>
leukemia <NA>
represents <NA>
the <NA>
third-leading <NA>
cause <NA>
of <NA>
death <NA>
in <NA>
U.S. <LOCATION>
children, <NA>
behind <NA>
accidents <NA>
and <NA>
birth <NA>
defects, <NA>
according <NA>
to <NA>
the <NA>
American_Cancer_Society <ORGANIZATION>
. <NA>
AP900111-0061 <DOCNO>
The <NA>
researchers, <NA>
based <NA>
at <NA>
the <NA>
University_of_Chicago <ORGANIZATION>
, <NA>
found <NA>
an <NA>
association <NA>
between <NA>
loss <NA>
of <NA>
the <NA>
genes <NA>
and <NA>
development <NA>
of <NA>
acute <NA>
lymphoblastic <NA>
leukemia, <NA>
the <NA>
most <NA>
common <NA>
form <NA>
of <NA>
childhood <NA>
leukemia. <NA>
They <NA>
tested <NA>
62 <NA>
patients <NA>
with <NA>
this <NA>
kind <NA>
of <NA>
leukemia <NA>
and <NA>
found <NA>
that <NA>
29_percent <PERCENT>
of <NA>
them <NA>
were <NA>
missing <NA>
the <NA>
interferon <NA>
genes. <NA>
Manuel <NA>
O. <NA>
Diaz <NA>
,_was_published_in_the_<ORGANIZATION>New_England_Journal_of_Medicine </PERSON>
. <NA>
AP880909-0135 <DOCNO>
The <NA>
death <NA>
rate <NA>
from <NA>
leukemia <NA>
was <NA>
nearly <NA>
60_percent <PERCENT>
higher <NA>
among <NA>
smokers <NA>
of <NA>
more <NA>
than <NA>
10 <NA>
cigarettes <NA>
a <NA>
day <NA>
than <NA>
among <NA>
non-smokers, <NA>
according <NA>
to <NA>
a <NA>
study <NA>
published <NA>
Friday <DATE>
. <NA>
While <NA>
no <NA>
direct <NA>
link <NA>
has <NA>
been <NA>
established <NA>
between <NA>
smoking <NA>
and <NA>
leukemia, <NA>
research <NA>
published <NA>
in <NA>
the <NA>
British <NA>
Medical <NA>
Journal <NA>
showed <NA>
that <NA>
the <NA>
leukemia <NA>
death <NA>
rate <NA>
among <NA>
people <NA>
who <NA>
smoked <NA>
fewer <NA>
than <NA>
10 <NA>
cigarettes <NA>
a <NA>
day <NA>
was <NA>
34_percent <PERCENT>
higher <NA>
than <NA>
among <NA>
non-smokers. <NA>
For <NA>
smokers <NA>
of <NA>
10 <NA>
to <NA>
20 <NA>
cigarettes <NA>
a <NA>
day <NA>
it <NA>
was <NA>
57_percent <PERCENT>
, <NA>
and <NA>
for <NA>
smokers <NA>
of <NA>
21 <NA>
or <NA>
more <NA>
cigarettes <NA>
63_percent <PERCENT>
, <NA>
the <NA>
study <NA>
showed. <NA>
Leo <NA>
Kinlen <NA>
,_director_of_the_<ORGANIZATION>Cancer_Epidemiology_Unit </PERSON>
at <NA>
the <NA>
University_of_Edinburgh <ORGANIZATION>
. <NA>
Kinlen <NA>
conducted <NA>
the <NA>
study <NA>
of <NA>
248,000 <NA>
U.S. <LOCATION>
military <NA>
veterans <NA>
with <NA>
Rogot <NA>
,_a_statistician_at_the_<ORGANIZATION>National_Heart </PERSON>
, <NA>
Lung <NA>
and <NA>
Blood_Institute_of_the_National_Institutes_of_Health <ORGANIZATION>
in <NA>
Bethesda <LOCATION>
, <NA>
Maryland <LOCATION>
. <NA>
'' <NA>
In <NA>
an <NA>
editorial <NA>
in <NA>
the <NA>
prestigious <NA>
weekly, <NA>
Professor <NA>
Nicholas_Wald <PERSON>
of <NA>
Bartholemew's <NA>
Hospital <NA>
in_<LOCATION>London </ORGANIZATION>
cautioned <NA>
that <NA>
no <NA>
cause-and-effect <NA>
relationship <NA>
had <NA>
been <NA>
established. <NA>
'' <NA>
It <NA>
should <NA>
therefore <NA>
be <NA>
added <NA>
to <NA>
the <NA>
World_Heath_Organization <ORGANIZATION>
's <NA>
list <NA>
of <NA>
tobacco-related <NA>
causes <NA>
of <NA>
death, <NA>
he <NA>
wrote. <NA>
The <NA>
study <NA>
was <NA>
conducted <NA>
on <NA>
data <NA>
collected <NA>
from <NA>
248,000 <NA>
veterans <NA>
between <NA>
1954 <DATE>
and <NA>
1969 <DATE>
, <NA>
the <NA>
researchers <NA>
wrote. <NA>
Thus <NA>
for <NA>
monocytic <NA>
and <NA>
myeloid <NA>
leukemias, <NA>
the <NA>
rate <NA>
among <NA>
smokers <NA>
of <NA>
more <NA>
than <NA>
20 <NA>
cigarettes <NA>
a <NA>
day <NA>
was <NA>
93_percent <PERCENT>
higher, <NA>
compared <NA>
with <NA>
48_percent <PERCENT>
for <NA>
lymphatic <NA>
leukemias. <NA>
For <NA>
smokers <NA>
of <NA>
10 <NA>
to <NA>
20 <NA>
cigarettes <NA>
a <NA>
day <NA>
the <NA>
rate <NA>
of <NA>
death <NA>
from <NA>
lymphatic <NA>
leukemia <NA>
was <NA>
76_percent <PERCENT>
higher, <NA>
and <NA>
for <NA>
one <NA>
to <NA>
10 <NA>
cigarettes, <NA>
40_percent <PERCENT>
higher. <NA>
The <NA>
death <NA>
rate <NA>
among <NA>
smokers <NA>
was <NA>
53_percent <PERCENT>
higher, <NA>
and <NA>
among <NA>
ex-smokers <NA>
39_percent <PERCENT>
. <NA>
LA121190-0080 <DOCNO>
Cigarette_smoking_appears_to_be_a_major_risk_factor_for_the_development_of_leukemia_and_may_be_responsible_for_more_than_1_in_5_cases_of_the_feared_blood_cancer,_according_to_a_study_by_<ORGANIZATION>Loma_Linda_University <P>
researchers. <NA>
<P>_The_results,_being_published_this_month_in_the_Journal_of_the_<ORGANIZATION>National_Cancer_Institute </P>
, <NA>
add <NA>
to <NA>
a <NA>
growing <NA>
list <NA>
of <NA>
cancers <NA>
that <NA>
have <NA>
been <NA>
linked <NA>
to <NA>
cigarette <NA>
smoking. <NA>
<P>_The_study_is_part_of_the_ongoing_<ORGANIZATION>Adventist_Health_Study </P>
, <NA>
a <NA>
major <NA>
epidemiological <NA>
investigation <NA>
of <NA>
the <NA>
causes <NA>
of <NA>
various <NA>
cancers <NA>
among <NA>
California <LOCATION>
residents. <NA>
<P>_The_results_are_"very_discouraging,"_said_<PERSON>Paul_K._Mills </P>
, <NA>
an <NA>
assistant <NA>
professor <NA>
of <NA>
preventive <NA>
medicine <NA>
at <NA>
Loma_Linda <LOCATION>
and <NA>
principal <NA>
author <NA>
of <NA>
the <NA>
study. <NA>
Clark <NA>
W. <NA>
Heath <NA>
Jr. <NA>
,_a_vice_president_of_the_<ORGANIZATION>American_Cancer_Society </PERSON>
, <NA>
wrote <NA>
in <NA>
an <NA>
editorial <NA>
published <NA>
in <NA>
the <NA>
medical <NA>
journal <NA>
along <NA>
with <NA>
the <NA>
study. <NA>
<P>_The_risk_of_developing_leukemia_was_also_increased_by_a_greater_number_of_cigarettes_smoked_daily_and_a_longer_duration_of_smoking,_which_<PERSON>Mills </P>
said <NA>
was <NA>
"important <NA>
evidence <NA>
of <NA>
a <NA>
causal <NA>
relationship. <NA>
Each <NA>
year, <NA>
there <NA>
are <NA>
about <NA>
27,000 <NA>
newly <NA>
diagnosed <NA>
cases <NA>
and <NA>
18,000 <NA>
deaths <NA>
attributed <NA>
to <NA>
leukemia <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
<P>_According_to_<LOCATION>Heath </P>
, <NA>
until <NA>
1986 <DATE>
it <NA>
was <NA>
generally <NA>
accepted <NA>
that <NA>
tobacco <NA>
use <NA>
was <NA>
not <NA>
a <NA>
significant <NA>
cause <NA>
of <NA>
leukemia. <NA>
Since <NA>
1988 <DATE>
, <NA>
several <NA>
studies, <NA>
including <NA>
a <NA>
large <NA>
study <NA>
of <NA>
U.S. <LOCATION>
military <NA>
veterans <NA>
and <NA>
two <NA>
American_Cancer_Society <ORGANIZATION>
studies, <NA>
had <NA>
provided <NA>
preliminary <NA>
evidence <NA>
of <NA>
a <NA>
link. <NA>
Those <NA>
that <NA>
have <NA>
been <NA>
identified, <NA>
such <NA>
as <NA>
the <NA>
chemical <NA>
benzene <NA>
and <NA>
ionizing <NA>
radiation, <NA>
appear <NA>
to <NA>
account <NA>
for <NA>
only <NA>
a <NA>
small <NA>
percentage <NA>
of <NA>
cases, <NA>
according <NA>
to <NA>
Heath <ORGANIZATION>
. <NA>
<P>_The_<LOCATION>Loma_Linda </P>
study <NA>
calculated <NA>
that <NA>
about <NA>
20% <PERCENT>
of <NA>
leukemia <NA>
cases <NA>
were <NA>
associated <NA>
with <NA>
prior <NA>
smoking. <NA>
<P>_On_the_basis_of_this_and_earlier_preliminary_studies,_<ORGANIZATION>Heath </P>
estimated <NA>
that <NA>
from <NA>
20% <PERCENT>
to <NA>
30% <PERCENT>
of <NA>
leukemia <NA>
cases <NA>
may <NA>
be <NA>
linked <NA>
to <NA>
smoking. <NA>
<P>_Because_cigarette_smoking_is_very_common_in_the_general_population_--_more_than_<PERCENT>25% </P>
of <NA>
adults <NA>
smoke <NA>
-- <NA>
the <NA>
proportion <NA>
of <NA>
total <NA>
leukemia <NA>
risk <NA>
that <NA>
may <NA>
be <NA>
attributed <NA>
to <NA>
cigarette <NA>
smoking <NA>
is <NA>
significant, <NA>
according <NA>
to <NA>
the <NA>
researchers. <NA>
<P>_In_a_related_finding,_the_<ORGANIZATION>Loma_Linda </P>
researchers <NA>
found <NA>
that <NA>
ex-smokers <NA>
among <NA>
the <NA>
Adventists <NA>
had <NA>
a <NA>
threefold <NA>
increased <NA>
risk <NA>
of <NA>
developing <NA>
myeloma, <NA>
another <NA>
bone-marrow <NA>
tumor, <NA>
as <NA>
compared <NA>
to <NA>
individuals <NA>
who <NA>
had <NA>
never <NA>
smoked. <NA>
<P>_The_<ORGANIZATION>Adventist_Health_Study </P>
began <NA>
in <NA>
1974 <DATE>
. <NA>
Participants <NA>
in <NA>
the <NA>
current <NA>
study <NA>
completed <NA>
a <NA>
questionnaire <NA>
about <NA>
their <NA>
lifestyle <NA>
in <NA>
1976 <DATE>
and <NA>
were <NA>
followed <NA>
for <NA>
the <NA>
development <NA>
of <NA>
new <NA>
cancers <NA>
through <NA>
the <NA>
end <NA>
of <NA>
1982 <DATE>
. <NA>
LA011590-0100 <DOCNO>
<P>_Researchers_from_the_<ORGANIZATION>University_of_Chicago </P>
found <NA>
an <NA>
association <NA>
between <NA>
loss <NA>
of <NA>
the <NA>
genes <NA>
and <NA>
development <NA>
of <NA>
acute <NA>
lymphoblastic <NA>
leukemia, <NA>
a <NA>
blood <NA>
cancer <NA>
that <NA>
is <NA>
the <NA>
most <NA>
common <NA>
form <NA>
of <NA>
childhood <NA>
leukemia. <NA>
<P>_They_tested_62_patients_with_this_kind_of_leukemia_and_found_that_<PERCENT>29% </P>
of <NA>
them <NA>
lacked <NA>
the <NA>
interferon <NA>
genes. <NA>
Manuel <NA>
O. <NA>
Diaz <NA>
,_was_published_in_the_<ORGANIZATION>New_England_Journal_of_Medicine </PERSON>
. <NA>
AP880524-0168 <DOCNO>
The <NA>
natural <NA>
protein <NA>
interferon, <NA>
combined <NA>
with <NA>
standard <NA>
chemotherapy <NA>
drugs, <NA>
shows <NA>
promise <NA>
in <NA>
controlling <NA>
multiple <NA>
myeloma, <NA>
a <NA>
lethal <NA>
form <NA>
of <NA>
bone <NA>
cancer, <NA>
researchers <NA>
said <NA>
Tuesday <DATE>
. <NA>
Martin <NA>
M. <NA>
Oken <NA>
of_the_<ORGANIZATION>University_of_Minnesota </PERSON>
. <NA>
In <NA>
the <NA>
latest <NA>
research, <NA>
presented <NA>
at <NA>
the <NA>
annual <NA>
meeting <NA>
of <NA>
the <NA>
American_Association_of_Clinical_Oncology <ORGANIZATION>
, <NA>
doctors <NA>
found <NA>
that <NA>
interferon <NA>
plus <NA>
chemotherapy <NA>
produced <NA>
complete <NA>
remissions <NA>
in <NA>
30_percent <PERCENT>
of <NA>
the <NA>
54 <NA>
patients <NA>
studied. <NA>
In <NA>
all, <NA>
41_percent <PERCENT>
of <NA>
the <NA>
patients <NA>
had <NA>
remissions <NA>
that <NA>
were <NA>
complete <NA>
or <NA>
nearly <NA>
complete. <NA>
In <NA>
an <NA>
earlier <NA>
study, <NA>
only <NA>
11_percent <PERCENT>
of <NA>
the <NA>
patients <NA>
reached <NA>
this <NA>
level <NA>
after <NA>
receiving <NA>
chemotherapy <NA>
alone. <NA>
In <NA>
another <NA>
study <NA>
presented <NA>
at <NA>
the <NA>
meeting, <NA>
doctors <NA>
from <NA>
the <NA>
University_of_North_Carolina <ORGANIZATION>
showed <NA>
promising <NA>
early <NA>
results <NA>
of <NA>
testing <NA>
interferon <NA>
against <NA>
chronic <NA>
myelogenous <NA>
leukemia. <NA>
James <NA>
Griffin <NA>
of_the_<ORGANIZATION>Dana-Farber_Cancer_Institute </PERSON>
in <NA>
Boston <LOCATION>
. <NA>
Howard <NA>
Ozer <NA>
and_his_colleagues_at_the_<ORGANIZATION>University_of_North_Carolina </PERSON>
found <NA>
they <NA>
could <NA>
reduce <NA>
the <NA>
outward <NA>
signs <NA>
of <NA>
myelogenous <NA>
leukemia <NA>
and <NA>
help <NA>
the <NA>
body <NA>
replace <NA>
defective <NA>
cells <NA>
with <NA>
normal <NA>
ones. <NA>
``For <NA>
the <NA>
first <NA>
time, <NA>
there <NA>
is <NA>
a <NA>
drug <NA>
available <NA>
that <NA>
potentially <NA>
keeps <NA>
the <NA>
abnormal <NA>
(cell) <NA>
clone <NA>
under <NA>
control <NA>
and <NA>
allows <NA>
the <NA>
normal <NA>
clone <NA>
to <NA>
come <NA>
back,'' <NA>
Ozer <PERSON>
said. <NA>
They <NA>
found <NA>
that <NA>
70_percent <PERCENT>
of <NA>
them <NA>
improved, <NA>
although <NA>
it <NA>
is <NA>
still <NA>
too <NA>
soon <NA>
to <NA>
know <NA>
how <NA>
the <NA>
treatment <NA>
affects <NA>
long-term <NA>
survival. <NA>
'' <NA>
Typically, <NA>
about <NA>
30_percent <PERCENT>
of <NA>
multiple <NA>
myeloma <NA>
patients <NA>
survive <NA>
for <NA>
five <NA>
years. <NA>
AP900104-0061 <DOCNO>
Researchers <NA>
found <NA>
that <NA>
among <NA>
women <NA>
treated <NA>
between <NA>
1960 <DATE>
and <NA>
1985 <DATE>
, <NA>
the <NA>
risk <NA>
of <NA>
leukemia <NA>
was <NA>
12 <NA>
times <NA>
higher <NA>
in <NA>
those <NA>
who <NA>
received <NA>
chemotherapy <NA>
rather <NA>
than <NA>
surgery <NA>
alone, <NA>
according <NA>
to <NA>
the <NA>
study <NA>
published <NA>
in <NA>
today's <NA>
New <NA>
England <NA>
Journal <NA>
of <NA>
Medicine. <NA>
John <NA>
M. <NA>
Kaldor <NA>
of_the_<ORGANIZATION>International_Agency_for_Research_on_Cancer </PERSON>
in <NA>
Lyon <LOCATION>
, <NA>
France <LOCATION>
, <NA>
was <NA>
based <NA>
on <NA>
114 <NA>
women <NA>
with <NA>
leukemia <NA>
who <NA>
were <NA>
among <NA>
99,113 <NA>
survivors <NA>
of <NA>
ovarian <NA>
cancer <NA>
in <NA>
seven <NA>
European <NA>
countries <NA>
and <NA>
Canada <LOCATION>
. <NA>
In <NA>
a <NA>
second <NA>
study, <NA>
the <NA>
same <NA>
researchers <NA>
found <NA>
that <NA>
the <NA>
risk <NA>
of <NA>
leukemia <NA>
is <NA>
also <NA>
substantially <NA>
increased <NA>
in <NA>
people <NA>
given <NA>
chemotherapy <NA>
for <NA>
Hodgkin <ORGANIZATION>
's <NA>
disease, <NA>
another <NA>
form <NA>
of <NA>
cancer. <NA>
But <NA>
since <NA>
Hodgkin <ORGANIZATION>
's <NA>
disease <NA>
is <NA>
often <NA>
curable <NA>
with <NA>
drugs, <NA>
the <NA>
benefits <NA>
of <NA>
treatment <NA>
clearly <NA>
outweigh <NA>
the <NA>
risks. <NA>
``The <NA>
risk <NA>
in <NA>
Hodgkin <LOCATION>
's <NA>
disease <NA>
is <NA>
well <NA>
worth <NA>
it, <NA>
because <NA>
the <NA>
treatment <NA>
does <NA>
extend <NA>
life. <NA>
Charles <NA>
A. <NA>
Coltman <NA>
Jr. <NA>
of_the_<ORGANIZATION>University_of_Texas_Health_Science_Center </PERSON>
at <NA>
San_Antonio <LOCATION>
. <NA>
``Management <NA>
of <NA>
ovarian <NA>
cancer <NA>
is <NA>
moving <NA>
ahead <NA>
very <NA>
rapidly,'' <NA>
said <NA>
Coltman <PERSON>
. <NA>
AP881122-0017 <DOCNO>
Alpha <NA>
interferon, <NA>
a <NA>
natural <NA>
disease <NA>
fighter <NA>
already <NA>
used <NA>
to <NA>
treat <NA>
leukemia, <NA>
can <NA>
now <NA>
be <NA>
used <NA>
to <NA>
battle <NA>
Kaposi <ORGANIZATION>
's <NA>
sarcoma, <NA>
a <NA>
cancer <NA>
that <NA>
primarily <NA>
attacks <NA>
AIDS <NA>
patients. <NA>
The <NA>
Food_and_Drug_Administration <ORGANIZATION>
announced <NA>
Monday <DATE>
that <NA>
alpha <NA>
interferon <NA>
was <NA>
shown <NA>
in <NA>
tests <NA>
to <NA>
be <NA>
effective <NA>
against <NA>
Kaposi's <ORGANIZATION>
and <NA>
now <NA>
is <NA>
approved <NA>
for <NA>
treatment <NA>
of <NA>
the <NA>
cancer <NA>
that <NA>
has <NA>
become <NA>
common <NA>
among <NA>
AIDS <NA>
victims. <NA>
Frank_E._Young <PERSON>
, <NA>
FDA <ORGANIZATION>
commissioner, <NA>
said <NA>
approval <NA>
of <NA>
the <NA>
man-made <NA>
alpha <NA>
interferon <NA>
``shows <NA>
biotechnology's <NA>
emerging <NA>
role <NA>
in <NA>
helping <NA>
modern <NA>
medicine <NA>
fight <NA>
some <NA>
of <NA>
the <NA>
most <NA>
serious <NA>
diseases <NA>
which <NA>
plague <NA>
mankind. <NA>
Alpha <NA>
interferon <NA>
was <NA>
used <NA>
experimentally <NA>
to <NA>
treat <NA>
Kaposi <ORGANIZATION>
's <NA>
in <NA>
a <NA>
number <NA>
of <NA>
studies, <NA>
including <NA>
some <NA>
conducted <NA>
at <NA>
the <NA>
National_Institute_of_Allergy_and_Infectious_Diseases <ORGANIZATION>
, <NA>
part <NA>
of <NA>
the <NA>
National_Institutes_of_Health <ORGANIZATION>
. <NA>
Anthony_S._Fauci <PERSON>
, <NA>
the <NA>
NIAID <ORGANIZATION>
director, <NA>
said <NA>
that <NA>
studies <NA>
by <NA>
Clifford <NA>
Lane <NA>
of_the_<ORGANIZATION>NIAID </PERSON>
``demonstrated <NA>
that <NA>
alpha <NA>
interferon <NA>
was <NA>
an <NA>
effective <NA>
anti-Kaposi's <NA>
sarcoma <NA>
agent'' <NA>
in <NA>
patients <NA>
who <NA>
were <NA>
in <NA>
the <NA>
early <NA>
stages <NA>
of <NA>
the <NA>
AIDS <NA>
infection. <NA>
According <NA>
to <NA>
the <NA>
FDA <ORGANIZATION>
, <NA>
several <NA>
human <NA>
studies <NA>
showed <NA>
that <NA>
high <NA>
doses <NA>
of <NA>
alpha <NA>
inteferon <NA>
would <NA>
reduce <NA>
Kaposi <ORGANIZATION>
's <NA>
tumors <NA>
in <NA>
40 <NA>
to <NA>
45_percent <PERCENT>
of <NA>
patients <NA>
who <NA>
were <NA>
in <NA>
early <NA>
stages <NA>
of <NA>
the <NA>
AIDS <NA>
infection. <NA>
Alpha <NA>
interferon <NA>
was <NA>
first <NA>
identified <NA>
in <NA>
1957 <DATE>
as <NA>
a <NA>
hormone-like <NA>
protein <NA>
that <NA>
is <NA>
a <NA>
natural <NA>
disease-fighting <NA>
component <NA>
of <NA>
the <NA>
blood. <NA>
In <NA>
the <NA>
early <NA>
1980s <DATE>
, <NA>
researchers <NA>
were <NA>
able <NA>
to <NA>
insert <NA>
the <NA>
gene <NA>
coded <NA>
for <NA>
alpha <NA>
interferon <NA>
into <NA>
a <NA>
bacteria <NA>
which <NA>
then <NA>
produces <NA>
the <NA>
protein <NA>
in <NA>
large <NA>
quantities. <NA>
The <NA>
FDA <ORGANIZATION>
said <NA>
that <NA>
alpha <NA>
interferon <NA>
is <NA>
marketed <NA>
by <NA>
Schering_Corp. <ORGANIZATION>
of <NA>
Kenilworth <LOCATION>
, <NA>
N.J. <LOCATION>
, <NA>
under <NA>
the <NA>
brand <NA>
name <NA>
Intron-A, <NA>
and <NA>
by <NA>
Hoffmann-La_Roche <PERSON>
of <NA>
Nutley <LOCATION>
, <NA>
N.J. <LOCATION>
under <NA>
the <NA>
brand <NA>
name <NA>
Roferon. <NA>
Both <NA>
products <NA>
were <NA>
first <NA>
approved <NA>
in <NA>
1986 <DATE>
for <NA>
the <NA>
treatment <NA>
of <NA>
hairy-cell <NA>
leukemia, <NA>
and <NA>
last_June <DATE>
for <NA>
the <NA>
treatment <NA>
of <NA>
genital <NA>
warts. <NA>
7 <NA>
,_AIDS_had_been_diagnosed_in_77,994_Americans,_of_whom_more_than_half,_or_43,888,_have_died_since_<DATE>June_1,_1981 </DATE>
, <NA>
according <NA>
to <NA>
the <NA>
government. <NA>
AP900523-0025 <DOCNO>
The <NA>
drug, <NA>
a <NA>
synthetic <NA>
form <NA>
of <NA>
vitamin <NA>
A <NA>
called <NA>
all-trans <NA>
retinoic <NA>
acid, <NA>
was <NA>
developed <NA>
in <NA>
China <LOCATION>
and <NA>
tested <NA>
in <NA>
France <LOCATION>
. <NA>
'' <NA>
Degos, <NA>
a <NA>
researcher <NA>
at <NA>
Hopital_Saint-Louis <ORGANIZATION>
in <NA>
Paris <LOCATION>
, <NA>
presented <NA>
evidence <NA>
that <NA>
this <NA>
indeed <NA>
is <NA>
possible <NA>
in <NA>
a <NA>
report <NA>
Tuesday <DATE>
at <NA>
the <NA>
annual <NA>
meeting <NA>
of <NA>
the <NA>
American_Society_of_Clinical_Oncology <ORGANIZATION>
. <NA>
He <NA>
tested <NA>
the <NA>
drug <NA>
on <NA>
victims <NA>
of <NA>
acute <NA>
promyelocytic <NA>
leukemia, <NA>
a <NA>
rare <NA>
blood <NA>
cancer <NA>
that <NA>
strikes <NA>
a <NA>
few <NA>
hundred <NA>
people <NA>
in <NA>
the <NA>
United_States <LOCATION>
each <NA>
year. <NA>
Charles <NA>
Schiffer <NA>
of_the_<ORGANIZATION>University_of_Maryland </PERSON>
. <NA>
'' <NA>
Dr. <NA>
Bruce_Chesen <PERSON>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
said <NA>
the <NA>
institute <NA>
plans <NA>
soon <NA>
to <NA>
sponsor <NA>
four <NA>
small <NA>
safety <NA>
studies <NA>
of <NA>
the <NA>
drug. <NA>
The <NA>
drug <NA>
was <NA>
developed <NA>
in <NA>
China <LOCATION>
by <NA>
Wang_Zeng_Yi <PERSON>
, <NA>
dean <NA>
of <NA>
Shanghai_University_II <ORGANIZATION>
, <NA>
a <NA>
French-speaking <NA>
medical <NA>
school. <NA>
It <NA>
is <NA>
now <NA>
being <NA>
produced <NA>
by <NA>
Hoffman_LaRoche <PERSON>
, <NA>
the <NA>
pharmaceutical <NA>
firm. <NA>
Steven <NA>
A. <NA>
Rosenberg <NA>
of_the_<ORGANIZATION>National_Cancer_Institute </PERSON>
outlined <NA>
the <NA>
first <NA>
results <NA>
of <NA>
his <NA>
pioneering <NA>
attempt <NA>
to <NA>
insert <NA>
foreign <NA>
genes <NA>
into <NA>
cancer <NA>
patients. <NA>
_A <NA>
survey <NA>
of <NA>
American <NA>
and <NA>
Caribbean <LOCATION>
blacks <NA>
in <NA>
central <NA>
Brooklyn <LOCATION>
showed <NA>
that <NA>
a <NA>
surprising <NA>
4_percent <PERCENT>
were <NA>
infected <NA>
with <NA>
cancer-causing <NA>
human <NA>
T-cell <NA>
leukemia <NA>
virus <NA>
Type <NA>
1, <NA>
or <NA>
HTLV-I. <NA>
Harvey <NA>
Dosik <NA>
of_<ORGANIZATION>Interfaith_Medical_Center </PERSON>
in <NA>
Brooklyn <LOCATION>
said <NA>
the <NA>
infection <NA>
rate <NA>
is <NA>
200 <NA>
times <NA>
higher <NA>
than <NA>
that <NA>
seen <NA>
nationwide <NA>
in <NA>
blood <NA>
donors. <NA>
Lode <NA>
J. <NA>
Swinnen <NA>
of_<ORGANIZATION>Loyola_University </PERSON>
in <NA>
Chicago <LOCATION>
said <NA>
he <NA>
had <NA>
found <NA>
evidence <NA>
that <NA>
OKT3, <NA>
an <NA>
antibody <NA>
treatment <NA>
widely <NA>
given <NA>
to <NA>
recipients <NA>
of <NA>
organ <NA>
transplants, <NA>
significantly <NA>
increases <NA>
their <NA>
risk <NA>
of <NA>
non-Hodgkins <NA>
lymphoma, <NA>
a <NA>
blood <NA>
cancer. <NA>
He <NA>
reviewed <NA>
154 <NA>
heart <NA>
transplant <NA>
patients <NA>
and <NA>
found <NA>
that <NA>
11_percent <PERCENT>
of <NA>
those <NA>
getting <NA>
OKT3 <NA>
since <NA>
1986 <DATE>
had <NA>
developed <NA>
the <NA>
disease. <NA>
AP880519-0175 <DOCNO>
Chen <NA>
,_who_published_his_study_in_<DATE>Friday </PERSON>
's <NA>
issue <NA>
of <NA>
the <NA>
journal <NA>
Science. <NA>
``The <NA>
chances <NA>
of <NA>
any <NA>
individual <NA>
being <NA>
infected <NA>
by <NA>
both <NA>
viruses <NA>
are <NA>
very <NA>
slim, <NA>
but <NA>
among <NA>
selected <NA>
populations, <NA>
such <NA>
as <NA>
intravenous <NA>
drug <NA>
abusers, <NA>
the <NA>
chances <NA>
are <NA>
quite <NA>
high,'' <NA>
said <NA>
Chen <PERSON>
, <NA>
of <NA>
the <NA>
University_of_California <ORGANIZATION>
, <NA>
Los_Angeles <LOCATION>
. <NA>
Except <NA>
among <NA>
IV <NA>
drug <NA>
abusers, <NA>
the <NA>
leukemia <NA>
virus <NA>
is <NA>
quite <NA>
rare <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
It <NA>
is <NA>
fairly <NA>
common <NA>
in <NA>
southern <NA>
Japan <LOCATION>
, <NA>
the <NA>
Caribbean <LOCATION>
and <NA>
parts <NA>
of <NA>
Africa <LOCATION>
, <NA>
Chen <PERSON>
said. <NA>
Stanley <NA>
H. <NA>
Weiss <NA>
,_chief_of_AIDS_epidemiology_at_<ORGANIZATION>New_Jersey_Medical_School </PERSON>
in <NA>
Newark <LOCATION>
. <NA>
Weiss <NA>
is <NA>
already <NA>
undertaking <NA>
such <NA>
research <NA>
in <NA>
the <NA>
Newark <LOCATION>
and <NA>
New_York <LOCATION>
area. <NA>
People <NA>
infected <NA>
by <NA>
HTLV-I <NA>
have <NA>
a <NA>
1_percent <PERCENT>
lifetime <NA>
chance <NA>
of <NA>
developing <NA>
a <NA>
blood <NA>
cancer <NA>
called <NA>
adult <NA>
T-cell <NA>
leukemia, <NA>
which <NA>
often <NA>
kills <NA>
quickly. <NA>
It <NA>
is <NA>
an <NA>
important <NA>
cause <NA>
of <NA>
leukemia <NA>
in <NA>
southern <NA>
Japan <LOCATION>
and <NA>
the <NA>
Caribbean <LOCATION>
. <NA>
Last <NA>
month, <NA>
the <NA>
American_Red_Cross <ORGANIZATION>
recommended <NA>
that <NA>
all <NA>
donated <NA>
blood <NA>
be <NA>
tested <NA>
for <NA>
HTLV-I <NA>
as <NA>
soon <NA>
as <NA>
scientists <NA>
develop <NA>
a <NA>
practical <NA>
test. <NA>
A <NA>
Red_Cross <ORGANIZATION>
study <NA>
found <NA>
about <NA>
one <NA>
out <NA>
of <NA>
every <NA>
4,286 <NA>
units <NA>
of <NA>
donated <NA>
blood <NA>
carries <NA>
HTLV-I. <NA>
A <NA>
study <NA>
performed <NA>
by <NA>
Weiss <PERSON>
when <NA>
he <NA>
worked <NA>
for <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
showed <NA>
HTLV-I <NA>
is <NA>
spreading <NA>
among <NA>
intravenous <NA>
drug <NA>
abusers, <NA>
with <NA>
infection <NA>
rates <NA>
of <NA>
12_percent <PERCENT>
among <NA>
New_Jersey <LOCATION>
addicts, <NA>
33_percent <PERCENT>
among <NA>
New_Orleans <LOCATION>
addicts <NA>
overall, <NA>
and <NA>
49_percent <PERCENT>
among <NA>
black <NA>
addicts <NA>
in <NA>
New_Orleans <LOCATION>
. <NA>
Infection <NA>
by <NA>
HTLV-I <NA>
apparently <NA>
activates <NA>
the <NA>
AIDS <NA>
virus <NA>
by <NA>
stimulating <NA>
AIDS-infected <NA>
white <NA>
blood <NA>
cells <NA>
to <NA>
divide, <NA>
according <NA>
to <NA>
the <NA>
study <NA>
Chen <NA>
performed <NA>
with <NA>
molecular <NA>
virologists <NA>
Jerome_Zack <PERSON>
, <NA>
Alan_Cann <PERSON>
and <NA>
James_Lugo <PERSON>
. <NA>
Dr. <NA>
Edward_L._Murphy_Jr. <PERSON>
, <NA>
a <NA>
National_Cancer_Institute <ORGANIZATION>
expert <NA>
on <NA>
HTLV-I, <NA>
agreed <NA>
with <NA>
Chen <NA>
that <NA>
the <NA>
problem <NA>
of <NA>
dual <NA>
infection <NA>
by <NA>
the <NA>
AIDS <NA>
and <NA>
leukemia <NA>
viruses <NA>
is <NA>
mainly <NA>
a <NA>
problem <NA>
for <NA>
U.S. <LOCATION>
drug <NA>
addicts <NA>
and <NA>
for <NA>
people <NA>
in <NA>
areas <NA>
such <NA>
as <NA>
the <NA>
Caribbean <LOCATION>
. <NA>
AP880414-0254 <DOCNO>
A <NA>
pharmaceutical <NA>
company <NA>
said <NA>
Thursday <DATE>
it <NA>
has <NA>
begun <NA>
selling <NA>
a <NA>
new <NA>
leukemia <NA>
drug, <NA>
the <NA>
fourth <NA>
new <NA>
cancer <NA>
agent <NA>
since <NA>
1983 <DATE>
and <NA>
the <NA>
third <NA>
leukemia <NA>
drug <NA>
in <NA>
10 <NA>
years <NA>
to <NA>
gain <NA>
federal <NA>
approval. <NA>
Novantrone <NA>
mitoxantrone <NA>
hydrochloride <NA>
is <NA>
to <NA>
be <NA>
used <NA>
in <NA>
combination <NA>
with <NA>
other <NA>
agents <NA>
for <NA>
treating <NA>
adults <NA>
with <NA>
acute <NA>
nonlymphocytic <NA>
leukemia, <NA>
Lederle_Laboratories <ORGANIZATION>
said <NA>
in <NA>
a <NA>
statement. <NA>
Novantrone <NA>
was <NA>
approved <NA>
by <NA>
the <NA>
Food_and_Drug_Administration <ORGANIZATION>
in <NA>
1987 <DATE>
, <NA>
but <NA>
the <NA>
agency's <NA>
official <NA>
rating <NA>
of <NA>
the <NA>
drug <NA>
indicates <NA>
it <NA>
represents <NA>
little <NA>
or <NA>
no <NA>
advantage <NA>
over <NA>
other <NA>
treatments. <NA>
The <NA>
other <NA>
three <NA>
new <NA>
cancer <NA>
drugs <NA>
approved <NA>
in <NA>
the <NA>
past <NA>
five <NA>
years <NA>
are <NA>
etoposide <NA>
for <NA>
testicular <NA>
cancer, <NA>
approved <NA>
in <NA>
1983 <DATE>
; <NA>
leuprolide <NA>
acetate <NA>
for <NA>
advanced <NA>
prostate <NA>
cancer, <NA>
1985 <DATE>
; <NA>
and <NA>
interferon, <NA>
approved <NA>
in <NA>
1986 <DATE>
to <NA>
fight <NA>
hairy <NA>
cell <NA>
leukemia, <NA>
said <NA>
John <NA>
Johnson <NA>
of_the_<ORGANIZATION>FDA </PERSON>
. <NA>
Lederle <ORGANIZATION>
is <NA>
a <NA>
division <NA>
of <NA>
American_Cyanamid_Co <ORGANIZATION>
. <NA>
AP900216-0033 <DOCNO>
``With <NA>
this <NA>
new <NA>
animal <NA>
model, <NA>
experimental <NA>
therapies <NA>
that <NA>
might <NA>
otherwise <NA>
be <NA>
tried <NA>
in <NA>
human <NA>
patients <NA>
can <NA>
now <NA>
be <NA>
tested <NA>
in <NA>
these <NA>
mice,'' <NA>
said <NA>
George_Daley <PERSON>
, <NA>
lead <NA>
researcher <NA>
in <NA>
the <NA>
study <NA>
conducted <NA>
at <NA>
the <NA>
Whitehead_Institute_for_Biomedical_Research <ORGANIZATION>
in <NA>
Cambridge <LOCATION>
, <NA>
Mass <LOCATION>
. <NA>
The <NA>
study, <NA>
published <NA>
today <DATE>
in <NA>
Science, <NA>
says <NA>
the <NA>
Whitehead <LOCATION>
researchers <NA>
used <NA>
intricate <NA>
genetic <NA>
engineering <NA>
to <NA>
inject <NA>
into <NA>
the <NA>
bone <NA>
marrow <NA>
of <NA>
laboratory <NA>
mice <NA>
the <NA>
human <NA>
gene <NA>
linked <NA>
to <NA>
chronic <NA>
myelogenous <NA>
leukemia <NA>
(CML), <NA>
a <NA>
form <NA>
of <NA>
a <NA>
blood <NA>
cancer <NA>
that <NA>
usually <NA>
attacks <NA>
adults <NA>
and <NA>
is <NA>
only <NA>
rarely <NA>
cured. <NA>
Daley <PERSON>
said <NA>
the <NA>
study <NA>
also <NA>
proves <NA>
CML <ORGANIZATION>
is <NA>
initiated <NA>
by <NA>
the <NA>
fusion <NA>
of <NA>
parts <NA>
from <NA>
two <NA>
broken <NA>
chromosomes, <NA>
a <NA>
finding <NA>
that <NA>
was <NA>
suggested <NA>
by <NA>
earlier <NA>
studies <NA>
in <NA>
other <NA>
laboratories. <NA>
Those <NA>
parts <NA>
have <NA>
been <NA>
identified <NA>
as <NA>
the <NA>
so-called <NA>
ABL <ORGANIZATION>
gene <NA>
from <NA>
chromosome <NA>
9 <NA>
and <NA>
a <NA>
gene <NA>
called <NA>
BCR <ORGANIZATION>
from <NA>
chromosome <NA>
22. <NA>
Daley <PERSON>
said <NA>
his <NA>
study <NA>
showed <NA>
that <NA>
transferring <NA>
the <NA>
BCR@ABL <NA>
gene <NA>
into <NA>
mouse <NA>
bone <NA>
marrow <NA>
and <NA>
then <NA>
putting <NA>
these <NA>
infected <NA>
cells <NA>
into <NA>
healthy <NA>
mice <NA>
could <NA>
produce <NA>
CML <ORGANIZATION>
in <NA>
those <NA>
mice. <NA>
``It <NA>
answers <NA>
a <NA>
question <NA>
of <NA>
basic <NA>
science, <NA>
that <NA>
is, <NA>
what <NA>
causes <NA>
the <NA>
disease,'' <NA>
said <NA>
Daley <PERSON>
. <NA>
George <NA>
Canellos <NA>
,_chief_of_medical_oncology_at_the_<ORGANIZATION>Dana-Farber_Institute </PERSON>
in <NA>
Boston <LOCATION>
, <NA>
said <NA>
the <NA>
Whitehead <LOCATION>
finding <NA>
is <NA>
``an <NA>
important <NA>
advance <NA>
in <NA>
understanding <NA>
the <NA>
disease. <NA>
``In <NA>
screening <NA>
biological <NA>
substances, <NA>
it <NA>
will <NA>
make <NA>
a <NA>
very <NA>
nice <NA>
model,'' <NA>
said <NA>
Canellos <PERSON>
. <NA>
Daley <PERSON>
said <NA>
the <NA>
mouse <NA>
can <NA>
be <NA>
used <NA>
to <NA>
test <NA>
``biological <NA>
inhibitors'' <NA>
that <NA>
would <NA>
prevent <NA>
the <NA>
P210 <NA>
protein <NA>
from <NA>
transforming <NA>
normal <NA>
cells <NA>
into <NA>
cancers. <NA>
To <NA>
create <NA>
the <NA>
mouse <NA>
model, <NA>
Daley <PERSON>
said <NA>
he <NA>
and <NA>
his <NA>
colleagues <NA>
inserted <NA>
the <NA>
human <NA>
BCR@ABL <NA>
gene <NA>
into <NA>
a <NA>
virus. <NA>
Daley <PERSON>
said <NA>
that <NA>
continued <NA>
studies <NA>
of <NA>
the <NA>
CML <ORGANIZATION>
mice <NA>
show <NA>
that <NA>
many <NA>
of <NA>
the <NA>
laboratory <NA>
animals <NA>
develop <NA>
the <NA>
``blast <NA>
crisis'' <NA>
phase <NA>
of <NA>
the <NA>
disease. <NA>
This, <NA>
he <NA>
said, <NA>
is <NA>
further <NA>
verification <NA>
that <NA>
the <NA>
course <NA>
of <NA>
the <NA>
disease <NA>
in <NA>
the <NA>
mice <NA>
mimics <NA>
CML <ORGANIZATION>
in <NA>
humans. <NA>
Van <NA>
Etten <NA>
and_<PERSON>David_Baltimore </PERSON>
, <NA>
both <NA>
of <NA>
the <NA>
Whitehead_Institute <ORGANIZATION>
, <NA>
were <NA>
coauthors <NA>
of <NA>
the <NA>
study <NA>
with <NA>
Daley <PERSON>
. <NA>
Science, <NA>
which <NA>
published <NA>
the <NA>
study, <NA>
is <NA>
the <NA>
journal <NA>
of <NA>
the <NA>
American_Association <ORGANIZATION>
for <NA>
the <NA>
Advancement_of_Science <ORGANIZATION>
. <NA>
AP891110-0134 <DOCNO>
Increases <NA>
in <NA>
leukemia <NA>
among <NA>
young <NA>
people <NA>
living <NA>
near <NA>
nuclear <NA>
plants <NA>
are <NA>
not <NA>
caused <NA>
by <NA>
exposure <NA>
to <NA>
radiation, <NA>
said <NA>
a <NA>
study <NA>
released <NA>
Friday <DATE>
. <NA>
Researchers <NA>
found <NA>
that <NA>
death <NA>
rates <NA>
from <NA>
leukemia <NA>
and <NA>
Hodgkin <ORGANIZATION>
's <NA>
disease <NA>
among <NA>
young <NA>
people <NA>
were <NA>
about <NA>
as <NA>
high <NA>
in <NA>
areas <NA>
that <NA>
were <NA>
only <NA>
considered <NA>
for <NA>
nuclear <NA>
plants <NA>
as <NA>
in <NA>
areas <NA>
that <NA>
actually <NA>
contained <NA>
nuclear <NA>
plants. <NA>
But <NA>
the <NA>
researchers <NA>
said <NA>
their <NA>
findings <NA>
indicate <NA>
an <NA>
increased <NA>
risk <NA>
of <NA>
leukemia <NA>
is <NA>
not <NA>
associated <NA>
with <NA>
exposure <NA>
to <NA>
radiation, <NA>
with <NA>
the <NA>
possible <NA>
exception <NA>
of <NA>
the <NA>
Sellafield <NA>
nuclear <NA>
reprocessing <NA>
plant <NA>
on <NA>
England <LOCATION>
's <NA>
northwest <NA>
coast. <NA>
The <NA>
Sellafield <ORGANIZATION>
plant <NA>
has <NA>
been <NA>
plagued <NA>
by <NA>
radioactive <NA>
leaks. <NA>
In <NA>
the <NA>
study <NA>
released <NA>
Friday <DATE>
, <NA>
researchers <NA>
from <NA>
the <NA>
Medical_Research_Council <ORGANIZATION>
and <NA>
the <NA>
Imperial_Cancer_Research_Fund <ORGANIZATION>
said <NA>
the <NA>
new <NA>
findings <NA>
suggest <NA>
that <NA>
areas <NA>
near <NA>
existing <NA>
and <NA>
potential <NA>
nuclear <NA>
sites <NA>
might <NA>
share <NA>
``unrecognized <NA>
risk <NA>
factors <NA>
other <NA>
than <NA>
environmental <NA>
radiation <NA>
pollution. <NA>
'' <NA>
Dr. <NA>
Sarah_Darby <PERSON>
of <NA>
the <NA>
Imperial_Cancer_Research_Fund <ORGANIZATION>
said <NA>
the <NA>
findings <NA>
point <NA>
to <NA>
something <NA>
possibly <NA>
``in <NA>
the <NA>
lifestyle <NA>
of <NA>
the <NA>
young <NA>
but <NA>
at <NA>
the <NA>
present <NA>
time <NA>
we <NA>
don't <NA>
have <NA>
a <NA>
great <NA>
deal <NA>
of <NA>
handle <NA>
on <NA>
it. <NA>
'' <NA>
The <NA>
researchers <NA>
investigated <NA>
death <NA>
statistics <NA>
in <NA>
400 <NA>
districts <NA>
of <NA>
England <LOCATION>
and <NA>
Wales <LOCATION>
near <NA>
existing <NA>
or <NA>
potential <NA>
nuclear <NA>
sites. <NA>
``Excess <NA>
mortality <NA>
due <NA>
to <NA>
leukemia <NA>
and <NA>
Hodgkin <ORGANIZATION>
's <NA>
disease <NA>
in <NA>
young <NA>
people <NA>
who <NA>
lived <NA>
near <NA>
potential <NA>
sites <NA>
was <NA>
similar <NA>
to <NA>
that <NA>
in <NA>
young <NA>
people <NA>
who <NA>
lived <NA>
near <NA>
existing <NA>
sites,'' <NA>
researchers <NA>
wrote. <NA>
Darby <NA>
said:_``There_was_a_<PERCENT>16_percent </PERSON>
increase <NA>
in <NA>
childhood <NA>
leukemia <NA>
mortality <NA>
in <NA>
areas <NA>
near <NA>
nuclear <NA>
installations <NA>
compared <NA>
with <NA>
the <NA>
rest <NA>
of <NA>
the <NA>
country <NA>
after <NA>
adjusting <NA>
for <NA>
factors <NA>
such <NA>
as <NA>
urban-rural <NA>
status. <NA>
When <NA>
the <NA>
same <NA>
analysis <NA>
was <NA>
carried <NA>
out <NA>
for <NA>
areas <NA>
near <NA>
potential <NA>
installations, <NA>
there <NA>
was <NA>
a <NA>
14_percent <PERCENT>
increase. <NA>
'' <NA>
Mel_Greaves <PERSON>
of <NA>
the <NA>
Leukemia_Research_Fund <ORGANIZATION>
, <NA>
who <NA>
originated <NA>
the <NA>
theory, <NA>
``has <NA>
biological <NA>
reasons <NA>
for <NA>
thinking <NA>
that <NA>
is <NA>
the <NA>
case,'' <NA>
she <NA>
said. <NA>
AP900215-0120 <DOCNO>
In <NA>
a <NA>
report <NA>
to <NA>
be <NA>
published <NA>
Friday <DATE>
in <NA>
the <NA>
magazine <NA>
Science, <NA>
researchers <NA>
at <NA>
the <NA>
Whitehead_Institute_for_Biomedical_Research <ORGANIZATION>
said <NA>
they <NA>
have <NA>
discovered <NA>
a <NA>
way <NA>
to <NA>
give <NA>
chronic <NA>
myelogenous <NA>
leukemia, <NA>
CML <ORGANIZATION>
, <NA>
to <NA>
laboratory <NA>
mice. <NA>
CML <ORGANIZATION>
is <NA>
a <NA>
form <NA>
of <NA>
leukemia <NA>
that <NA>
usually <NA>
attacks <NA>
adults <NA>
and <NA>
is <NA>
only <NA>
rarely <NA>
cured. <NA>
``With <NA>
this <NA>
new <NA>
animal <NA>
model, <NA>
experimental <NA>
therapies <NA>
that <NA>
might <NA>
otherwise <NA>
be <NA>
tried <NA>
in <NA>
human <NA>
patients <NA>
can <NA>
now <NA>
be <NA>
tested <NA>
in <NA>
these <NA>
mice,'' <NA>
said <NA>
George_Daley <PERSON>
, <NA>
lead <NA>
researcher <NA>
in <NA>
the <NA>
study <NA>
at <NA>
Whitehead <LOCATION>
. <NA>
'' <NA>
Daley <PERSON>
said <NA>
the <NA>
study <NA>
also <NA>
proves <NA>
that <NA>
CML <ORGANIZATION>
is <NA>
initiated <NA>
by <NA>
the <NA>
fusion <NA>
of <NA>
parts <NA>
from <NA>
two <NA>
broken <NA>
chromosomes, <NA>
a <NA>
finding <NA>
that <NA>
had <NA>
been <NA>
suggested <NA>
by <NA>
earlier <NA>
studies <NA>
in <NA>
other <NA>
laboratories. <NA>
Those <NA>
parts <NA>
have <NA>
been <NA>
identified <NA>
as <NA>
the <NA>
so-called <NA>
ABL <ORGANIZATION>
gene <NA>
from <NA>
chromosome <NA>
9 <NA>
and <NA>
a <NA>
gene <NA>
called <NA>
BCR <ORGANIZATION>
from <NA>
chromosome <NA>
22. <NA>
Daley <PERSON>
said <NA>
his <NA>
study <NA>
showed <NA>
that <NA>
transferring <NA>
the <NA>
BCR@ABL <NA>
gene <NA>
into <NA>
mouse <NA>
bone <NA>
marrow <NA>
and <NA>
then <NA>
putting <NA>
these <NA>
infected <NA>
cells <NA>
into <NA>
healthy <NA>
mice <NA>
could <NA>
produce <NA>
CML <ORGANIZATION>
in <NA>
those <NA>
mice. <NA>
``It <NA>
answers <NA>
a <NA>
question <NA>
of <NA>
basic <NA>
science, <NA>
that <NA>
is, <NA>
what <NA>
causes <NA>
the <NA>
disease,'' <NA>
said <NA>
Daley <PERSON>
. <NA>
George <NA>
Canellos <NA>
,_chief_of_medical_oncology_at_the_<ORGANIZATION>Dana-Farber_Institute </PERSON>
in <NA>
Boston <LOCATION>
, <NA>
described <NA>
the <NA>
Whitehead <LOCATION>
finding <NA>
as <NA>
``an <NA>
important <NA>
advance <NA>
in <NA>
understanding <NA>
the <NA>
disease. <NA>
Daley <PERSON>
said <NA>
that <NA>
the <NA>
mouse <NA>
can <NA>
be <NA>
used <NA>
to <NA>
test <NA>
``biological <NA>
inhibitors'' <NA>
that <NA>
would <NA>
prevent <NA>
the <NA>
P210 <NA>
protein <NA>
from <NA>
transforming <NA>
normal <NA>
cells <NA>
into <NA>
cancers. <NA>
To <NA>
create <NA>
the <NA>
mouse <NA>
model, <NA>
Daley <PERSON>
said <NA>
he <NA>
and <NA>
his <NA>
collegues <NA>
inserted <NA>
the <NA>
human <NA>
BCR@ABL <NA>
gene <NA>
into <NA>
a <NA>
virus. <NA>
Daley <PERSON>
said <NA>
that <NA>
continued <NA>
studies <NA>
of <NA>
the <NA>
CML <ORGANIZATION>
mice <NA>
shows <NA>
that <NA>
many <NA>
of <NA>
the <NA>
laboratory <NA>
animals <NA>
develop <NA>
the <NA>
``blast <NA>
crisis'' <NA>
phase <NA>
of <NA>
the <NA>
disease. <NA>
This, <NA>
he <NA>
said, <NA>
is <NA>
further <NA>
verification <NA>
that <NA>
the <NA>
course <NA>
of <NA>
the <NA>
disease <NA>
in <NA>
the <NA>
mice <NA>
is <NA>
similar <NA>
to <NA>
CML <ORGANIZATION>
in <NA>
humans. <NA>
Co-authors <NA>
of <NA>
the <NA>
study <NA>
with <NA>
Daley <PERSON>
were <NA>
Van <NA>
Etten <NA>
and_<PERSON>David_Baltimore </PERSON>
, <NA>
both <NA>
of <NA>
the <NA>
Whitehead_Institute <ORGANIZATION>
. <NA>
Science, <NA>
which <NA>
published <NA>
the <NA>
study, <NA>
is <NA>
the <NA>
journal <NA>
of <NA>
the <NA>
American_Association <ORGANIZATION>
for <NA>
the <NA>
Advancement_of_Science <ORGANIZATION>
. <NA>
WSJ880128-0006 <DOCNO>
Researchers <NA>
in <NA>
New_York_City <LOCATION>
reported <NA>
evidence <NA>
that <NA>
some <NA>
hospital <NA>
patients <NA>
who <NA>
had <NA>
received <NA>
multiple <NA>
blood <NA>
transfusions <NA>
had <NA>
been <NA>
infected <NA>
with <NA>
the <NA>
virus. <NA>
This <NA>
follows <NA>
other, <NA>
tentative <NA>
reports <NA>
in <NA>
recent <NA>
months <NA>
hinting <NA>
that <NA>
1% <PERCENT>
to <NA>
4% <PERCENT>
of <NA>
blood <NA>
donors <NA>
in <NA>
some <NA>
localities <NA>
and <NA>
as <NA>
many <NA>
as <NA>
9% <PERCENT>
of <NA>
drug <NA>
addicts <NA>
tested <NA>
in <NA>
New_York_City <LOCATION>
may <NA>
be <NA>
infected <NA>
with <NA>
the <NA>
virus. <NA>
Such <NA>
reports <NA>
prompted <NA>
the <NA>
American_Red_Cross <ORGANIZATION>
last <NA>
November <DATE>
to <NA>
urge <NA>
rapid <NA>
development <NA>
and <NA>
federal <NA>
approval <NA>
of <NA>
a <NA>
definitive <NA>
test <NA>
that <NA>
could <NA>
be <NA>
used <NA>
to <NA>
screen <NA>
blood <NA>
donors <NA>
for <NA>
evidence <NA>
of <NA>
infection <NA>
by <NA>
the <NA>
cancer <NA>
virus. <NA>
The <NA>
virus <NA>
is <NA>
known <NA>
to <NA>
cause <NA>
a <NA>
rare <NA>
but <NA>
rapidly <NA>
fatal <NA>
type <NA>
of <NA>
leukemia <NA>
that, <NA>
until <NA>
now, <NA>
has <NA>
been <NA>
confined <NA>
largely <NA>
to <NA>
southern <NA>
Japan <LOCATION>
, <NA>
and <NA>
certain <NA>
areas <NA>
in <NA>
Africa <LOCATION>
and <NA>
the <NA>
Caribbean <LOCATION>
. <NA>
It <NA>
also <NA>
has <NA>
been <NA>
linked <NA>
to <NA>
a <NA>
multiple <NA>
sclerosis <NA>
-- <NA>
like <NA>
nerve <NA>
ailment, <NA>
called <NA>
tropical <NA>
spastic <NA>
paraparesis, <NA>
occurring <NA>
in <NA>
children <NA>
in <NA>
the <NA>
Caribbean <LOCATION>
. <NA>
Although <NA>
only <NA>
1% <PERCENT>
of <NA>
people <NA>
infected <NA>
with <NA>
the <NA>
virus <NA>
develop <NA>
leukemia, <NA>
the <NA>
blood <NA>
cancer <NA>
doesn't <NA>
occur <NA>
until <NA>
many <NA>
years, <NA>
perhaps <NA>
decades, <NA>
after <NA>
the <NA>
initial <NA>
infection. <NA>
The <NA>
newest <NA>
evidence <NA>
of <NA>
the <NA>
virus's <NA>
presence <NA>
in <NA>
the <NA>
blood <NA>
supply <NA>
was <NA>
reported <NA>
in <NA>
the <NA>
New <NA>
England <NA>
Journal <NA>
of <NA>
Medicine <NA>
by <NA>
a <NA>
research <NA>
team <NA>
at <NA>
Memorial_Sloan-Kettering_Cancer_Center <ORGANIZATION>
in <NA>
New_York <LOCATION>
. <NA>
Last <NA>
fall, <NA>
the <NA>
Red_Cross <ORGANIZATION>
said <NA>
it <NA>
had <NA>
completed <NA>
preliminary <NA>
screening <NA>
of <NA>
blood <NA>
from <NA>
40,000 <NA>
healthy <NA>
donors <NA>
and <NA>
found <NA>
10 <NA>
who <NA>
might <NA>
be <NA>
positive <NA>
for <NA>
HTLV-1 <NA>
exposure. <NA>
Studies <NA>
in <NA>
Japan <LOCATION>
have <NA>
confirmed <NA>
that <NA>
HTLV-1 <NA>
can <NA>
be <NA>
transmitted <NA>
by <NA>
blood <NA>
transfusions, <NA>
but <NA>
so <NA>
far <NA>
there <NA>
aren't <NA>
any <NA>
known <NA>
cases <NA>
of <NA>
T-cell <NA>
leukemia <NA>
developing <NA>
in <NA>
people <NA>
so <NA>
infected. <NA>
The <NA>
New_York <LOCATION>
scientists <NA>
noted, <NA>
however, <NA>
that <NA>
patients <NA>
such <NA>
as <NA>
theirs, <NA>
who <NA>
receive <NA>
multiple <NA>
transfusions, <NA>
can <NA>
serve <NA>
as <NA>
a <NA>
"sensitive <NA>
indicator" <NA>
of <NA>
the <NA>
virus's <NA>
presence <NA>
in <NA>
the <NA>
blood <NA>
supply. <NA>
AP900802-0028 <DOCNO>
A <NA>
study <NA>
in <NA>
the <NA>
New_England_Journal_of_Medicine <ORGANIZATION>
indicates <NA>
that <NA>
shots <NA>
of <NA>
a <NA>
synthetic <NA>
form <NA>
of <NA>
the <NA>
natural <NA>
protein <NA>
interferon <NA>
can <NA>
prevent <NA>
the <NA>
virus <NA>
from <NA>
destroying <NA>
the <NA>
liver <NA>
in <NA>
nearly <NA>
half <NA>
the <NA>
people <NA>
chronically <NA>
infected. <NA>
One <NA>
in <NA>
10 <NA>
victims <NA>
can <NA>
be <NA>
cured, <NA>
while <NA>
the <NA>
drug <NA>
had <NA>
no <NA>
benefits <NA>
for <NA>
60_percent <PERCENT>
of <NA>
the <NA>
169 <NA>
people <NA>
studied <NA>
in <NA>
clinical <NA>
trials, <NA>
researchers <NA>
said. <NA>
Hepatitis <NA>
B <NA>
is <NA>
the <NA>
chief <NA>
underlying <NA>
cause <NA>
of <NA>
liver <NA>
cancer <NA>
and <NA>
cirrhosis <NA>
and <NA>
the <NA>
world's <NA>
ninth-leading <NA>
cause <NA>
of <NA>
death, <NA>
just <NA>
behind <NA>
lung <NA>
disease <NA>
and <NA>
well <NA>
ahead <NA>
of <NA>
AIDS, <NA>
according <NA>
to <NA>
the <NA>
World_Health_Organization <ORGANIZATION>
. <NA>
An <NA>
estimated <NA>
1 <NA>
million <NA>
to <NA>
1.5 <NA>
million <NA>
people <NA>
in <NA>
the <NA>
United_States <LOCATION>
are <NA>
long-term <NA>
carriers <NA>
of <NA>
the <NA>
hepatitis <NA>
B <NA>
virus. <NA>
Worldwide, <NA>
300 <NA>
million <NA>
people, <NA>
or <NA>
5_percent <PERCENT>
of <NA>
the <NA>
world's <NA>
population, <NA>
are <NA>
chronically <NA>
infected. <NA>
Baruch <NA>
S. <NA>
Blumberg <NA>
of_the_<ORGANIZATION>Fox_Chase_Cancer_Center </PERSON>
in <NA>
Philadelphia <LOCATION>
. <NA>
Blumberg <PERSON>
won <NA>
the <NA>
Nobel_Prize <ORGANIZATION>
in <NA>
medicine <NA>
in <NA>
1976 <DATE>
for <NA>
identifying <NA>
the <NA>
virus. <NA>
Although <NA>
the <NA>
Food_and_Drug_Administration <ORGANIZATION>
has <NA>
not <NA>
yet <NA>
recommended <NA>
interferon <NA>
for <NA>
hepatitis <NA>
B, <NA>
physicians <NA>
can <NA>
use <NA>
it <NA>
any <NA>
way <NA>
they <NA>
choose, <NA>
and <NA>
Blumberg <PERSON>
said <NA>
some <NA>
doctors <NA>
have <NA>
already <NA>
begun <NA>
prescribing <NA>
it <NA>
for <NA>
this <NA>
disease. <NA>
``We <NA>
can <NA>
be <NA>
relatively <NA>
sure <NA>
what <NA>
doctors <NA>
will <NA>
find <NA>
in <NA>
practice: <NA>
Ten_percent <PERCENT>
will <NA>
be <NA>
cured <NA>
and <NA>
40 <NA>
or <NA>
50_percent <PERCENT>
will <NA>
be <NA>
made <NA>
better <NA>
and <NA>
their <NA>
liver <NA>
disease <NA>
will <NA>
be <NA>
stopped <NA>
in <NA>
its <NA>
tracks,'' <NA>
said <NA>
Jay <NA>
H. <NA>
Hoofnagle <NA>
of_the_<ORGANIZATION>National_Institute_of_Diabetes </PERSON>
and <NA>
Digestive_and_Kidney_Diseases <ORGANIZATION>
. <NA>
``For <NA>
now, <NA>
interferon <NA>
alpha <NA>
offers <NA>
the <NA>
best <NA>
hope'' <NA>
for <NA>
treating <NA>
chronic <NA>
hepatitis <NA>
B, <NA>
Hoofnagle <PERSON>
wrote. <NA>
The <NA>
FDA <ORGANIZATION>
has <NA>
approved <NA>
use <NA>
of <NA>
the <NA>
drug <NA>
for <NA>
hairy-cell <NA>
leukemia, <NA>
AIDS-related <NA>
Kaposi <ORGANIZATION>
's <NA>
sarcoma <NA>
and <NA>
genital <NA>
warts. <NA>
In <NA>
hepatitis <NA>
B, <NA>
Perrillo <PERSON>
said <NA>
the <NA>
treatment <NA>
appears <NA>
to <NA>
offer <NA>
the <NA>
best <NA>
chance <NA>
of <NA>
a <NA>
cure <NA>
if <NA>
given <NA>
during <NA>
the <NA>
first <NA>
two <NA>
years <NA>
of <NA>
infection. <NA>
WSJ870120-0009 <DOCNO>
The <NA>
virus, <NA>
until <NA>
now, <NA>
has <NA>
been <NA>
confined <NA>
to <NA>
small <NA>
areas <NA>
of <NA>
Japan <LOCATION>
, <NA>
the <NA>
Caribbean <LOCATION>
and <NA>
the <NA>
Mediterranean <LOCATION>
. <NA>
Although <NA>
it <NA>
is <NA>
far <NA>
too <NA>
early <NA>
to <NA>
tell <NA>
how <NA>
many <NA>
people <NA>
have <NA>
been <NA>
infected <NA>
and <NA>
how <NA>
many <NA>
will <NA>
actually <NA>
develop <NA>
cancer <NA>
or <NA>
the <NA>
nerve <NA>
disease, <NA>
evidence <NA>
already <NA>
suggests <NA>
that <NA>
many <NA>
drug <NA>
addicts <NA>
in <NA>
the <NA>
U.S. <LOCATION>
have <NA>
been <NA>
exposed <NA>
to <NA>
the <NA>
virus. <NA>
And <NA>
there <NA>
is <NA>
at <NA>
least <NA>
one <NA>
cluster <NA>
of <NA>
cases <NA>
of <NA>
the <NA>
rare <NA>
leukemia <NA>
in <NA>
New_York <LOCATION>
's <NA>
Bedford-Stuyvesant <LOCATION>
neighborhood, <NA>
although <NA>
doctors <NA>
don't <NA>
know <NA>
how <NA>
the <NA>
victims <NA>
acquired <NA>
the <NA>
virus. <NA>
In <NA>
an <NA>
unannounced <NA>
move, <NA>
the <NA>
American_Red_Cross <ORGANIZATION>
late <NA>
last <NA>
week <NA>
began <NA>
testing <NA>
for <NA>
evidence <NA>
of <NA>
the <NA>
virus <NA>
in <NA>
blood <NA>
donated <NA>
by <NA>
30,000 <NA>
people <NA>
in <NA>
six <NA>
unidentified <NA>
cities <NA>
around <NA>
the <NA>
country. <NA>
"We <NA>
have <NA>
evidence <NA>
now <NA>
that <NA>
a <NA>
virus <NA>
spread <NA>
by <NA>
blood <NA>
and <NA>
associated <NA>
with <NA>
a <NA>
very <NA>
serious <NA>
disease <NA>
has <NA>
been <NA>
detected <NA>
in <NA>
the <NA>
U.S. <LOCATION>
," <NA>
says <NA>
Gerald <NA>
Sandler <NA>
,_medical_director_of_the_<ORGANIZATION>Red_Cross </PERSON>
. <NA>
"Since <NA>
this <NA>
is <NA>
happening, <NA>
it <NA>
is <NA>
the <NA>
responsibility <NA>
of <NA>
the <NA>
American_Red_Cross <ORGANIZATION>
to <NA>
be <NA>
at <NA>
the <NA>
head <NA>
of <NA>
a <NA>
scientific <NA>
investigation <NA>
to <NA>
quantify <NA>
the <NA>
incidence <NA>
of <NA>
the <NA>
virus's <NA>
presence <NA>
and <NA>
spread. <NA>
" <NA>
Adds <NA>
Bernard_Poiesz <PERSON>
, <NA>
head <NA>
of <NA>
the <NA>
division <NA>
of <NA>
hematology-oncology <NA>
at <NA>
the <NA>
State_University_of_New_York <ORGANIZATION>
in <NA>
Syracuse <LOCATION>
: <NA>
"Incidence <NA>
of <NA>
the <NA>
virus <NA>
in <NA>
the <NA>
U.S. <LOCATION>
has <NA>
been <NA>
sporadic, <NA>
but <NA>
it <NA>
is <NA>
increasing <NA>
now. <NA>
Although <NA>
the <NA>
cancer <NA>
threat <NA>
alone <NA>
has <NA>
worried <NA>
health <NA>
officials <NA>
for <NA>
several <NA>
months, <NA>
those <NA>
concerns <NA>
have <NA>
increased <NA>
following <NA>
reports <NA>
that <NA>
link <NA>
the <NA>
virus <NA>
with <NA>
a <NA>
nerve <NA>
condition <NA>
known <NA>
as <NA>
tropical <NA>
spastic <NA>
paraparesis <NA>
or <NA>
TSP, <NA>
explains <NA>
William_A._Blattner <PERSON>
of <NA>
the <NA>
environmental <NA>
epidemiology <NA>
branch <NA>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
. <NA>
It <NA>
was <NA>
first <NA>
identified <NA>
in <NA>
the <NA>
1960s <DATE>
in <NA>
Jamaica <LOCATION>
. <NA>
Last <NA>
fall, <NA>
however, <NA>
French <NA>
researchers <NA>
in <NA>
Martinique <LOCATION>
linked <NA>
the <NA>
nerve <NA>
disease <NA>
to <NA>
the <NA>
virus <NA>
after <NA>
finding <NA>
that <NA>
many <NA>
TSP <NA>
victims <NA>
had <NA>
been <NA>
infected <NA>
with <NA>
the <NA>
leukemia <NA>
virus. <NA>
Subsequently, <NA>
Japanese <NA>
researchers <NA>
found <NA>
that <NA>
many <NA>
TSP <NA>
victims <NA>
in <NA>
Japan <LOCATION>
had <NA>
previously <NA>
had <NA>
blood <NA>
transfusions. <NA>
Although <NA>
the <NA>
incidence <NA>
of <NA>
TSP <ORGANIZATION>
in <NA>
the <NA>
U.S. <LOCATION>
isn't <NA>
known, <NA>
the <NA>
links <NA>
between <NA>
the <NA>
leukemia <NA>
virus, <NA>
the <NA>
nerve <NA>
disease <NA>
and <NA>
blood <NA>
transfusions <NA>
have <NA>
apparently <NA>
spurred <NA>
the <NA>
preliminary <NA>
screening <NA>
of <NA>
blood <NA>
supplies <NA>
by <NA>
the <NA>
Red_Cross <ORGANIZATION>
. <NA>
Less <NA>
than <NA>
a <NA>
decade <NA>
ago, <NA>
U.S. <LOCATION>
and <NA>
Japanese <NA>
scientists <NA>
proved <NA>
that <NA>
HTLV-I <NA>
was <NA>
responsible <NA>
for <NA>
a <NA>
type <NA>
of <NA>
leukemia <NA>
seen <NA>
in <NA>
southern <NA>
Japan <LOCATION>
. <NA>
"The <NA>
median <NA>
survival <NA>
is <NA>
three <NA>
months," <NA>
says <NA>
Harvey_Dosik <PERSON>
, <NA>
director <NA>
of <NA>
medicine <NA>
at <NA>
the <NA>
Interfaith_Medical_Center <ORGANIZATION>
in <NA>
Brooklyn <LOCATION>
, <NA>
N.Y. <LOCATION>
The <NA>
15 <NA>
cases <NA>
constitute <NA>
the <NA>
largest <NA>
cluster <NA>
of <NA>
the <NA>
leukemia <NA>
in <NA>
the <NA>
U.S. <LOCATION>
The <NA>
victims <NA>
were <NA>
all <NA>
blacks <NA>
who <NA>
moved <NA>
into <NA>
the <NA>
Bedford-Stuyvesant <LOCATION>
ghetto <NA>
in <NA>
Brooklyn <LOCATION>
from <NA>
the <NA>
Carribbean <LOCATION>
and <NA>
the <NA>
southern <NA>
U.S. <LOCATION>
, <NA>
areas <NA>
where <NA>
the <NA>
presence <NA>
of <NA>
the <NA>
virus <NA>
has <NA>
been <NA>
known <NA>
for <NA>
some <NA>
time. <NA>
In <NA>
1984 <DATE>
, <NA>
British <NA>
health <NA>
officials, <NA>
while <NA>
screening <NA>
for <NA>
AIDS, <NA>
first <NA>
noted <NA>
that <NA>
about <NA>
4% <PERCENT>
of <NA>
addicts <NA>
there <NA>
had <NA>
developed <NA>
antibodies <NA>
to <NA>
HTLV-I, <NA>
evidence <NA>
that <NA>
they <NA>
had <NA>
been <NA>
exposed <NA>
to <NA>
the <NA>
virus. <NA>
National <NA>
Institutes <NA>
of <NA>
Health <NA>
checked_blood_samples_taken_five_years_ago_from_56_drug_addicts_in_the_<LOCATION>Queens </ORGANIZATION>
section <NA>
of <NA>
New_York <LOCATION>
. <NA>
The <NA>
results <NA>
indicated <NA>
that <NA>
as <NA>
early <NA>
as <NA>
1981 <DATE>
as <NA>
many <NA>
as <NA>
9% <PERCENT>
of <NA>
the <NA>
intravenous <NA>
drug <NA>
addicts <NA>
had <NA>
been <NA>
exposed <NA>
to <NA>
HTLV-I. <NA>
Some <NA>
researchers <NA>
are <NA>
also <NA>
worried <NA>
that <NA>
blood <NA>
screening <NA>
such <NA>
as <NA>
that <NA>
being <NA>
done <NA>
by <NA>
the <NA>
Red_Cross <ORGANIZATION>
may <NA>
not <NA>
give <NA>
a <NA>
broad <NA>
enough <NA>
picture <NA>
of <NA>
the <NA>
prevalence <NA>
of <NA>
HTLV-I. <NA>
The <NA>
Red_Cross <ORGANIZATION>
screening <NA>
program <NA>
was <NA>
made <NA>
possible <NA>
by <NA>
the <NA>
development <NA>
of <NA>
test <NA>
kits <NA>
by <NA>
Cellular_Products_Co. <ORGANIZATION>
, <NA>
a <NA>
Buffalo <LOCATION>
, <NA>
N.Y. <LOCATION>
, <NA>
biotechnology <NA>
company, <NA>
and <NA>
by <NA>
Du_Pont_Co. <ORGANIZATION>
in <NA>
Wilmington <LOCATION>
, <NA>
Del <LOCATION>
. <NA>
Cellular <NA>
Products <NA>
began <NA>
working <NA>
on <NA>
a <NA>
test <NA>
at <NA>
the <NA>
"insistence <NA>
of <NA>
Dr. <NA>
Poiesz" <NA>
in <NA>
Syracuse <LOCATION>
, <NA>
"who <NA>
told <NA>
us <NA>
he <NA>
was <NA>
seeing <NA>
enough <NA>
instances <NA>
in <NA>
his <NA>
lab <NA>
to <NA>
warrant <NA>
nationwide <NA>
screening <NA>
soon," <NA>
says <NA>
Richard_Montagna <PERSON>
, <NA>
Cellular's <NA>
president. <NA>
Robert <NA>
Gallo <NA>
at_the_<ORGANIZATION>National_Cancer_Institute </PERSON>
in <NA>
1978 <DATE>
. <NA>
A <NA>
Du_Pont <ORGANIZATION>
spokesman <NA>
says <NA>
the <NA>
company <NA>
is <NA>
gearing <NA>
up <NA>
to <NA>
produce <NA>
six <NA>
million <NA>
test <NA>
kits <NA>
a <NA>
year, <NA>
based <NA>
on <NA>
Du_Pont <ORGANIZATION>
's <NA>
own <NA>
studies <NA>
of <NA>
the <NA>
spread <NA>
of <NA>
the <NA>
virus. <NA>
WSJ880803-0161 <DOCNO>
In <NA>
your <NA>
second-front-page <NA>
article <NA>
"Approved <NA>
Drugs <NA>
Find <NA>
Unapproved <NA>
Uses" <NA>
( <NA>
July_12 <DATE>
), <NA>
your <NA>
approach <NA>
to <NA>
the <NA>
problem <NA>
of <NA>
Food_and_Drug_Administration <ORGANIZATION>
approval <NA>
of <NA>
medicines <NA>
fails <NA>
to <NA>
take <NA>
into <NA>
account <NA>
the <NA>
complexities <NA>
of <NA>
modern <NA>
medicine. <NA>
" <NA>
"Well, <NA>
Doc <PERSON>
," <NA>
you <NA>
answer, <NA>
"I'll <NA>
go <NA>
ahead <NA>
and <NA>
take <NA>
the <NA>
drugs <NA>
anyway; <NA>
those <NA>
odds <NA>
sound <NA>
pretty <NA>
good. <NA>
Since <NA>
you <NA>
have <NA>
a <NA>
rare <NA>
disease, <NA>
you <NA>
certainly <NA>
cannot <NA>
expect <NA>
these <NA>
drug <NA>
companies <NA>
to <NA>
spend <NA>
millions_of_dollars <MONEY>
to <NA>
get <NA>
approval <NA>
for <NA>
such <NA>
a <NA>
rare <NA>
problem, <NA>
can <NA>
you? <NA>
I'd <NA>
like <NA>
to <NA>
give <NA>
you <NA>
the <NA>
drugs, <NA>
but <NA>
since <NA>
you <NA>
live <NA>
in <NA>
Massachusetts <LOCATION>
, <NA>
your <NA>
insurer <NA>
makes <NA>
me <NA>
take <NA>
assignment <NA>
for <NA>
your <NA>
treatment, <NA>
and <NA>
not <NA>
only <NA>
will <NA>
they <NA>
not <NA>
pay <NA>
me, <NA>
by <NA>
law <NA>
you <NA>
can't <NA>
pay <NA>
me <NA>
out <NA>
of <NA>
your <NA>
pocket <NA>
either. <NA>
" <NA>
"But <NA>
Doc <PERSON>
, <NA>
you're <NA>
an <NA>
expert <NA>
in <NA>
cancer <NA>
medicine; <NA>
certainly <NA>
if <NA>
you <NA>
tell <NA>
the <NA>
insurer <NA>
that <NA>
this <NA>
is <NA>
the <NA>
best <NA>
thing <NA>
for <NA>
me, <NA>
it <NA>
will <NA>
be <NA>
OK." <NA>
"I <NA>
wish <NA>
it <NA>
were <NA>
that <NA>
simple, <NA>
X <NA>
,"_I_go_on,_"but_your_policy_clearly_states_that_only_drugs_approved_by_the_<ORGANIZATION>FDA </PERSON>
for <NA>
that <NA>
disease <NA>
can <NA>
be <NA>
reimbursed; <NA>
how <NA>
else <NA>
can <NA>
they <NA>
hold <NA>
down <NA>
runaway <NA>
costs? <NA>
) <NA>
and <NA>
it <NA>
only <NA>
took <NA>
the <NA>
FDA <ORGANIZATION>
a <NA>
few <NA>
years <NA>
to <NA>
approve <NA>
the <NA>
application <NA>
for <NA>
that <NA>
use. <NA>
" <NA>
"Well, <NA>
I <NA>
certainly <NA>
understand <NA>
the <NA>
problem, <NA>
Doc <PERSON>
. <NA>
Let's <NA>
just <NA>
write <NA>
to <NA>
the <NA>
FDA <ORGANIZATION>
, <NA>
tell <NA>
them <NA>
the <NA>
facts <NA>
you <NA>
told <NA>
me, <NA>
and <NA>
they'll <NA>
approve <NA>
it. <NA>
X <NA>
,_but_you_don't_understand_the_<ORGANIZATION>FDA </PERSON>
. <NA>
As <NA>
we <NA>
discussed, <NA>
that <NA>
usually <NA>
requires <NA>
several <NA>
years <NA>
and <NA>
costs <NA>
tens_of_millions_of_dollars <MONEY>
. <NA>
" <NA>
"But, <NA>
Doc <PERSON>
, <NA>
I'm <NA>
going <NA>
to <NA>
die <NA>
of <NA>
this," <NA>
you <NA>
plead. <NA>
Anyway, <NA>
this_morning <TIME>
already, <NA>
I've <NA>
had <NA>
to <NA>
tell <NA>
one <NA>
women <NA>
with <NA>
chronic <NA>
myelocytic <NA>
leukemia <NA>
that <NA>
I <NA>
would <NA>
like <NA>
to <NA>
treat <NA>
her <NA>
with <NA>
alpha-interferon, <NA>
but <NA>
unfortunately <NA>
she <NA>
didn't <NA>
have <NA>
hairy <NA>
cell <NA>
leukemia. <NA>
I <NA>
figured <NA>
that <NA>
by <NA>
1990 <DATE>
we'd <NA>
have <NA>
thought <NA>
about <NA>
it. <NA>
" <NA>
Joseph_J._Muscato <PERSON>
M.D. <NA>
Columbia <ORGANIZATION>
, <NA>
Mo <LOCATION>
. <NA>
AP880630-0223 <DOCNO>
Isolation <NA>
of <NA>
the <NA>
special <NA>
cell <NA>
type, <NA>
called <NA>
a <NA>
stem <NA>
cell, <NA>
eluded <NA>
researchers <NA>
for <NA>
30 <NA>
years <NA>
until <NA>
achieved <NA>
by <NA>
doctors <NA>
at <NA>
Stanford_University_Medical_Center <ORGANIZATION>
in <NA>
Northern_California <LOCATION>
and <NA>
Royal_Melbourne_Hospital <ORGANIZATION>
in <NA>
Australia <LOCATION>
. <NA>
The <NA>
research <NA>
is <NA>
outlined <NA>
in <NA>
Friday <DATE>
's <NA>
issue <NA>
of <NA>
the <NA>
journal <NA>
Science. <NA>
Irving <NA>
Weissman <NA>
,_a_<ORGANIZATION>Stanford </PERSON>
professor <NA>
of <NA>
pathology <NA>
and <NA>
cancer <NA>
biology <NA>
who <NA>
headed <NA>
the <NA>
study <NA>
team. <NA>
Only <NA>
about <NA>
one <NA>
in <NA>
20,000 <NA>
cells <NA>
in <NA>
bone <NA>
marrow <NA>
is <NA>
a <NA>
stem <NA>
cell, <NA>
said <NA>
Weissman <PERSON>
. <NA>
If <NA>
human <NA>
stem <NA>
cells <NA>
can <NA>
be <NA>
purified, <NA>
they <NA>
might <NA>
be <NA>
transplanted <NA>
without <NA>
other <NA>
cells <NA>
in <NA>
bone <NA>
marrow, <NA>
thus <NA>
avoiding <NA>
the <NA>
failure <NA>
of <NA>
the <NA>
transplants, <NA>
Weissman <PERSON>
said. <NA>
By <NA>
separating <NA>
stem <NA>
cells <NA>
from <NA>
the <NA>
extracted <NA>
marrow, <NA>
the <NA>
stem <NA>
cells <NA>
can <NA>
be <NA>
reimplanted <NA>
free <NA>
of <NA>
any <NA>
cancer <NA>
cells, <NA>
preventing <NA>
the <NA>
cancer <NA>
from <NA>
recurring, <NA>
Weissman <PERSON>
said. <NA>
WSJ910516-0166 <DOCNO>
The <NA>
drug <NA>
used <NA>
in <NA>
the <NA>
experimental <NA>
treatment <NA>
is <NA>
known <NA>
as <NA>
tretinoin, <NA>
which <NA>
belongs <NA>
to <NA>
a <NA>
class <NA>
of <NA>
chemicals <NA>
called <NA>
retinoic <NA>
acids <NA>
that <NA>
are <NA>
related <NA>
to <NA>
vitamin <NA>
A. <NA>
Tretinoin <NA>
is <NA>
sold <NA>
in <NA>
ointment <NA>
form <NA>
as <NA>
Retin-A, <NA>
the <NA>
acne <NA>
medication <NA>
produced <NA>
by <NA>
Johnson_&amp;_Johnson <ORGANIZATION>
's <NA>
Ortho_Pharmaceutical <ORGANIZATION>
division. <NA>
The <NA>
tretinoin <NA>
used <NA>
in <NA>
the <NA>
leukemia <NA>
patients, <NA>
however, <NA>
is <NA>
a <NA>
pill <NA>
that <NA>
was <NA>
prepared <NA>
for <NA>
the <NA>
experiment <NA>
by <NA>
chemists <NA>
at <NA>
Hoffmann-La_Roche_Inc. <ORGANIZATION>
, <NA>
the <NA>
U.S. <LOCATION>
arm <NA>
of <NA>
Roche_Holding_Ltd. <ORGANIZATION>
of <NA>
Switzerland <LOCATION>
. <NA>
Raymond <NA>
P. <NA>
Warrell <NA>
Jr. <NA>
of_Memorial_Sloan-Kettering_and_his_colleagues_in_<LOCATION>New_York </PERSON>
and <NA>
at <NA>
Anderson <NA>
Cancer <NA>
Center <NA>
in_<LOCATION>Houston </ORGANIZATION>
reported <NA>
in <NA>
this <NA>
week's <NA>
New_England_Journal_of_Medicine <ORGANIZATION>
. <NA>
But, <NA>
he <NA>
added, <NA>
the <NA>
U.S. <LOCATION>
group <NA>
is <NA>
the <NA>
first <NA>
to <NA>
show <NA>
that <NA>
the <NA>
drug <NA>
works <NA>
by <NA>
triggering <NA>
the <NA>
immature <NA>
cancer <NA>
cells <NA>
to <NA>
mature, <NA>
or <NA>
to <NA>
"differentiate," <NA>
in <NA>
the <NA>
biologists <NA>
jargon. <NA>
LA022290-0150 <DOCNO>
Medical_researchers_unveiled_new_evidence_<DATE>Wednesday <P>
showing <NA>
that <NA>
doctors <NA>
don't <NA>
need <NA>
a <NA>
perfect <NA>
match <NA>
when <NA>
they <NA>
try <NA>
to <NA>
transplant <NA>
bone <NA>
marrow <NA>
into <NA>
someone <NA>
whose <NA>
blood-producing <NA>
cells <NA>
have <NA>
been <NA>
damaged <NA>
by <NA>
leukemia <NA>
or <NA>
another <NA>
deadly <NA>
illness. <NA>
<P>_But_researchers_at_the_<ORGANIZATION>Medical_College_of_Wisconsin </P>
, <NA>
using <NA>
special <NA>
techniques <NA>
to <NA>
cleanse <NA>
the <NA>
donated <NA>
marrow, <NA>
found <NA>
that <NA>
transplants <NA>
can <NA>
be <NA>
successful <NA>
when <NA>
the <NA>
protein <NA>
pattern <NA>
in <NA>
the <NA>
donor's <NA>
marrow <NA>
is <NA>
similar <NA>
to, <NA>
but <NA>
not <NA>
identical <NA>
to, <NA>
the <NA>
recipient's. <NA>
<P>_The_ability_to_use_marrow_from_unrelated_donors_is_important_because_only_about_<PERCENT>30% </P>
of <NA>
patients <NA>
who <NA>
might <NA>
benefit <NA>
from <NA>
a <NA>
bone <NA>
marrow <NA>
transplant <NA>
will <NA>
have <NA>
a <NA>
brother <NA>
or <NA>
sister <NA>
whose <NA>
marrow <NA>
is <NA>
perfectly <NA>
matched, <NA>
Ash <ORGANIZATION>
said. <NA>
The <NA>
birth <NA>
is <NA>
expected <NA>
in <NA>
April <DATE>
. <NA>
<P>_In_the_four-year_study_of_55_patients,_the_transplants_were_successful_in_<PERCENT>48% </P>
of <NA>
patientswith <NA>
early <NA>
leukemia, <NA>
32% <PERCENT>
of <NA>
the <NA>
volunteers <NA>
whose <NA>
leukemia <NA>
had <NA>
reached <NA>
an <NA>
advanced <NA>
stage, <NA>
and <NA>
63% <PERCENT>
of <NA>
the <NA>
patients <NA>
who <NA>
suffered <NA>
from <NA>
diseases <NA>
other <NA>
than <NA>
leukemia. <NA>
AP900727-0024 <DOCNO>
Researchers <NA>
have <NA>
been <NA>
unable <NA>
to <NA>
definitively <NA>
link <NA>
fallout <NA>
from <NA>
atomic <NA>
explosions <NA>
in <NA>
Nevada <LOCATION>
during <NA>
the <NA>
1950s <DATE>
to <NA>
the <NA>
higher <NA>
than <NA>
normal <NA>
leukemia <NA>
rate <NA>
in <NA>
neighboring <NA>
Utah <LOCATION>
, <NA>
although <NA>
a <NA>
new <NA>
study <NA>
does <NA>
suggest <NA>
a <NA>
link. <NA>
Weapons <NA>
tests <NA>
in <NA>
Nevada <LOCATION>
by <NA>
the <NA>
old <NA>
Atomic <NA>
Energy <NA>
Commission <NA>
may_have_caused_the_higher_cancer_rate_in_the_neighboring_state,_but_the_evidence_is_weak,_according_to_a_study_conducted_by_<ORGANIZATION>University_of_Utah </ORGANIZATION>
researchers <NA>
to <NA>
be <NA>
published <NA>
in <NA>
next <NA>
week's <NA>
Journal <NA>
of <NA>
the <NA>
American_Medical_Association <ORGANIZATION>
. <NA>
``The <NA>
excess <NA>
of <NA>
acute <NA>
leukemias <NA>
in <NA>
southwestern <NA>
Utah <LOCATION>
is <NA>
probably <NA>
not <NA>
due <NA>
to <NA>
chance <NA>
and <NA>
may <NA>
be <NA>
attributable <NA>
to <NA>
fallout <NA>
radiation. <NA>
But <NA>
no <NA>
such <NA>
increased <NA>
risk <NA>
was <NA>
found <NA>
outside <NA>
southwest <NA>
Utah <LOCATION>
, <NA>
it <NA>
said. <NA>
Joseph <NA>
L. <NA>
Lyon <NA>
,_one_of_the_researchers_with_the_<ORGANIZATION>University_of_Utah's_Department_of_Family_and_Preventative_Medicine </PERSON>
. <NA>
House <NA>
last_month_approved_a_bill_creating_a_<MONEY>$100_million </ORGANIZATION>
trust <NA>
fund <NA>
to <NA>
compensate <NA>
those <NA>
living <NA>
downwind <NA>
from <NA>
the <NA>
Nevada <LOCATION>
test <NA>
site <NA>
for <NA>
alleged <NA>
radiation <NA>
injuries. <NA>
Up <NA>
to <NA>
1,300 <NA>
alleged <NA>
fallout <NA>
victims <NA>
could <NA>
collect <NA>
up <NA>
to <NA>
$50,000 <MONEY>
each <NA>
under <NA>
the <NA>
legislation, <NA>
now <NA>
being <NA>
considered <NA>
by <NA>
the <NA>
Senate <ORGANIZATION>
. <NA>
More <NA>
than <NA>
100 <NA>
atomic <NA>
bombs <NA>
were <NA>
set <NA>
off <NA>
above <NA>
ground <NA>
in <NA>
Nevada <LOCATION>
between <NA>
1951 <DATE>
and <NA>
1958 <DATE>
, <NA>
researchers <NA>
said. <NA>
Fallout <NA>
from <NA>
those <NA>
blasts <NA>
spread <NA>
across <NA>
southwestern <NA>
Utah <LOCATION>
. <NA>
But <NA>
because <NA>
leukemia <NA>
leaves <NA>
no <NA>
traces <NA>
as <NA>
to <NA>
its <NA>
source, <NA>
it <NA>
was <NA>
impossible <NA>
to <NA>
determine <NA>
whether <NA>
individual <NA>
deaths <NA>
were <NA>
caused <NA>
by <NA>
exposure <NA>
to <NA>
fallout, <NA>
Lyon <LOCATION>
said <NA>
Thursday <DATE>
. <NA>
You <NA>
can't <NA>
sort <NA>
out <NA>
the <NA>
random <NA>
cases <NA>
from <NA>
those <NA>
involving <NA>
fallout,'' <NA>
Lyon <LOCATION>
said. <NA>
Researchers <NA>
analyzed <NA>
more <NA>
than <NA>
6,500 <NA>
deaths <NA>
in <NA>
Utah <LOCATION>
between <NA>
1952 <DATE>
and <NA>
1981 <DATE>
for <NA>
the <NA>
$6.8_million <MONEY>
, <NA>
federally <NA>
funded <NA>
study. <NA>
They <NA>
confined <NA>
their <NA>
analysis <NA>
to <NA>
members <NA>
of <NA>
the <NA>
Mormon_Church <ORGANIZATION>
, <NA>
because <NA>
church <NA>
records <NA>
could <NA>
be <NA>
used <NA>
to <NA>
determine <NA>
who <NA>
had <NA>
died <NA>
and <NA>
moved <NA>
into <NA>
or <NA>
out <NA>
of <NA>
the <NA>
area <NA>
during <NA>
the <NA>
testing <NA>
period. <NA>
But <NA>
those <NA>
studies <NA>
didn't <NA>
directly <NA>
link <NA>
that <NA>
higher <NA>
rate <NA>
to <NA>
radiation <NA>
fallout, <NA>
Lyon <LOCATION>
said. <NA>
In <NA>
Washington_County <LOCATION>
, <NA>
where <NA>
the <NA>
highest <NA>
radiation <NA>
levels <NA>
were <NA>
recorded, <NA>
there <NA>
were <NA>
17 <NA>
leukemia <NA>
deaths. <NA>
AP900405-0064 <DOCNO>
Researchers <NA>
said <NA>
data <NA>
is <NA>
too <NA>
inconclusive <NA>
to <NA>
embrace <NA>
the <NA>
results <NA>
reported <NA>
on <NA>
Wednesday <DATE>
by <NA>
Joseph <NA>
M. <NA>
Cummins <NA>
,_head_of_the_<ORGANIZATION>Amarillo_Cell_Culture_Co </PERSON>
. <NA>
Inc. <NA>
Cummins <PERSON>
said <NA>
that <NA>
alpha <NA>
interferon <NA>
given <NA>
to <NA>
patients <NA>
in <NA>
a <NA>
wafer <NA>
form <NA>
in <NA>
small <NA>
amounts <NA>
``has <NA>
reduced <NA>
the <NA>
symptoms <NA>
of <NA>
a <NA>
person <NA>
suffering <NA>
from <NA>
AIDS. <NA>
'' <NA>
A <NA>
veterinarian, <NA>
Cummins <PERSON>
said <NA>
he <NA>
began <NA>
experiments <NA>
with <NA>
interferon <NA>
to <NA>
treat <NA>
illnesses <NA>
in <NA>
cattle. <NA>
Davy <NA>
K. <NA>
Koech <NA>
,_the_director_of_the_<ORGANIZATION>Kenyan_Medical_Research_Institute </PERSON>
in <NA>
Nairobi <LOCATION>
, <NA>
for <NA>
use <NA>
on <NA>
AIDS <NA>
patients. <NA>
Koech <NA>
was_desperate_enough_to_try_something_new,''_<PERSON>Cummins </PERSON>
said <NA>
Wednesday <DATE>
. <NA>
'' <NA>
In <NA>
the <NA>
current <NA>
issue <NA>
of <NA>
Biotechnology_Newswatch <ORGANIZATION>
, <NA>
Koech <PERSON>
reported <NA>
that <NA>
within <NA>
days <NA>
of <NA>
taking <NA>
oral <NA>
alpha <NA>
interferon <NA>
all <NA>
of <NA>
his <NA>
99 <NA>
AIDS <NA>
patients <NA>
in <NA>
the <NA>
test <NA>
group <NA>
developed <NA>
an <NA>
appetite. <NA>
Dr. <NA>
Anthony_S._Fauci <PERSON>
, <NA>
head <NA>
of <NA>
the <NA>
National_Institutes_of_Allergy <ORGANIZATION>
and <NA>
Infectious <NA>
Disease <NA>
in <NA>
Bethesda <LOCATION>
, <NA>
Md. <LOCATION>
, <NA>
said <NA>
Wednesday <DATE>
the <NA>
results <NA>
from <NA>
Africa <LOCATION>
were <NA>
``astounding <NA>
and <NA>
very <NA>
difficult <NA>
to <NA>
believe,'' <NA>
but <NA>
``you <NA>
have <NA>
to <NA>
keep <NA>
an <NA>
open <NA>
mind. <NA>
'' <NA>
Dr. <NA>
Sidney_Wolfe <PERSON>
, <NA>
director <NA>
of <NA>
the <NA>
Health_Research_Group <ORGANIZATION>
in <NA>
Washington <LOCATION>
, <NA>
D.C. <LOCATION>
, <NA>
said <NA>
there <NA>
is <NA>
not <NA>
enough <NA>
data <NA>
on <NA>
the <NA>
tests <NA>
to <NA>
make <NA>
an <NA>
opinion. <NA>
Food <NA>
and <NA>
Drug <NA>
Administration <NA>
has_approved_alpha_interferon_to_treat_<PERSON>Kaposi </ORGANIZATION>
's <NA>
sarcoma, <NA>
a <NA>
cancer <NA>
that <NA>
occurs <NA>
commonly <NA>
among <NA>
people <NA>
with <NA>
AIDS. <NA>
Cummins <PERSON>
said <NA>
a <NA>
veterinarian <NA>
called <NA>
him <NA>
last <NA>
year <NA>
seeking <NA>
interferon <NA>
``to <NA>
treat <NA>
a <NA>
big <NA>
dog <NA>
for <NA>
leukemia. <NA>
The <NA>
man <NA>
agreed <NA>
to <NA>
talk <NA>
to <NA>
The_Associated_Press <ORGANIZATION>
upon <NA>
condition <NA>
of <NA>
anonymiity. <NA>
``I <NA>
contracted <NA>
AIDS <NA>
along <NA>
with <NA>
three <NA>
other <NA>
people <NA>
who <NA>
split <NA>
infected <NA>
blood <NA>
during <NA>
a <NA>
transfusion,'' <NA>
he <NA>
said <NA>
Wednesday <DATE>
. <NA>
Anderson <NA>
Center <NA>
in_<LOCATION>Houston </ORGANIZATION>
, <NA>
said <NA>
Wednesday <DATE>
that <NA>
Cummins <PERSON>
' <NA>
use <NA>
of <NA>
interferon <NA>
to <NA>
treat <NA>
animals <NA>
with <NA>
leukemia <NA>
produced <NA>
``some <NA>
intriguing <NA>
results. <NA>
'' <NA>
``We <NA>
are <NA>
going <NA>
to <NA>
start <NA>
studies <NA>
ourselves <NA>
with <NA>
interferon <NA>
for <NA>
cancer <NA>
treatment,'' <NA>
Gutterman <PERSON>
said. <NA>
WSJ870320-0168 <DOCNO>
"His <NA>
skin <NA>
was <NA>
sloughing <NA>
off <NA>
all <NA>
over <NA>
his <NA>
body," <NA>
recalls <NA>
Marshall_M._Kaplan <PERSON>
, <NA>
the <NA>
Tufts_University <ORGANIZATION>
gastroenterologist <NA>
who <NA>
had <NA>
been <NA>
tending <NA>
the <NA>
patient's <NA>
liver <NA>
problems. <NA>
The <NA>
methotrexate <NA>
story <NA>
begins <NA>
in <NA>
the <NA>
mid-1940s <NA>
when <NA>
the <NA>
late <NA>
Sidney_Farber <PERSON>
and <NA>
his <NA>
colleagues <NA>
at <NA>
Children's_Hospital <ORGANIZATION>
in <NA>
Boston <LOCATION>
were <NA>
attempting <NA>
the <NA>
first <NA>
use <NA>
of <NA>
chemicals <NA>
in <NA>
the <NA>
treatment <NA>
of <NA>
acute <NA>
childhood <NA>
leukemia, <NA>
then <NA>
an <NA>
invariably <NA>
fatal <NA>
blood <NA>
cancer. <NA>
In <NA>
1948 <DATE>
, <NA>
in <NA>
an <NA>
historic <NA>
research <NA>
paper, <NA>
the <NA>
Boston <LOCATION>
researchers <NA>
reported <NA>
the <NA>
first <NA>
remissions <NA>
of <NA>
acute <NA>
leukemia <NA>
through <NA>
chemotherapy. <NA>
The <NA>
Boston <LOCATION>
discovery <NA>
led <NA>
chemists <NA>
at <NA>
Lederle_Laboratories <ORGANIZATION>
, <NA>
the <NA>
pharmaceutical <NA>
subsidiary <NA>
of <NA>
American_Cyanamid_Co. <ORGANIZATION>
, <NA>
to <NA>
synthesize <NA>
an <NA>
improved <NA>
version <NA>
of <NA>
aminopterin <NA>
they <NA>
called <NA>
a-methopterin, <NA>
to <NA>
which <NA>
Lederle <ORGANIZATION>
's <NA>
marketing <NA>
people <NA>
affixed <NA>
the <NA>
brand <NA>
name, <NA>
Methotrexate <NA>
(the <NA>
brand <NA>
name <NA>
has <NA>
since <NA>
slid <NA>
into <NA>
generic <NA>
use). <NA>
METHOTREXATE <NA>
PROVED <NA>
even <NA>
better <NA>
at <NA>
bringing <NA>
about <NA>
remissions <NA>
of <NA>
acute <NA>
lymphoblastic <NA>
leukemia, <NA>
and <NA>
today <NA>
it <NA>
is <NA>
one <NA>
of <NA>
the <NA>
drugs <NA>
achieving <NA>
cures <NA>
of <NA>
leukemia <NA>
in <NA>
about <NA>
50% <PERCENT>
of <NA>
afflicted <NA>
children. <NA>
By <NA>
1956 <DATE>
, <NA>
cancer <NA>
researchers <NA>
reported <NA>
another <NA>
first: <NA>
Women <NA>
developing <NA>
an <NA>
unusual <NA>
cancer <NA>
of <NA>
the <NA>
placenta <NA>
during <NA>
pregnancy <NA>
had <NA>
been <NA>
permanently <NA>
cured <NA>
by <NA>
methotrexate, <NA>
the <NA>
first <NA>
cancer <NA>
ever <NA>
cured <NA>
by <NA>
chemotherapy. <NA>
In <NA>
the <NA>
early <NA>
1960s <DATE>
, <NA>
serendipity <NA>
struck <NA>
again. <NA>
A <NA>
New_York <LOCATION>
dermatologist <NA>
reported <NA>
instances <NA>
of <NA>
some <NA>
patients <NA>
being <NA>
relieved <NA>
of <NA>
psoriasis, <NA>
a <NA>
chronic <NA>
and <NA>
severely <NA>
disturbing <NA>
skin <NA>
disease, <NA>
when <NA>
treated <NA>
with <NA>
methotrexate. <NA>
This <NA>
led <NA>
William_O'Brien <PERSON>
and <NA>
Roger_Black <PERSON>
at <NA>
the <NA>
National_Institutes_of_Health <ORGANIZATION>
to <NA>
run <NA>
a <NA>
controlled <NA>
trial <NA>
on <NA>
21 <NA>
psoriasis <NA>
patients. <NA>
O'Brien <NA>
,_who_did_the_first_trial_of_methotrexate_in_arthritis_and_who_is_now_a_professor_at_the_<ORGANIZATION>University_of_Virginia </PERSON>
. <NA>
Because <NA>
of <NA>
its <NA>
toxicity, <NA>
he <NA>
says, <NA>
"we <NA>
don't <NA>
use <NA>
it <NA>
anymore <NA>
here <NA>
in <NA>
Charlottesville <LOCATION>
. <NA>
" <NA>
Meanwhile, <NA>
in <NA>
Boston <LOCATION>
, <NA>
WSJ910208-0083 <DOCNO>
A <NA>
recent <NA>
Environmental_Protection_Agency <ORGANIZATION>
report <NA>
said <NA>
that <NA>
electro-magnetic <NA>
fields <NA>
from <NA>
electric <NA>
power <NA>
lines <NA>
are <NA>
a <NA>
possible <NA>
-- <NA>
if <NA>
not <NA>
proven <NA>
-- <NA>
cause <NA>
of <NA>
cancer. <NA>
And <NA>
frequently-cited <NA>
studies <NA>
of <NA>
Denver <LOCATION>
residents <NA>
found <NA>
correlations <NA>
between <NA>
childhood <NA>
cancer <NA>
and <NA>
neighboring <NA>
power <NA>
lines. <NA>
Peters <NA>
's_work_"adds_to_the_body_of_evidence"_that_some_still-unexplained_process_may_be_increasing_the_risk_of_cancer,_said_<PERSON>George_Hidy </PERSON>
, <NA>
who <NA>
heads <NA>
the <NA>
environment <NA>
division <NA>
of <NA>
the <NA>
Electric_Power_Research_Institute <ORGANIZATION>
, <NA>
an <NA>
industry-financed <NA>
group <NA>
that <NA>
paid <NA>
for <NA>
the <NA>
study. <NA>
The <NA>
results <NA>
of <NA>
the <NA>
University_of_Southern_California <ORGANIZATION>
study <NA>
had <NA>
been <NA>
widely <NA>
awaited <NA>
because <NA>
of <NA>
a <NA>
large <NA>
sample <NA>
size <NA>
-- <NA>
some <NA>
232 <NA>
children <NA>
with <NA>
leukemia <NA>
and <NA>
an <NA>
equal <NA>
number <NA>
of <NA>
healthy <NA>
children <NA>
-- <NA>
as <NA>
well <NA>
as <NA>
detailed <NA>
readings <NA>
of <NA>
electrical <NA>
and <NA>
magnetic <NA>
fields <NA>
that <NA>
were <NA>
a <NA>
part <NA>
of <NA>
the <NA>
research's <NA>
design. <NA>
Results <NA>
of <NA>
the <NA>
research <NA>
were <NA>
discussed <NA>
yesterday <NA>
at <NA>
a <NA>
scientific <NA>
conference <NA>
in <NA>
Carmel <LOCATION>
, <NA>
Calif <LOCATION>
. <NA>
Peters <NA>
and_in_material_prepared_by_the_<ORGANIZATION>Electric_Power_Research_Institute </PERSON>
. <NA>
According <NA>
to <NA>
the <NA>
Electric_Power_Research_Institute <ORGANIZATION>
, <NA>
the <NA>
appliances <NA>
found <NA>
to <NA>
have <NA>
strong <NA>
correlations <NA>
were <NA>
hair-dryers <NA>
and <NA>
black-and-white <NA>
television <NA>
sets. <NA>
The <NA>
study, <NA>
begun <NA>
in <NA>
1986 <DATE>
as <NA>
an <NA>
expansion <NA>
of <NA>
an <NA>
existing <NA>
work <NA>
on <NA>
various <NA>
potentially <NA>
leukemia-related <NA>
environmental <NA>
factors, <NA>
included <NA>
a <NA>
wide <NA>
range <NA>
of <NA>
factors <NA>
such <NA>
as <NA>
household <NA>
chemicals, <NA>
cigarette <NA>
smoke <NA>
and <NA>
parent's <NA>
occupations. <NA>
AP880505-0077 <DOCNO>
The <NA>
virus, <NA>
first <NA>
isolated <NA>
in <NA>
1980 <DATE>
, <NA>
is <NA>
called <NA>
human <NA>
T-cell <NA>
lymphoma-leukemia <NA>
virus <NA>
Type <NA>
1, <NA>
or <NA>
HTLV-I. <NA>
Satyakam <NA>
Bhagavati <NA>
of_the_<ORGANIZATION>State_University_of_New_York_Health_Science_Center </PERSON>
in <NA>
Brooklyn <LOCATION>
. <NA>
It <NA>
was <NA>
published <NA>
in <NA>
the <NA>
New_England_Journal_of_Medicine <ORGANIZATION>
. <NA>
Health <NA>
experts <NA>
say <NA>
HTLV-I <NA>
is <NA>
spreading <NA>
among <NA>
drug <NA>
addicts <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
Clusters <NA>
of <NA>
chronic <NA>
progressive <NA>
myelopathy <NA>
occur <NA>
in <NA>
tropical <NA>
parts <NA>
of <NA>
the <NA>
world, <NA>
including <NA>
the <NA>
Caribbean <LOCATION>
, <NA>
where <NA>
the <NA>
virus <NA>
is <NA>
also <NA>
relatively <NA>
common. <NA>
Bruce_J._Brew <PERSON>
and <NA>
Richard_W._Price_of_Memorial_Sloan-Kettering_Cancer_Center <ORGANIZATION>
in <NA>
New_York <LOCATION>
said <NA>
it's <NA>
puzzling <NA>
why <NA>
the <NA>
disease <NA>
is <NA>
rare <NA>
even <NA>
where <NA>
the <NA>
virus <NA>
is <NA>
widespread. <NA>
SJMN91-06307182 <DOCNO>
Samuel <NA>
Broder <NA>
,_<ORGANIZATION>National_Cancer_Institute_director. </PERSON>
; <NA>
"This <NA>
is <NA>
potentially <NA>
very <NA>
important <NA>
for <NA>
gene <NA>
therapy <NA>
for <NA>
dozens <NA>
of <NA>
diseases," <NA>
said <NA>
the <NA>
NCI <ORGANIZATION>
immunologist <NA>
who <NA>
last <NA>
year <NA>
became <NA>
the <NA>
first <NA>
physician <NA>
to <NA>
use <NA>
gene <NA>
therapy <NA>
to <NA>
treat <NA>
patients <NA>
-- <NA>
two <NA>
children <NA>
suffering <NA>
from <NA>
a <NA>
lethal <NA>
immune <NA>
system <NA>
disease <NA>
known <NA>
as <NA>
adenisine <NA>
deaminase <NA>
deficiency. <NA>
; <NA>
It <NA>
was <NA>
not <NA>
announced <NA>
in <NA>
a <NA>
scientific <NA>
journal <NA>
but <NA>
by <NA>
a <NA>
for-profit <NA>
company <NA>
that <NA>
kept <NA>
quiet <NA>
about <NA>
its <NA>
work <NA>
until <NA>
it <NA>
had <NA>
obtained <NA>
U.S. <LOCATION>
patents <NA>
on <NA>
the <NA>
process <NA>
of <NA>
isolating <NA>
the <NA>
stem <NA>
cell <NA>
and <NA>
on <NA>
the <NA>
cell <NA>
itself. <NA>
; <NA>
Ethical <NA>
questions; <NA>
By <NA>
patenting <NA>
the <NA>
bone <NA>
marrow <NA>
stem <NA>
cell, <NA>
Systemix <ORGANIZATION>
"introduces <NA>
us <NA>
into <NA>
a <NA>
new <NA>
era <NA>
of <NA>
ethical <NA>
problems <NA>
in <NA>
medicine," <NA>
said <NA>
Peter <NA>
Quesenberry <NA>
,_vice_president_of_medical_and_scientific_affairs_of_the_<ORGANIZATION>Leukemia_Society_of_America </PERSON>
. <NA>
"; <NA>
Systemix <ORGANIZATION>
plans <NA>
clinical <NA>
trials <NA>
to <NA>
test <NA>
bone <NA>
marrow <NA>
stem <NA>
cell <NA>
therapy <NA>
in <NA>
people <NA>
early <NA>
next <NA>
year. <NA>
WSJ870722-0113 <DOCNO>
"For <NA>
the <NA>
first <NA>
time, <NA>
we <NA>
are <NA>
able <NA>
to <NA>
regulate <NA>
blood <NA>
cells," <NA>
says <NA>
David_Golde <PERSON>
, <NA>
a <NA>
researcher <NA>
at <NA>
the <NA>
University_of_California <ORGANIZATION>
in <NA>
Los_Angeles <LOCATION>
. <NA>
But <NA>
preliminary <NA>
reports <NA>
on <NA>
the <NA>
drugs, <NA>
including <NA>
one <NA>
expected <NA>
to <NA>
appear <NA>
soon <NA>
in <NA>
the <NA>
New_England_Journal_of_Medicine <ORGANIZATION>
, <NA>
show <NA>
they <NA>
bolster <NA>
certain <NA>
kinds <NA>
of <NA>
white <NA>
blood <NA>
cells <NA>
with <NA>
remarkable <NA>
consistency. <NA>
Jerome_Groopman <PERSON>
, <NA>
a <NA>
researcher <NA>
at <NA>
New_England_Deaconess_Hospital <ORGANIZATION>
in <NA>
Boston <LOCATION>
, <NA>
says, <NA>
"Preliminary <NA>
trials <NA>
indicate <NA>
that <NA>
the <NA>
CSFs <NA>
are <NA>
the <NA>
most <NA>
exciting <NA>
and <NA>
promising" <NA>
of <NA>
biotechnology's <NA>
immune-system <NA>
modifiers, <NA>
which <NA>
include <NA>
much-touted <NA>
drugs <NA>
like <NA>
interferon <NA>
and <NA>
interleukin-2. <NA>
And <NA>
compared <NA>
with <NA>
drugs <NA>
like <NA>
interferon, <NA>
which <NA>
have <NA>
broad <NA>
actions <NA>
that <NA>
are <NA>
difficult <NA>
to <NA>
register, <NA>
"CSFs <NA>
have <NA>
very <NA>
direct <NA>
effects <NA>
that <NA>
make <NA>
it <NA>
easy <NA>
to <NA>
devise <NA>
clinical <NA>
trials <NA>
needed <NA>
to <NA>
get <NA>
them <NA>
approved" <NA>
for <NA>
marketing, <NA>
says <NA>
Stuart_Weisbrod <PERSON>
, <NA>
an <NA>
analyst <NA>
with <NA>
Prudential-Bache_Securities_Inc <ORGANIZATION>
. <NA>
Two <NA>
of <NA>
the <NA>
new <NA>
drugs <NA>
are <NA>
in <NA>
clinical <NA>
trials: <NA>
GM-CSF, <NA>
made <NA>
by <NA>
both <NA>
Genetics_Institute_Inc. <ORGANIZATION>
and <NA>
Immunex_Corp. <ORGANIZATION>
, <NA>
which <NA>
promotes <NA>
infection-fighting <NA>
cells <NA>
called <NA>
granulocytes <NA>
and <NA>
macrophages; <NA>
and <NA>
GCSF <ORGANIZATION>
, <NA>
made <NA>
by <NA>
Amgen_Corp. <ORGANIZATION>
, <NA>
which <NA>
boosts <NA>
granulocytes. <NA>
EPO, <NA>
made <NA>
by <NA>
both <NA>
Amgen <ORGANIZATION>
and <NA>
Genetics_Institute <ORGANIZATION>
, <NA>
boosts <NA>
oxygen-carrying <NA>
red <NA>
blood <NA>
cells <NA>
and <NA>
also <NA>
has <NA>
proved <NA>
very <NA>
promising <NA>
in <NA>
early <NA>
clinical <NA>
trials. <NA>
To <NA>
get <NA>
marketing <NA>
approval <NA>
for <NA>
the <NA>
drugs, <NA>
"I <NA>
think <NA>
it <NA>
will <NA>
only <NA>
be <NA>
necessary <NA>
to <NA>
show <NA>
reduced <NA>
morbidity <NA>
from <NA>
infections <NA>
rather <NA>
than <NA>
from <NA>
cancer," <NA>
says <NA>
Jordan_Gutterman <PERSON>
, <NA>
a <NA>
cancer <NA>
researcher <NA>
testing <NA>
GM-CSF <NA>
at <NA>
Houston <LOCATION>
's <NA>
A <NA>
spokesman <NA>
for <NA>
the <NA>
Food_and_Drug_Administration <ORGANIZATION>
says <NA>
it's <NA>
too <NA>
early <NA>
to <NA>
comment <NA>
on <NA>
possible <NA>
standards <NA>
to <NA>
be <NA>
applied <NA>
to <NA>
CSFs. <NA>
Ironically, <NA>
three <NA>
of <NA>
18 <NA>
patients <NA>
in <NA>
an <NA>
AIDS <NA>
study <NA>
reported <NA>
in <NA>
May <DATE>
developed <NA>
signs <NA>
of <NA>
infection <NA>
by <NA>
a <NA>
tuberculosis-like <NA>
bacteria <NA>
after <NA>
taking <NA>
GM-CSF. <NA>
Boston <LOCATION>
's <NA>
Golde <NA>
,_the_<ORGANIZATION>UCLA </PERSON>
researcher, <NA>
who <NA>
is <NA>
working <NA>
with <NA>
GM-CSF. <NA>
Last <NA>
year, <NA>
for <NA>
example, <NA>
Genetics_Institute <ORGANIZATION>
scientists <NA>
identified <NA>
a <NA>
new <NA>
member <NA>
of <NA>
the <NA>
CSF <NA>
family <NA>
called <NA>
interleukin-3, <NA>
or <NA>
IL-3, <NA>
which <NA>
apparently <NA>
affects <NA>
a <NA>
broad <NA>
range <NA>
of <NA>
cells <NA>
and <NA>
may <NA>
amplify <NA>
effects <NA>
of <NA>
other <NA>
CSFs. <NA>
"When <NA>
granulocytes <NA>
sense <NA>
bacteria, <NA>
they <NA>
get <NA>
very <NA>
angry <NA>
and <NA>
dump <NA>
out <NA>
a <NA>
toxic <NA>
substance <NA>
that's <NA>
essentially <NA>
like <NA>
bleach," <NA>
says <NA>
Robert_Kamen <PERSON>
, <NA>
Genetics_Institute <ORGANIZATION>
's <NA>
senior <NA>
vice <NA>
president, <NA>
scientific <NA>
affairs. <NA>
In <NA>
test-tube <NA>
studies, <NA>
the <NA>
drug <NA>
has <NA>
converted <NA>
leukemia <NA>
cancer <NA>
cells <NA>
that <NA>
are <NA>
multiplying <NA>
out <NA>
of <NA>
control <NA>
into <NA>
normal <NA>
cells, <NA>
says <NA>
Philip_Whitcome <PERSON>
, <NA>
Amgen <ORGANIZATION>
's <NA>
director <NA>
of <NA>
strategic <NA>
planning. <NA>
Christopher_Henney <PERSON>
, <NA>
Immunex <ORGANIZATION>
's <NA>
scientific <NA>
director, <NA>
says <NA>
the <NA>
company <NA>
hopes <NA>
the <NA>
combination <NA>
will <NA>
help <NA>
offset <NA>
cancer <NA>
patients' <NA>
immune <NA>
suppression <NA>
from <NA>
radiation <NA>
treatments. <NA>
AP900215-0131 <DOCNO>
Here <NA>
are <NA>
some <NA>
developments <NA>
on <NA>
the <NA>
health <NA>
front <NA>
Thursday <DATE>
: <NA>
Here <NA>
are <NA>
some <NA>
developments <NA>
on <NA>
the <NA>
health <NA>
front <NA>
Thursday <DATE>
: <NA>
Here <NA>
are <NA>
some <NA>
developments <NA>
on <NA>
the <NA>
health <NA>
front <NA>
Thursday <DATE>
: <NA>
Here <NA>
are <NA>
some <NA>
developments <NA>
on <NA>
the <NA>
health <NA>
front <NA>
Thursday <DATE>
: <NA>
Here <NA>
are <NA>
some <NA>
developments <NA>
on <NA>
the <NA>
health <NA>
front <NA>
Thursday <DATE>
: <NA>
WSJ900801-0140 <DOCNO>
It <NA>
would <NA>
also <NA>
clear <NA>
the <NA>
way <NA>
for <NA>
Schering-Plough_Corp. <ORGANIZATION>
to <NA>
market <NA>
the <NA>
biotechnology <NA>
product <NA>
for <NA>
a <NA>
form <NA>
of <NA>
the <NA>
disease <NA>
which <NA>
is <NA>
formally <NA>
known <NA>
as <NA>
chronic <NA>
non-A, <NA>
non-B <NA>
hepatitis. <NA>
A <NA>
virus <NA>
responsible <NA>
for <NA>
about <NA>
85% <PERCENT>
of <NA>
such <NA>
cases <NA>
was <NA>
recently <NA>
identified <NA>
and <NA>
dubbed <NA>
hepatitis <NA>
C, <NA>
making <NA>
antibody <NA>
testing <NA>
possible. <NA>
World-wide, <NA>
the <NA>
number <NA>
of <NA>
cases <NA>
of <NA>
the <NA>
disease <NA>
is <NA>
increasing <NA>
and <NA>
has <NA>
assumed <NA>
"epidemic" <NA>
proportions <NA>
in <NA>
Japan <LOCATION>
, <NA>
according <NA>
to <NA>
Robert_J._Spiegel <PERSON>
, <NA>
a <NA>
Schering <ORGANIZATION>
vice <NA>
president <NA>
of <NA>
clinical <NA>
research. <NA>
Schering <ORGANIZATION>
, <NA>
based <NA>
in <NA>
Kenilworth <LOCATION>
, <NA>
N.J. <LOCATION>
, <NA>
said <NA>
it <NA>
was <NA>
"immensely <NA>
pleased" <NA>
by <NA>
yesterday's <NA>
action, <NA>
which <NA>
virtually <NA>
ensures <NA>
a <NA>
much <NA>
broader <NA>
market <NA>
for <NA>
interferon. <NA>
In <NA>
New_York_Stock_Exchange <ORGANIZATION>
composite <NA>
trading, <NA>
Schering <ORGANIZATION>
closed <NA>
at <NA>
$48.875 <MONEY>
, <NA>
up <NA>
37.5_cents <MONEY>
. <NA>
To <NA>
win <NA>
the <NA>
panel's <NA>
approval, <NA>
Schering <ORGANIZATION>
scientists <NA>
presented <NA>
data <NA>
on <NA>
more <NA>
than <NA>
300 <NA>
patients, <NA>
showing <NA>
that <NA>
liver <NA>
inflammation <NA>
subsided <NA>
in <NA>
53% <PERCENT>
of <NA>
the <NA>
patients <NA>
treated <NA>
with <NA>
alpha <NA>
interferon, <NA>
as <NA>
opposed <NA>
to <NA>
7% <PERCENT>
of <NA>
untreated <NA>
patients. <NA>
Conversely, <NA>
16% <PERCENT>
of <NA>
the <NA>
untreated <NA>
control <NA>
group <NA>
worsened <NA>
during <NA>
the <NA>
study, <NA>
compared <NA>
with <NA>
2% <PERCENT>
of <NA>
the <NA>
treated <NA>
group. <NA>
"These <NA>
are <NA>
impressive <NA>
data," <NA>
said <NA>
Jordan_Gutterman <PERSON>
, <NA>
a <NA>
panel <NA>
member <NA>
and <NA>
a <NA>
pioneer <NA>
interferon <NA>
researcher <NA>
at <NA>
the <NA>
To <NA>
date, <NA>
interferon <NA>
has <NA>
received <NA>
approval <NA>
for <NA>
use <NA>
in <NA>
a <NA>
rare <NA>
cancer <NA>
known <NA>
as <NA>
hairy-cell <NA>
leukemia, <NA>
which <NA>
affects <NA>
about <NA>
2,500 <NA>
people <NA>
in <NA>
the <NA>
U.S. <LOCATION>
, <NA>
and <NA>
in <NA>
Kaposi <LOCATION>
's <NA>
Sarcoma <LOCATION>
, <NA>
an <NA>
AIDS-related <NA>
malignancy <NA>
with <NA>
a <NA>
roughly <NA>
equal <NA>
number <NA>
of <NA>
patients, <NA>
Schering <ORGANIZATION>
said. <NA>
The <NA>
FDA <ORGANIZATION>
has <NA>
also <NA>
approved <NA>
its <NA>
use <NA>
in <NA>
treating <NA>
genital <NA>
warts. <NA>
But <NA>
analysts <NA>
said <NA>
FDA <ORGANIZATION>
approval <NA>
for <NA>
chronic <NA>
non-A, <NA>
non-B <NA>
hepatitis <NA>
would <NA>
expand <NA>
its <NA>
potential <NA>
market <NA>
at <NA>
least <NA>
five-fold. <NA>
"We <NA>
see <NA>
this <NA>
as <NA>
adding <NA>
another <NA>
$100_million <MONEY>
to <NA>
Schering <ORGANIZATION>
's <NA>
annual <NA>
interferon <NA>
sales," <NA>
doubling <NA>
last <NA>
year's <NA>
level, <NA>
said <NA>
Michael_Sorell <PERSON>
, <NA>
an <NA>
analyst <NA>
with <NA>
Morgan_Stanley <ORGANIZATION>
in <NA>
New_York <LOCATION>
. <NA>
Sorell <NA>
predicted_<MONEY>$300_million </PERSON>
to <NA>
$400_million <MONEY>
in <NA>
sales <NA>
"looks <NA>
readily <NA>
achievable" <NA>
by <NA>
1993 <DATE>
to <NA>
1994 <DATE>
. <NA>
In <NA>
the <NA>
evolution <NA>
of <NA>
biotechnology, <NA>
Schering <ORGANIZATION>
's <NA>
Interferon <NA>
was <NA>
touted <NA>
in <NA>
the <NA>
1970s <DATE>
as <NA>
a <NA>
panacea, <NA>
only <NA>
to <NA>
prove <NA>
disappointing <NA>
and <NA>
only <NA>
narrowly <NA>
useful <NA>
at <NA>
first. <NA>
" <NA>
On <NA>
Monday <DATE>
, <NA>
an <NA>
FDA <ORGANIZATION>
panel <NA>
withheld <NA>
approval <NA>
from <NA>
interleukin-2 <NA>
as <NA>
a <NA>
treatment <NA>
for <NA>
kidney <NA>
cancer, <NA>
demanding <NA>
additional <NA>
information <NA>
from <NA>
its <NA>
maker, <NA>
Cetus_Corp. <ORGANIZATION>
of <NA>
Emeryville <LOCATION>
, <NA>
Calif <LOCATION>
. <NA>
In <NA>
a <NA>
separate <NA>
action, <NA>
the <NA>
FDA <ORGANIZATION>
advisory <NA>
panel <NA>
recommended <NA>
that <NA>
the <NA>
agency <NA>
grant <NA>
Treatment <NA>
IND <NA>
(investigational <NA>
new <NA>
drug) <NA>
status <NA>
to <NA>
Immunex_Corp. <ORGANIZATION>
's <NA>
GM-CSF <NA>
product. <NA>
However, <NA>
the <NA>
panel <NA>
asked <NA>
Seattle-based <NA>
Immunex <ORGANIZATION>
for <NA>
more <NA>
study <NA>
data <NA>
before <NA>
making <NA>
a <NA>
formal <NA>
recommendation <NA>
to <NA>
the <NA>
FDA <ORGANIZATION>
on <NA>
market <NA>
approval. <NA>
AP901119-0032 <DOCNO>
Michael_Sancilio <PERSON>
of <NA>
Virginia_Beach <LOCATION>
left <NA>
Johns_Hopkins_Hospital <ORGANIZATION>
in <NA>
Baltimore <LOCATION>
on <NA>
Saturday <DATE>
three <NA>
months <NA>
after <NA>
becoming <NA>
the <NA>
first <NA>
leukemia <NA>
patient <NA>
to <NA>
undergo <NA>
the <NA>
experimental <NA>
transplant. <NA>
``Although <NA>
doctors <NA>
are <NA>
reluctant <NA>
to <NA>
say <NA>
Michael <PERSON>
is <NA>
cured, <NA>
Michael <PERSON>
appears <NA>
to <NA>
have <NA>
defeated <NA>
a <NA>
rare <NA>
form <NA>
of <NA>
leukemia <NA>
for <NA>
which <NA>
previously <NA>
existed <NA>
no <NA>
known <NA>
cure,'' <NA>
Virginia_BEach_General_Hospital <ORGANIZATION>
said <NA>
in <NA>
a <NA>
statement. <NA>
Doctors <NA>
there <NA>
had <NA>
collected <NA>
so-called <NA>
stem <NA>
cells <NA>
from <NA>
his <NA>
sister's <NA>
umbilical <NA>
cord <NA>
for <NA>
transplant <NA>
in <NA>
Baltimore <LOCATION>
. <NA>
Doctors <NA>
gave <NA>
Michael <PERSON>
five <NA>
tablespoons <NA>
of <NA>
the <NA>
blood. <NA>
Leslie <NA>
Wasserman <NA>
Jr. <NA>
said_<DATE>Sunday </PERSON>
. <NA>
``God <NA>
deserves <NA>
all <NA>
the <NA>
credit,'' <NA>
said <NA>
Michael <PERSON>
's <NA>
grandmother, <NA>
Rachel_Sancilio <PERSON>
. <NA>
'' <NA>
Umbilical <NA>
cord <NA>
blood <NA>
transplants <NA>
have <NA>
been <NA>
performed <NA>
three <NA>
other <NA>
times, <NA>
once <NA>
in <NA>
Cincinnati <LOCATION>
and <NA>
twice <NA>
in <NA>
France <LOCATION>
, <NA>
to <NA>
treat <NA>
a <NA>
different <NA>
disease, <NA>
Fanconi <ORGANIZATION>
's <NA>
anemia. <NA>
Eight <NA>
months <NA>
ago, <NA>
Michael <PERSON>
was <NA>
diagnosed <NA>
with <NA>
a <NA>
form <NA>
known <NA>
as <NA>
chronic <NA>
myelogenous <NA>
leukemia, <NA>
which <NA>
cannot <NA>
be <NA>
controlled <NA>
with <NA>
drugs <NA>
and <NA>
usually <NA>
kills <NA>
within <NA>
a <NA>
year <NA>
of <NA>
diagnosis. <NA>
The <NA>
boy's <NA>
sister, <NA>
Christina <PERSON>
, <NA>
was <NA>
born <NA>
May_1 <DATE>
. <NA>
Michael <PERSON>
's <NA>
blood <NA>
type <NA>
did <NA>
not <NA>
match <NA>
hers, <NA>
but <NA>
the <NA>
siblings <NA>
were <NA>
otherwise <NA>
compatible, <NA>
and <NA>
doctors <NA>
found <NA>
that <NA>
he <NA>
was <NA>
not <NA>
overly <NA>
likely <NA>
to <NA>
reject <NA>
the <NA>
umbilical <NA>
cord <NA>
blood. <NA>
Because <NA>
of <NA>
the <NA>
procedure, <NA>
Michael <PERSON>
has <NA>
``another <NA>
chance <NA>
at <NA>
life'' <NA>
- <NA>
and <NA>
a <NA>
new <NA>
blood <NA>
type, <NA>
the <NA>
hospital <NA>
said. <NA>
AP881104-0025 <DOCNO>
The <NA>
$7_million <MONEY>
study, <NA>
funded <NA>
by <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
, <NA>
is <NA>
intended <NA>
to <NA>
determine <NA>
whether <NA>
people <NA>
living <NA>
downwind <NA>
of <NA>
above-ground <NA>
atomic <NA>
bomb <NA>
tests <NA>
in <NA>
Nevada <LOCATION>
in <NA>
the <NA>
1950s <DATE>
and <NA>
1960s <DATE>
suffered <NA>
an <NA>
increased <NA>
rate <NA>
of <NA>
cancer. <NA>
Walter <NA>
Stevens <NA>
,_interim_dean_of_the_<ORGANIZATION>University_of_Utah_Medical_School </PERSON>
and <NA>
director <NA>
of <NA>
the <NA>
study. <NA>
However, <NA>
he <NA>
said <NA>
Thursday <DATE>
there <NA>
is <NA>
``no <NA>
strong <NA>
evidence <NA>
that <NA>
would <NA>
convince <NA>
me <NA>
... <NA>
that <NA>
there <NA>
was <NA>
a <NA>
relationship'' <NA>
between <NA>
fallout <NA>
and <NA>
disease. <NA>
Stevens <PERSON>
emphasized <NA>
that <NA>
epidemiological <NA>
findings <NA>
still <NA>
are <NA>
being <NA>
analyzed <NA>
and <NA>
that <NA>
no <NA>
final <NA>
conclusions <NA>
would <NA>
be <NA>
drawn <NA>
until <NA>
a <NA>
draft <NA>
report <NA>
had <NA>
been <NA>
reviewed <NA>
by <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
. <NA>
The <NA>
draft <NA>
likely <NA>
will <NA>
be <NA>
delivered <NA>
to <NA>
NCI <ORGANIZATION>
by <NA>
mid-November <NA>
and <NA>
the <NA>
finished <NA>
report <NA>
released <NA>
next <NA>
March <DATE>
, <NA>
he <NA>
said. <NA>
For <NA>
years, <NA>
people <NA>
living <NA>
in <NA>
southwestern <NA>
Utah <LOCATION>
, <NA>
southeastern <NA>
Nevada <LOCATION>
and <NA>
northeastern <NA>
Arizona <LOCATION>
have <NA>
feared <NA>
that <NA>
exposure <NA>
to <NA>
about <NA>
80 <NA>
open-air <NA>
tests <NA>
at <NA>
the <NA>
Nevada <LOCATION>
Test <NA>
Site <NA>
had <NA>
increased <NA>
the <NA>
potential <NA>
for <NA>
leukemia <NA>
and <NA>
thyroid <NA>
cancers. <NA>
In <NA>
1979 <DATE>
, <NA>
Joseph <NA>
L. <NA>
Lyon <NA>
,_an_<ORGANIZATION>University_of_Utah </PERSON>
epidemiologist <NA>
who <NA>
is <NA>
working <NA>
on <NA>
the <NA>
current <NA>
study, <NA>
published <NA>
a <NA>
paper <NA>
showing <NA>
a <NA>
2.4-fold <NA>
increase <NA>
in <NA>
childhood <NA>
leukemia <NA>
in <NA>
the <NA>
areas <NA>
of <NA>
southern <NA>
Utah <LOCATION>
heavily <NA>
dusted <NA>
by <NA>
fallout. <NA>
In <NA>
1982 <DATE>
, <NA>
U.S. <LOCATION>
District <NA>
Judge_Bruce_Jenkins <PERSON>
ruled <NA>
the <NA>
government <NA>
had <NA>
failed <NA>
to <NA>
warn <NA>
residents <NA>
of <NA>
radiation <NA>
hazards. <NA>
Researchers <NA>
located <NA>
the <NA>
names <NA>
of <NA>
1,177 <NA>
people <NA>
from <NA>
all <NA>
over <NA>
Utah <LOCATION>
who <NA>
had <NA>
died <NA>
of <NA>
leukemia <NA>
between <NA>
1952 <DATE>
and <NA>
1966 <DATE>
and <NA>
selected <NA>
as <NA>
controls <NA>
another <NA>
5,600 <NA>
people <NA>
who <NA>
had <NA>
died <NA>
of <NA>
other <NA>
causes. <NA>
The <NA>
subjects <NA>
were <NA>
matched <NA>
where <NA>
possible <NA>
in <NA>
age, <NA>
residence, <NA>
health <NA>
and <NA>
lifestyle <NA>
to <NA>
ensure <NA>
valid <NA>
comparisons, <NA>
Stevens <PERSON>
said. <NA>
In <NA>
the <NA>
thyroid <NA>
study, <NA>
2,829 <NA>
subjects <NA>
in <NA>
southern <NA>
Utah <LOCATION>
, <NA>
southeastern <NA>
Nevada <LOCATION>
and <NA>
southern <NA>
Arizona <LOCATION>
were <NA>
identified <NA>
as <NA>
having <NA>
been <NA>
exposed, <NA>
and <NA>
about <NA>
280 <NA>
were <NA>
found <NA>
to <NA>
have <NA>
thyroid <NA>
abnormalities. <NA>
Stevens <PERSON>
said <NA>
the <NA>
research <NA>
has <NA>
been <NA>
greatly <NA>
aided <NA>
by <NA>
the <NA>
release <NA>
of <NA>
previously <NA>
classified <NA>
information <NA>
from <NA>
the <NA>
Department_of_Energy <ORGANIZATION>
on <NA>
the <NA>
amount <NA>
of <NA>
radiation <NA>
emitted <NA>
by <NA>
the <NA>
tests. <NA>
Stevens <PERSON>
said <NA>
the <NA>
study <NA>
could <NA>
prove <NA>
to <NA>
be <NA>
a <NA>
milestone <NA>
in <NA>
research <NA>
on <NA>
the <NA>
effects <NA>
of <NA>
exposure <NA>
to <NA>
radiation, <NA>
with <NA>
particular <NA>
significance <NA>
to <NA>
safety <NA>
concerns <NA>
at <NA>
the <NA>
nation's <NA>
nuclear <NA>
production <NA>
plants. <NA>
AP880607-0013 <DOCNO>
The <NA>
Food_and_Drug_Administration <ORGANIZATION>
announced <NA>
Monday <DATE>
that <NA>
it <NA>
has <NA>
OK'd <NA>
direct <NA>
injection <NA>
of <NA>
genetically <NA>
engineered <NA>
alpha <NA>
interferon <NA>
into <NA>
the <NA>
warts. <NA>
The <NA>
FDA <ORGANIZATION>
said <NA>
a <NA>
study <NA>
of <NA>
192 <NA>
patients <NA>
showed <NA>
they <NA>
exhibited <NA>
marked <NA>
improvement <NA>
after <NA>
receiving <NA>
interferon <NA>
injections <NA>
three <NA>
times <NA>
a <NA>
week <NA>
for <NA>
up <NA>
to <NA>
three <NA>
weeks. <NA>
Of <NA>
the <NA>
192, <NA>
42_percent <PERCENT>
experienced <NA>
complete <NA>
clearing <NA>
of <NA>
all <NA>
their <NA>
treated <NA>
warts, <NA>
24_percent <PERCENT>
had <NA>
a <NA>
75_percent <PERCENT>
to <NA>
99_percent <PERCENT>
reduction <NA>
in <NA>
the <NA>
size <NA>
of <NA>
their <NA>
treated <NA>
warts <NA>
and <NA>
18_percent <PERCENT>
had <NA>
a <NA>
50_percent <PERCENT>
to <NA>
74_percent <PERCENT>
reduction <NA>
in <NA>
the <NA>
size <NA>
of <NA>
their <NA>
treated <NA>
warts, <NA>
the <NA>
FDA <ORGANIZATION>
said. <NA>
Alpha <NA>
interferon <NA>
was <NA>
first <NA>
approved <NA>
in <NA>
June_1986 <DATE>
as <NA>
a <NA>
treatment <NA>
for <NA>
hairy <NA>
cell <NA>
leukemia <NA>
_ <NA>
a <NA>
rare <NA>
form <NA>
of <NA>
leukemia. <NA>
Schering_Corp. <ORGANIZATION>
of <NA>
Kenilworth <LOCATION>
, <NA>
N.J. <LOCATION>
, <NA>
will <NA>
market <NA>
the <NA>
alpha <NA>
interferon <NA>
treatment <NA>
under <NA>
the <NA>
Intron-A <NA>
brand <NA>
name. <NA>
AP900809-0001 <DOCNO>
A <NA>
leukemia <NA>
patient <NA>
whose <NA>
plight <NA>
prompted <NA>
50,000 <NA>
people <NA>
to <NA>
step <NA>
forward <NA>
as <NA>
possible <NA>
bone-marrow <NA>
donors <NA>
will <NA>
undergo <NA>
a <NA>
transplant <NA>
of <NA>
bone <NA>
marrow <NA>
from <NA>
her <NA>
mother <NA>
Thursday <DATE>
, <NA>
a <NA>
hospital <NA>
spokeswoman <NA>
said <NA>
Wednesday <DATE>
. <NA>
The <NA>
operation <NA>
on <NA>
Allison_Atlas <PERSON>
, <NA>
20, <NA>
is <NA>
expected <NA>
to <NA>
take <NA>
at <NA>
least <NA>
four <NA>
hours <NA>
and <NA>
could <NA>
last <NA>
six <NA>
hours <NA>
or <NA>
more, <NA>
said <NA>
Fred_Hutchinson_Cancer_Research_Center <ORGANIZATION>
spokeswoman <NA>
Alice_Burgess <PERSON>
. <NA>
Doctors <NA>
are <NA>
scheduled <NA>
to <NA>
extract <NA>
the <NA>
marrow <NA>
from <NA>
Miss_Atlas <LOCATION>
' <NA>
mother <NA>
at <NA>
9_a.m. <TIME>
, <NA>
the <NA>
spokeswoman <NA>
said. <NA>
But <NA>
the <NA>
New_York_University <ORGANIZATION>
student <NA>
from <NA>
Bethesda <LOCATION>
, <NA>
Md. <LOCATION>
, <NA>
decided <NA>
to <NA>
undergo <NA>
the <NA>
operation <NA>
while <NA>
she <NA>
is <NA>
still <NA>
strong <NA>
enough. <NA>
She <NA>
began <NA>
chemotherapy <NA>
July_31 <DATE>
, <NA>
and <NA>
has <NA>
responded <NA>
well, <NA>
Burgess <PERSON>
said. <NA>
Doctors <NA>
said <NA>
a <NA>
patient <NA>
with <NA>
Miss_Atlas <PERSON>
' <NA>
type <NA>
of <NA>
leukemia <NA>
can <NA>
expect <NA>
a <NA>
60_percent <PERCENT>
chance <NA>
of <NA>
recovery <NA>
if <NA>
the <NA>
transplant <NA>
marrow <NA>
is <NA>
perfectly <NA>
matched. <NA>
They <NA>
were <NA>
unsuccessful, <NA>
but <NA>
the <NA>
effort <NA>
raised <NA>
$3_million <MONEY>
to <NA>
process <NA>
blood <NA>
samples <NA>
from <NA>
the <NA>
50,000 <NA>
people <NA>
in <NA>
the <NA>
United_States <LOCATION>
and <NA>
Israel <LOCATION>
who <NA>
volunteered. <NA>
SJMN91-06024248 <DOCNO>
; <NA>
The <NA>
cancer-causing <NA>
potential <NA>
of <NA>
dioxin <NA>
is <NA>
of <NA>
concern, <NA>
in <NA>
part, <NA>
because <NA>
it <NA>
was <NA>
a <NA>
contaminant <NA>
of <NA>
Agent <NA>
Orange, <NA>
a <NA>
tree-killing <NA>
chemical <NA>
used <NA>
widely <NA>
during <NA>
the <NA>
Vietnam <LOCATION>
War. <NA>
; <NA>
PARENTS' <NA>
SMOKING <NA>
LINKED <NA>
TO <NA>
CHILDREN'S <NA>
HEALTH <NA>
RISK; <NA>
Fathers <NA>
who <NA>
smoke <NA>
have <NA>
an <NA>
increased <NA>
risk <NA>
of <NA>
having <NA>
children <NA>
with <NA>
brain <NA>
cancer <NA>
and <NA>
leukemia, <NA>
suggesting <NA>
that <NA>
smoking <NA>
might <NA>
have <NA>
damaged <NA>
the <NA>
fathers' <NA>
sperm, <NA>
researchers <NA>
said <NA>
Wednesday. <DATE>
; <NA>
That <NA>
conclusion <NA>
is <NA>
speculative, <NA>
said <NA>
one <NA>
of <NA>
the <NA>
study's <NA>
authors, <NA>
Dale_P._Sandler <PERSON>
of <NA>
the <NA>
National_Institute_of_Environmental_Health_Sciences_in_Research_Triangle_Park <ORGANIZATION>
, <NA>
N.C <LOCATION>
. <NA>
; <NA>
"I <NA>
don't <NA>
think <NA>
anyone <NA>
before <NA>
has <NA>
demonstrated <NA>
that <NA>
the <NA>
association <NA>
is <NA>
not <NA>
just <NA>
for <NA>
mild <NA>
illnesses <NA>
but <NA>
for <NA>
really <NA>
serious <NA>
infections <NA>
as <NA>
well," <NA>
said <NA>
Anne_T._Berg <PERSON>
of <NA>
the <NA>
Yale_University_School_of_Medicine <ORGANIZATION>
, <NA>
the <NA>
principal <NA>
author <NA>
of <NA>
the <NA>
study. <NA>
; <NA>
But <NA>
creating <NA>
the <NA>
gene <NA>
is <NA>
still <NA>
"a <NA>
long <NA>
way <NA>
from <NA>
putting <NA>
it <NA>
into <NA>
a <NA>
patient," <NA>
cautioned <NA>
Louis_Kunkel <PERSON>
of <NA>
Children's_Hospital <ORGANIZATION>
in <NA>
Boston <LOCATION>
, <NA>
Harvard_Medical_School <ORGANIZATION>
and <NA>
the <NA>
Hughes <PERSON>
institute <NA>
there. <NA>
Yet <NA>
none <NA>
of <NA>
the <NA>
five <NA>
elderly <NA>
patients <NA>
reported <NA>
with <NA>
PCP <ORGANIZATION>
had <NA>
a <NA>
faulty <NA>
immune <NA>
system. <NA>
AP880429-0036 <DOCNO>
The <NA>
American_Red_Cross <ORGANIZATION>
is <NA>
``right <NA>
on <NA>
target'' <NA>
with <NA>
plans <NA>
to <NA>
start <NA>
testing <NA>
donated <NA>
blood <NA>
for <NA>
a <NA>
rare <NA>
virus <NA>
linked <NA>
to <NA>
a <NA>
vicious <NA>
form <NA>
of <NA>
adult <NA>
leukemia, <NA>
says <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
researcher <NA>
who <NA>
first <NA>
discovered <NA>
the <NA>
virus. <NA>
Dr. <NA>
Robert_Gallo <PERSON>
, <NA>
a <NA>
scientist <NA>
credited <NA>
with <NA>
discovering <NA>
the <NA>
human <NA>
T-lymphotropic <NA>
virus <NA>
type <NA>
1, <NA>
or <NA>
HTLV-1, <NA>
said <NA>
the <NA>
nation's <NA>
blood <NA>
supply <NA>
should <NA>
be <NA>
tested <NA>
to <NA>
protect <NA>
future <NA>
generations <NA>
from <NA>
the <NA>
slow-acting <NA>
but <NA>
dangerous <NA>
virus. <NA>
The <NA>
recommendation <NA>
was <NA>
made <NA>
after <NA>
a <NA>
Red_Cross <ORGANIZATION>
survey <NA>
found <NA>
10 <NA>
units <NA>
infected <NA>
with <NA>
the <NA>
virus <NA>
out <NA>
of <NA>
39,898 <NA>
units <NA>
tested. <NA>
``I <NA>
think <NA>
there <NA>
are <NA>
as <NA>
many <NA>
people <NA>
infected <NA>
with <NA>
this <NA>
virus <NA>
as <NA>
are <NA>
infected <NA>
with <NA>
the <NA>
AIDS <NA>
virus,'' <NA>
Gallo <PERSON>
said. <NA>
Alan_E._Williams <PERSON>
, <NA>
a <NA>
research <NA>
scientist <NA>
at <NA>
the <NA>
Red_Cross <ORGANIZATION>
laboratory <NA>
in <NA>
Rockville <LOCATION>
, <NA>
Md. <LOCATION>
, <NA>
said <NA>
his <NA>
research <NA>
team <NA>
estimates <NA>
that <NA>
the <NA>
risk <NA>
of <NA>
becoming <NA>
infected <NA>
with <NA>
the <NA>
HTLV-1 <NA>
leukemia <NA>
virus <NA>
is <NA>
about <NA>
2,800 <NA>
in <NA>
12 <NA>
million, <NA>
or <NA>
about <NA>
1 <NA>
chance <NA>
in <NA>
4,286 <NA>
for <NA>
every <NA>
unit <NA>
of <NA>
blood <NA>
transfused <NA>
annually. <NA>
``The <NA>
danger <NA>
is <NA>
minimal <NA>
but <NA>
not <NA>
insignificant,'' <NA>
Williams <PERSON>
said. <NA>
For <NA>
that <NA>
reason, <NA>
he <NA>
said, <NA>
the <NA>
Red_Cross <ORGANIZATION>
``wants <NA>
to <NA>
take <NA>
an <NA>
active <NA>
stance <NA>
to <NA>
keep <NA>
the <NA>
situation <NA>
from <NA>
getting <NA>
worse, <NA>
as <NA>
it <NA>
possibly <NA>
could. <NA>
'' <NA>
Williams <PERSON>
said <NA>
current <NA>
methods <NA>
of <NA>
testing <NA>
donated <NA>
blood <NA>
for <NA>
the <NA>
virus <NA>
take <NA>
up <NA>
to <NA>
three <NA>
days <NA>
and <NA>
a <NA>
more <NA>
practical <NA>
test <NA>
must <NA>
be <NA>
developed <NA>
before <NA>
HTLV-1 <NA>
screening <NA>
can <NA>
begin. <NA>
He <NA>
said <NA>
at <NA>
least <NA>
three <NA>
drug <NA>
companies, <NA>
which <NA>
he <NA>
declined <NA>
to <NA>
name, <NA>
are <NA>
trying <NA>
to <NA>
develop <NA>
screening <NA>
tests, <NA>
but <NA>
these <NA>
are <NA>
months <NA>
from <NA>
possible <NA>
approval <NA>
by <NA>
the <NA>
Food_and_Drug_Administration <ORGANIZATION>
. <NA>
The <NA>
NCI <ORGANIZATION>
researcher <NA>
discovered <NA>
and <NA>
identified <NA>
the <NA>
HTLV-1 <NA>
virus <NA>
in <NA>
1978 <DATE>
. <NA>
Gallo <PERSON>
said <NA>
his <NA>
understanding <NA>
of <NA>
HTLV-1, <NA>
a <NA>
retrovirus <NA>
that <NA>
takes <NA>
over <NA>
genetic <NA>
control <NA>
of <NA>
cells <NA>
it <NA>
attacks, <NA>
led <NA>
him <NA>
to <NA>
look <NA>
for <NA>
a <NA>
retrovirus <NA>
as <NA>
the <NA>
cause <NA>
of <NA>
AIDS. <NA>
Gallo <PERSON>
said <NA>
HTLV-1 <NA>
may <NA>
be <NA>
rare <NA>
in <NA>
the <NA>
continental <NA>
United_States <LOCATION>
, <NA>
but <NA>
it <NA>
is <NA>
endemic <NA>
in <NA>
parts <NA>
of <NA>
Europe <LOCATION>
, <NA>
Alaska <LOCATION>
, <NA>
Africa <LOCATION>
and <NA>
the <NA>
Orient <LOCATION>
. <NA>
``In <NA>
time, <NA>
due <NA>
to <NA>
increased <NA>
travel <NA>
and <NA>
increased <NA>
sexual <NA>
contact, <NA>
these <NA>
kinds <NA>
of <NA>
virus <NA>
are <NA>
all <NA>
increasing <NA>
(in <NA>
the <NA>
continental <NA>
U.S. <LOCATION>
),'' <NA>
said <NA>
Gallo <PERSON>
. <NA>
'' <NA>
Gallo <NA>
added, <NA>
``I'm <NA>
very <NA>
glad <NA>
to <NA>
see <NA>
the <NA>
way <NA>
the <NA>
Red_Cross <ORGANIZATION>
has <NA>
responded. <NA>
Edward <NA>
Murphy <NA>
,_a_<ORGANIZATION>National_Cancer_Institute </PERSON>
researcher <NA>
who <NA>
has <NA>
studied <NA>
the <NA>
HTLV-1 <NA>
virus <NA>
extensively, <NA>
said <NA>
it <NA>
is <NA>
linked <NA>
to <NA>
adult <NA>
T-cell <NA>
leukemia-lymphoma, <NA>
a <NA>
type <NA>
of <NA>
blood <NA>
cancer <NA>
usually <NA>
fatal <NA>
within <NA>
six <NA>
months. <NA>
Another <NA>
disease <NA>
closely <NA>
linked <NA>
to <NA>
the <NA>
virus, <NA>
said <NA>
Murphy <PERSON>
, <NA>
is <NA>
tropical <NA>
spastic <NA>
paraparesis, <NA>
in <NA>
which <NA>
the <NA>
virus <NA>
attacks <NA>
nerve <NA>
cells <NA>
that <NA>
control <NA>
the <NA>
lower <NA>
extremities <NA>
and <NA>
causes <NA>
paralysis <NA>
and <NA>
eventually <NA>
death. <NA>
The <NA>
incubation <NA>
period <NA>
for <NA>
expression <NA>
of <NA>
the <NA>
leukemia <NA>
is <NA>
thought <NA>
to <NA>
be <NA>
30 <NA>
years <NA>
or <NA>
more, <NA>
but <NA>
people <NA>
exposed <NA>
to <NA>
the <NA>
virus <NA>
become <NA>
infectious <NA>
within <NA>
two <NA>
weeks <NA>
to <NA>
six <NA>
months, <NA>
said <NA>
Murphy <PERSON>
. <NA>
HTLV-1 <NA>
also <NA>
is <NA>
thought <NA>
to <NA>
be <NA>
spread <NA>
through <NA>
mother's <NA>
milk, <NA>
said <NA>
Murphy <PERSON>
. <NA>
Williams <PERSON>
said <NA>
the <NA>
Red_Cross <ORGANIZATION>
survey <NA>
checked <NA>
for <NA>
HTLV-1 <NA>
in <NA>
samples <NA>
from <NA>
eight <NA>
different <NA>
blood <NA>
banks. <NA>
Blood <NA>
donors <NA>
who <NA>
tested <NA>
positive <NA>
for <NA>
the <NA>
virus <NA>
were <NA>
found <NA>
in <NA>
Atlanta <LOCATION>
, <NA>
Washington <LOCATION>
, <NA>
Birmingham <LOCATION>
, <NA>
Ala. <LOCATION>
and <NA>
Los_Angeles <LOCATION>
. <NA>
Paul <NA>
,_<LOCATION>Minn. </LOCATION>
, <NA>
Portland <LOCATION>
, <NA>
Ore. <LOCATION>
, <NA>
Baltimore <LOCATION>
and <NA>
Miami <LOCATION>
, <NA>
but <NA>
no <NA>
HTLV-1 <NA>
was <NA>
found. <NA>
Though <NA>
the <NA>
positive <NA>
tests <NA>
totaled <NA>
only <NA>
10 <NA>
out <NA>
of <NA>
more <NA>
than <NA>
39,000 <NA>
samples <NA>
tested, <NA>
Williams <PERSON>
said, <NA>
``a <NA>
highly <NA>
selective <NA>
group'' <NA>
was <NA>
used. <NA>
AP900928-0040 <DOCNO>
But <NA>
help <NA>
may <NA>
be <NA>
on <NA>
the <NA>
way, <NA>
according <NA>
to <NA>
a <NA>
study <NA>
published <NA>
today <DATE>
in <NA>
the <NA>
journal <NA>
Science. <NA>
Yunis <NA>
,_of_the_<ORGANIZATION>University_of_Miami_Jackson_Memorial_Hospital_Medical_Center </PERSON>
, <NA>
reports <NA>
that <NA>
he <NA>
and <NA>
his <NA>
colleagues <NA>
have <NA>
discovered <NA>
``by <NA>
chance'' <NA>
that <NA>
an <NA>
experimental <NA>
cancer <NA>
drug <NA>
blocks <NA>
hair <NA>
loss <NA>
in <NA>
laboratory <NA>
rats <NA>
injected <NA>
with <NA>
some <NA>
chemotherapy <NA>
agents. <NA>
They <NA>
lost <NA>
all <NA>
their <NA>
hair,'' <NA>
said <NA>
Yunis <PERSON>
. <NA>
ImuVert <NA>
combined <NA>
with <NA>
a <NA>
third <NA>
cancer <NA>
drug, <NA>
cyclophosphamide, <NA>
however, <NA>
did <NA>
not <NA>
prevent <NA>
hair <NA>
loss <NA>
in <NA>
the <NA>
rats, <NA>
said <NA>
Yunis <PERSON>
. <NA>
Dr. <NA>
Ed_Gelmann <PERSON>
, <NA>
chief <NA>
of <NA>
the <NA>
department <NA>
of <NA>
medical <NA>
oncology <NA>
at <NA>
Georgetown_University <ORGANIZATION>
in <NA>
Washington <LOCATION>
, <NA>
said <NA>
that <NA>
if <NA>
a <NA>
way <NA>
can <NA>
be <NA>
found <NA>
to <NA>
prevent <NA>
hair <NA>
loss <NA>
``patients <NA>
will <NA>
feel <NA>
much <NA>
better <NA>
about <NA>
chemotherapy. <NA>
He <NA>
said <NA>
the <NA>
drug <NA>
teamed <NA>
with <NA>
ARA-C <NA>
halted <NA>
the <NA>
progression <NA>
of <NA>
leukemia <NA>
in <NA>
all <NA>
but <NA>
20_percent <PERCENT>
of <NA>
the <NA>
laboratory <NA>
rats <NA>
tested. <NA>
Gregory <NA>
Curt <NA>
,_director_of_the_clinical_oncology_department_at_the_<ORGANIZATION>National_Cancer_Institute </PERSON>
, <NA>
said <NA>
controlling <NA>
hair <NA>
loss <NA>
during <NA>
chemotherapy <NA>
``is <NA>
a <NA>
very <NA>
serious <NA>
thing <NA>
for <NA>
patients. <NA>
``For <NA>
both <NA>
men <NA>
and <NA>
women, <NA>
it <NA>
is <NA>
one <NA>
of <NA>
the <NA>
side <NA>
effects <NA>
that <NA>
concerns <NA>
people <NA>
the <NA>
most <NA>
because <NA>
it <NA>
changes <NA>
one's <NA>
body <NA>
image,'' <NA>
said <NA>
Curt <PERSON>
. <NA>
He <NA>
said <NA>
ImuVert <ORGANIZATION>
is <NA>
a <NA>
drug <NA>
known <NA>
as <NA>
a <NA>
biological <NA>
response <NA>
modifier <NA>
because <NA>
it <NA>
alters <NA>
the <NA>
way <NA>
some <NA>
cells <NA>
in <NA>
the <NA>
immune <NA>
system <NA>
act. <NA>
If <NA>
the <NA>
precise <NA>
effect <NA>
of <NA>
this <NA>
drug <NA>
on <NA>
the <NA>
hair <NA>
follicles <NA>
could <NA>
be <NA>
identified, <NA>
then <NA>
new <NA>
drugs <NA>
with <NA>
this <NA>
action <NA>
could <NA>
be <NA>
developed, <NA>
said <NA>
Yunis <PERSON>
. <NA>
Science, <NA>
which <NA>
today <NA>
published <NA>
the <NA>
University <ORGANIZATION>
of <NA>
Miami <LOCATION>
research <NA>
report, <NA>
is <NA>
the <NA>
journal <NA>
of <NA>
the <NA>
American_Association <ORGANIZATION>
for <NA>
the <NA>
Advancement_of_Science <ORGANIZATION>
. <NA>
Coauthors <NA>
of <NA>
the <NA>
paper <NA>
with <NA>
Yunis <PERSON>
are <NA>
Atif_M._Hussein <PERSON>
and <NA>
Joaquin_J._Jimenez <PERSON>
of <NA>
the <NA>
University_of_Miami <ORGANIZATION>
, <NA>
and <NA>
Catherine_A._McCall <PERSON>
of <NA>
Cell_Technology_Inc <ORGANIZATION>
. <NA>
AP901008-0062 <DOCNO>
E. <NA>
Donnall <NA>
Thomas <NA>
,_who_blazed_a_new_path_for_the_treatment_of_leukemia_when_he_performed_the_first_human_bone_marrow_transplant_in_<DATE>1956 </PERSON>
, <NA>
said <NA>
today <DATE>
he <NA>
always <NA>
considered <NA>
the <NA>
Nobel <NA>
Prize <NA>
``a <NA>
long <NA>
shot <NA>
at <NA>
best. <NA>
'' <NA>
Thomas, <NA>
70, <NA>
of <NA>
Bellevue <LOCATION>
, <NA>
Wash. <LOCATION>
, <NA>
and <NA>
Joseph_E._Murray <PERSON>
, <NA>
71, <NA>
were <NA>
awarded <NA>
the <NA>
Nobel <NA>
Prize <NA>
in <NA>
medicine <NA>
today, <NA>
officials <NA>
in <NA>
Stockhom <LOCATION>
, <NA>
Sweden <LOCATION>
announced. <NA>
Murray, <NA>
affiliated <NA>
with <NA>
Brigham_and_Women's_Hospital <ORGANIZATION>
in <NA>
Boston <LOCATION>
, <NA>
was <NA>
recognized <NA>
for <NA>
his <NA>
discovery <NA>
of <NA>
a <NA>
method <NA>
to <NA>
prevent <NA>
tissue <NA>
rejection <NA>
when <NA>
organs <NA>
are <NA>
transplanted <NA>
in <NA>
people. <NA>
Thomas, <NA>
with <NA>
the <NA>
Fred_Hutchinson_Cancer_Research_Center <ORGANIZATION>
in <NA>
Seattle <LOCATION>
, <NA>
said <NA>
he <NA>
learned <NA>
of <NA>
the <NA>
good <NA>
news <NA>
when <NA>
awakened <NA>
by <NA>
a <NA>
reporter's <NA>
telephone <NA>
call <NA>
early <NA>
this_morning <TIME>
. <NA>
``I <NA>
really <NA>
thought <NA>
this <NA>
work <NA>
was <NA>
too <NA>
clinical <NA>
to <NA>
ever <NA>
win <NA>
the <NA>
prize,'' <NA>
Thomas <PERSON>
said. <NA>
'' <NA>
The <NA>
prize <NA>
shared <NA>
by <NA>
Murray <PERSON>
and <NA>
Thomas <PERSON>
, <NA>
worth <NA>
$695,000 <MONEY>
, <NA>
is <NA>
endowed <NA>
by <NA>
the <NA>
will <NA>
of <NA>
dynamite <NA>
inventor <NA>
Alfred_Nobel <PERSON>
, <NA>
who <NA>
died <NA>
in <NA>
1896 <DATE>
. <NA>
Thomas <PERSON>
said <NA>
he <NA>
hasn't <NA>
had <NA>
time <NA>
yet <NA>
to <NA>
think <NA>
of <NA>
what <NA>
he <NA>
will <NA>
do <NA>
with <NA>
the <NA>
money. <NA>
Thomas <PERSON>
, <NA>
who <NA>
took <NA>
after <NA>
his <NA>
father <NA>
and <NA>
fulfilled <NA>
his <NA>
childhood <NA>
desire <NA>
to <NA>
become <NA>
a <NA>
doctor, <NA>
performed <NA>
the <NA>
first <NA>
human <NA>
bone <NA>
marrow <NA>
transplant <NA>
in <NA>
Cooperstown <LOCATION>
, <NA>
N.Y. <LOCATION>
, <NA>
in <NA>
1956 <DATE>
. <NA>
Thomas <NA>
joined <NA>
the <NA>
University_of_Washington <ORGANIZATION>
faculty <NA>
in <NA>
1963 <DATE>
and <NA>
went <NA>
to <NA>
the <NA>
Hutchinson <PERSON>
center <NA>
when <NA>
it <NA>
opened <NA>
in <NA>
1975 <DATE>
. <NA>
It's <NA>
been <NA>
very <NA>
gratifying <NA>
to <NA>
see <NA>
the <NA>
procedure <NA>
become <NA>
accepted <NA>
as <NA>
the <NA>
primary <NA>
form <NA>
of <NA>
treatment <NA>
for <NA>
leukemia,'' <NA>
Thomas <PERSON>
said. <NA>
AP891128-0127 <DOCNO>
The <NA>
Food_and_Drug_Administration <ORGANIZATION>
is <NA>
allowing <NA>
wider <NA>
distribution <NA>
of <NA>
a <NA>
leukemia <NA>
drug <NA>
that <NA>
has <NA>
been <NA>
shown <NA>
effective <NA>
in <NA>
patients <NA>
who <NA>
aren't <NA>
helped <NA>
by <NA>
other <NA>
treatments, <NA>
an <NA>
FDA <ORGANIZATION>
spokesman <NA>
said <NA>
Tuesday <DATE>
. <NA>
The <NA>
FDA <ORGANIZATION>
has <NA>
approved <NA>
wider <NA>
distribution <NA>
of <NA>
the <NA>
drug <NA>
under <NA>
a <NA>
``treatment <NA>
IND,'' <NA>
which <NA>
is <NA>
shorthand <NA>
for <NA>
treatment <NA>
use <NA>
of <NA>
an <NA>
investigational <NA>
new <NA>
drug, <NA>
said <NA>
FDA <ORGANIZATION>
spokesman <NA>
Jeff_Nesbit <PERSON>
. <NA>
A <NA>
treatment <NA>
IND <ORGANIZATION>
allows <NA>
patients <NA>
with <NA>
serious <NA>
or <NA>
immediately <NA>
life-threatening <NA>
diseases <NA>
to <NA>
get <NA>
an <NA>
experimental <NA>
drug <NA>
while <NA>
controlled <NA>
testing <NA>
in <NA>
human <NA>
clinical <NA>
trials <NA>
continues. <NA>
The <NA>
drug <NA>
was <NA>
developed <NA>
by <NA>
Triton_Biosciences_Inc. <ORGANIZATION>
, <NA>
a <NA>
Shell_Oil_Co. <ORGANIZATION>
subsidiary <NA>
based <NA>
in <NA>
Alameda <LOCATION>
, <NA>
Calif. <LOCATION>
and <NA>
clinical <NA>
trials <NA>
are <NA>
being <NA>
conducted <NA>
by <NA>
National_Cancer_Institute <ORGANIZATION>
. <NA>
Triton <ORGANIZATION>
plans <NA>
to <NA>
market <NA>
the <NA>
drug <NA>
under <NA>
the <NA>
trade <NA>
name <NA>
Fludara_I.V. <ORGANIZATION>
AP900814-0015 <DOCNO>
Michael_Sancilio <PERSON>
received <NA>
the <NA>
transfusion <NA>
at <NA>
Johns_Hopkins_Oncology_Center <ORGANIZATION>
on <NA>
Monday <DATE>
. <NA>
His <NA>
3-month-old <NA>
sister, <NA>
Christina <PERSON>
, <NA>
is <NA>
too <NA>
young <NA>
to <NA>
donate <NA>
bone <NA>
marrow, <NA>
the <NA>
usual <NA>
treatment <NA>
for <NA>
Michael <PERSON>
's <NA>
form <NA>
of <NA>
leukemia, <NA>
and <NA>
doctors <NA>
were <NA>
afraid <NA>
he <NA>
wouldn't <NA>
survive <NA>
the <NA>
three-month <NA>
wait <NA>
before <NA>
his <NA>
sister <NA>
became <NA>
old <NA>
enough. <NA>
``We <NA>
didn't <NA>
have <NA>
any <NA>
other <NA>
choice,'' <NA>
said <NA>
the <NA>
youngsters' <NA>
mother, <NA>
Denise_Sancilio <PERSON>
. <NA>
It <NA>
has <NA>
been <NA>
performed <NA>
three <NA>
other <NA>
times, <NA>
once <NA>
in <NA>
Cincinnati <LOCATION>
and <NA>
twice <NA>
in <NA>
France <LOCATION>
, <NA>
to <NA>
treat <NA>
a <NA>
different <NA>
disease, <NA>
Fanconi <ORGANIZATION>
's <NA>
anemia. <NA>
Michael <PERSON>
, <NA>
who <NA>
has <NA>
juvenile <NA>
chronic <NA>
myelogenous <NA>
leukemia, <NA>
is <NA>
at <NA>
extreme <NA>
risk <NA>
of <NA>
infection <NA>
in <NA>
the <NA>
meantime <NA>
because <NA>
his <NA>
cancerous <NA>
bone <NA>
marrow <NA>
had <NA>
to <NA>
be <NA>
destroyed <NA>
as <NA>
part <NA>
of <NA>
the <NA>
treatment. <NA>
``He's <NA>
been <NA>
on <NA>
and <NA>
off <NA>
sleeping <NA>
all <NA>
day,'' <NA>
Michael <PERSON>
's <NA>
father, <NA>
Tony <PERSON>
, <NA>
said <NA>
Monday <DATE>
night <TIME>
. <NA>
Sancilio <NA>
said_she_was_7{_months_pregnant_with_<PERSON>Christina </PERSON>
when <NA>
she <NA>
learned <NA>
Michael <PERSON>
had <NA>
a <NA>
form <NA>
of <NA>
leukemia <NA>
that <NA>
cannot <NA>
be <NA>
controlled <NA>
with <NA>
drugs <NA>
and <NA>
usually <NA>
kills <NA>
within <NA>
a <NA>
year <NA>
of <NA>
diagnosis. <NA>
The <NA>
umbilical <NA>
cord <NA>
blood <NA>
was <NA>
frozen <NA>
when <NA>
Christina <PERSON>
was <NA>
born <NA>
May_1 <DATE>
. <NA>
A <NA>
total <NA>
of <NA>
2.7 <NA>
ounces <NA>
were <NA>
given <NA>
to <NA>
Michael <PERSON>
after <NA>
chemotherapy <NA>
to <NA>
destroy <NA>
his <NA>
cancerous <NA>
marrow. <NA>
Tests <NA>
on <NA>
Michael <PERSON>
's <NA>
parents <NA>
and <NA>
his <NA>
7-year-old <NA>
brother, <NA>
also <NA>
named <NA>
Tony, <NA>
showed <NA>
they <NA>
were <NA>
not <NA>
compatible <NA>
marrow <NA>
donors. <NA>
The <NA>
family <NA>
lives <NA>
in <NA>
Virginia_Beach <LOCATION>
, <NA>
Va <LOCATION>
. <NA>
Anderson <NA>
Cancer <NA>
Center <NA>
in_<LOCATION>Houston </ORGANIZATION>
. <NA>
SJMN91-06080197 <DOCNO>
"I <NA>
think <NA>
it's <NA>
disturbing," <NA>
said <NA>
Steve_Wing <PERSON>
, <NA>
a <NA>
University_of_North_Carolina <ORGANIZATION>
epidemiologist <NA>
who <NA>
was <NA>
the <NA>
principal <NA>
author <NA>
of <NA>
the <NA>
study. <NA>
; <NA>
Wing <NA>
and <NA>
his <NA>
colleagues <NA>
examined <NA>
the <NA>
records <NA>
of <NA>
8,318 <NA>
white <NA>
men <NA>
who <NA>
worked <NA>
at <NA>
Oak_Ridge <ORGANIZATION>
from <NA>
1943 <DATE>
to <NA>
1972 <DATE>
. <NA>
; <NA>
But <NA>
of <NA>
the <NA>
1,524 <NA>
who <NA>
are <NA>
known <NA>
to <NA>
have <NA>
died, <NA>
28 <NA>
died <NA>
of <NA>
leukemia, <NA>
and <NA>
two <NA>
others <NA>
had <NA>
leukemia <NA>
among <NA>
other <NA>
illnesses, <NA>
a <NA>
rate <NA>
" <NA>
63_percent <PERCENT>
higher <NA>
than <NA>
expected," <NA>
the <NA>
researchers <NA>
found. <NA>
; <NA>
Wing's <NA>
study <NA>
was <NA>
financed <NA>
by <NA>
the <NA>
Energy_Department <ORGANIZATION>
, <NA>
which <NA>
operates <NA>
Oak_Ridge <ORGANIZATION>
, <NA>
as <NA>
part <NA>
of <NA>
a <NA>
long-term <NA>
study <NA>
begun <NA>
in <NA>
1943 <DATE>
of <NA>
the <NA>
effects <NA>
on <NA>
workers <NA>
and <NA>
nearby <NA>
residents <NA>
of <NA>
the <NA>
nuclear <NA>
weapons <NA>
manufacturing <NA>
operations. <NA>
; <NA>
Assistant <NA>
Energy <NA>
Secretary <NA>
Paul_Ziemer <PERSON>
, <NA>
a <NA>
former <NA>
health <NA>
physicist <NA>
at <NA>
Oak_Ridge <LOCATION>
, <NA>
said <NA>
Wing <PERSON>
's <NA>
report <NA>
was <NA>
"clearly <NA>
a <NA>
real <NA>
finding," <NA>
but <NA>
he <NA>
said <NA>
it <NA>
would <NA>
be <NA>
premature <NA>
to <NA>
decrease <NA>
the <NA>
permissible-exposure <NA>
standard <NA>
on <NA>
that <NA>
basis <NA>
alone. <NA>
; <NA>
International <NA>
agencies <NA>
that <NA>
set <NA>
exposure <NA>
limits <NA>
are <NA>
constantly <NA>
re-evaluating <NA>
available <NA>
data <NA>
and <NA>
will <NA>
consider <NA>
Wing's <NA>
findings <NA>
among <NA>
others <NA>
in <NA>
deciding <NA>
whether <NA>
to <NA>
recommend <NA>
that <NA>
limits <NA>
be <NA>
tightened, <NA>
Ziemer <PERSON>
said. <NA>
AP900810-0046 <DOCNO>
Allison_Atlas <PERSON>
, <NA>
20, <NA>
opted <NA>
for <NA>
the <NA>
surgery <NA>
Thursday <DATE>
although <NA>
her <NA>
mother's <NA>
tissue <NA>
is <NA>
not <NA>
a <NA>
perfect <NA>
match. <NA>
Her <NA>
condition <NA>
today <NA>
at <NA>
Fred_Hutchinson_Cancer_Research_Center <ORGANIZATION>
was <NA>
withheld <NA>
at <NA>
the <NA>
family's <NA>
request, <NA>
said <NA>
hospital <NA>
spokeswoman <NA>
Alice_Burgess <PERSON>
. <NA>
The <NA>
marrow <NA>
from <NA>
her <NA>
54-year-old <NA>
mother, <NA>
Arline_Atlas <PERSON>
, <NA>
matched <NA>
only <NA>
four <NA>
of <NA>
six <NA>
antigens, <NA>
or <NA>
cell <NA>
identifiers, <NA>
from <NA>
her <NA>
daughter's <NA>
marrow. <NA>
``They're <NA>
both <NA>
fighters,'' <NA>
said <NA>
Sy_Atlas <PERSON>
, <NA>
a <NA>
cousin. <NA>
'' <NA>
Miss <NA>
Atlas, <NA>
a <NA>
student <NA>
at <NA>
New_York_University <ORGANIZATION>
when <NA>
she <NA>
became <NA>
ill <NA>
last <NA>
year, <NA>
heightened <NA>
awareness <NA>
of <NA>
the <NA>
need <NA>
for <NA>
bone-marrow <NA>
donors <NA>
with <NA>
a <NA>
publicity <NA>
campaign <NA>
that <NA>
drew <NA>
50,000 <NA>
volunteers <NA>
in <NA>
the <NA>
United_States <LOCATION>
and <NA>
Israel <LOCATION>
. <NA>
Supporters <NA>
raised <NA>
$3_million <MONEY>
, <NA>
including <NA>
a <NA>
six-figure <NA>
check <NA>
from <NA>
actor <NA>
Dustin_Hoffman <PERSON>
, <NA>
to <NA>
process <NA>
the <NA>
50,000 <NA>
blood <NA>
tests. <NA>
Miss <NA>
Atlas, <NA>
of <NA>
Bethesda <LOCATION>
, <NA>
Md. <LOCATION>
, <NA>
will <NA>
recuperate <NA>
in <NA>
a <NA>
sterile <NA>
environment <NA>
at <NA>
the <NA>
cancer <NA>
center, <NA>
where <NA>
more <NA>
than <NA>
3,000 <NA>
bone-marrow <NA>
transplants <NA>
have <NA>
been <NA>
performed, <NA>
more <NA>
than <NA>
any <NA>
other <NA>
clinic. <NA>
Anatoly_Grishchenko <PERSON>
, <NA>
a <NA>
leukemia-stricken <NA>
Soviet <NA>
helicopter <NA>
pilot <NA>
who <NA>
flew <NA>
firefighting <NA>
missions <NA>
over <NA>
the <NA>
damaged <NA>
Chernobyl <NA>
nuclear <NA>
reactor, <NA>
underwent <NA>
a <NA>
bone <NA>
marrow <NA>
transplant <NA>
at <NA>
the <NA>
center <NA>
earlier <NA>
this <NA>
year. <NA>
He <NA>
died <NA>
July_3 <DATE>
of <NA>
complications <NA>
of <NA>
a <NA>
lung <NA>
infection <NA>
that <NA>
took <NA>
hold <NA>
during <NA>
the <NA>
period <NA>
when <NA>
he <NA>
had <NA>
no <NA>
natural <NA>
defenses. <NA>
Before <NA>
the <NA>
operation, <NA>
Miss_Atlas <LOCATION>
reassured <NA>
her <NA>
mother <NA>
with <NA>
humor <NA>
and <NA>
encouraged <NA>
family <NA>
members. <NA>
``She <NA>
was <NA>
really <NA>
cool,'' <NA>
Sy_Atlas <PERSON>
said <NA>
in <NA>
a <NA>
TV <NA>
interview <NA>
from <NA>
Washington <LOCATION>
, <NA>
D.C. <LOCATION>
``Last <NA>
night, <NA>
talking <NA>
with <NA>
her <NA>
mom, <NA>
she <NA>
jokingly <NA>
said <NA>
... <NA>
`Mom, <NA>
your <NA>
marrow <NA>
better <NA>
be <NA>
good <NA>
for <NA>
me <NA>
tomorrow. <NA>
AP880511-0277 <DOCNO>
A <NA>
biologist <NA>
said <NA>
Wednesday <DATE>
that <NA>
a <NA>
newly <NA>
discovered <NA>
herpes <NA>
virus <NA>
spread <NA>
by <NA>
casual <NA>
contact <NA>
might <NA>
be <NA>
a <NA>
sixth <NA>
cancer-causing <NA>
virus <NA>
and <NA>
appears <NA>
to <NA>
work <NA>
with <NA>
the <NA>
AIDS <NA>
virus <NA>
in <NA>
wiping <NA>
out <NA>
the <NA>
immune <NA>
system <NA>
of <NA>
AIDS <NA>
victims. <NA>
Robert_Gallo <PERSON>
, <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
's <NA>
chief <NA>
of <NA>
tumor-cell <NA>
biology, <NA>
said <NA>
more <NA>
evidence <NA>
was <NA>
needed <NA>
before <NA>
the <NA>
highly <NA>
contagious <NA>
Herpes <NA>
6, <NA>
or <NA>
human <NA>
B-lymphocyte <NA>
virus, <NA>
could <NA>
be <NA>
blamed <NA>
for <NA>
causing <NA>
certain <NA>
types <NA>
of <NA>
cancers. <NA>
Gallo <NA>
spoke <NA>
at <NA>
the <NA>
annual <NA>
meeting <NA>
of <NA>
the <NA>
American_Society_for_Microbiology <ORGANIZATION>
, <NA>
which <NA>
convened <NA>
here <NA>
Sunday <DATE>
. <NA>
Researchers <NA>
have <NA>
found <NA>
a <NA>
high <NA>
prevalence <NA>
of <NA>
antibodies <NA>
to <NA>
the <NA>
Herpes <NA>
6 <NA>
virus <NA>
in <NA>
people <NA>
with <NA>
Hodgkin <ORGANIZATION>
's <NA>
disease, <NA>
Burkitt <ORGANIZATION>
's <NA>
lymphoma, <NA>
non-Hodgkin's <NA>
lymphoma <NA>
and <NA>
childhood <NA>
acute <NA>
leukemia, <NA>
Gallo <PERSON>
said. <NA>
``One <NA>
could <NA>
argue <NA>
the <NA>
virus <NA>
must <NA>
be <NA>
playing <NA>
a <NA>
role <NA>
to <NA>
be <NA>
detected <NA>
so <NA>
readily <NA>
in <NA>
those <NA>
tumors,'' <NA>
Gallo <PERSON>
said. <NA>
The <NA>
Herpes <NA>
6 <NA>
virus <NA>
also <NA>
has <NA>
been <NA>
found <NA>
alongside <NA>
the <NA>
AIDS <NA>
virus <NA>
in <NA>
T-4 <NA>
cells, <NA>
which <NA>
mastermind <NA>
the <NA>
immune <NA>
system <NA>
and <NA>
are <NA>
the <NA>
prime <NA>
target <NA>
of <NA>
acquired <NA>
immune <NA>
deficiency <NA>
syndrome, <NA>
Gallo <PERSON>
said. <NA>
Since <NA>
the <NA>
AIDS <NA>
virus <NA>
kills <NA>
only <NA>
a <NA>
small <NA>
percentage <NA>
of <NA>
T-4 <NA>
cells <NA>
at <NA>
a <NA>
time, <NA>
Gallo <PERSON>
said, <NA>
the <NA>
new <NA>
herpes <NA>
virus <NA>
might <NA>
explain <NA>
the <NA>
total <NA>
annihilation <NA>
of <NA>
T-4 <NA>
cells <NA>
in <NA>
AIDS <NA>
patients. <NA>
Tests <NA>
to <NA>
detect <NA>
Herpes <NA>
6 <NA>
have <NA>
differed <NA>
widely <NA>
on <NA>
its <NA>
prevalence <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
One <NA>
test <NA>
indicated <NA>
that <NA>
it <NA>
is <NA>
carried <NA>
by <NA>
between <NA>
5_percent <PERCENT>
and <NA>
30_percent <PERCENT>
of <NA>
the <NA>
population; <NA>
another <NA>
indicated <NA>
between <NA>
70_percent <PERCENT>
and <NA>
90_percent <PERCENT>
. <NA>
AP880609-0061 <DOCNO>
The <NA>
rate <NA>
of <NA>
leukemia <NA>
among <NA>
young <NA>
people <NA>
living <NA>
near <NA>
a <NA>
nuclear <NA>
complex <NA>
in <NA>
a <NA>
barren <NA>
area <NA>
of <NA>
northern <NA>
Scotland <LOCATION>
is <NA>
nearly <NA>
twice <NA>
Britain <LOCATION>
's <NA>
national <NA>
rate, <NA>
a <NA>
report <NA>
published <NA>
today <NA>
says. <NA>
The <NA>
report <NA>
by <NA>
the <NA>
government-sponsored <NA>
Committee_on_Medical_Aspects_of_Radiation <ORGANIZATION>
in <NA>
the <NA>
Environment <NA>
says <NA>
six <NA>
known <NA>
cases <NA>
of <NA>
leukemia <NA>
were <NA>
diagnosed <NA>
among <NA>
young <NA>
people <NA>
under <NA>
24 <NA>
who <NA>
lived <NA>
within <NA>
15 <NA>
miles <NA>
of <NA>
the <NA>
plant <NA>
in <NA>
Dounreay <LOCATION>
between <NA>
1968 <DATE>
and <NA>
1984 <DATE>
. <NA>
Five <NA>
of <NA>
the <NA>
victims <NA>
lived <NA>
within <NA>
7.8 <NA>
miles <NA>
of <NA>
the <NA>
nuclear <NA>
complex, <NA>
the <NA>
center <NA>
for <NA>
Britain <LOCATION>
's <NA>
fast-breeder <NA>
reactor <NA>
research <NA>
program, <NA>
the <NA>
study <NA>
says. <NA>
The <NA>
report <NA>
says <NA>
the <NA>
reason <NA>
for <NA>
the <NA>
number <NA>
of <NA>
leukemia <NA>
cases <NA>
is <NA>
not <NA>
known, <NA>
though <NA>
the <NA>
findings <NA>
echo <NA>
a <NA>
1986 <DATE>
government <NA>
investigation <NA>
showing <NA>
the <NA>
childhood <NA>
leukemia <NA>
rate <NA>
near <NA>
the <NA>
Sellafield <NA>
nuclear <NA>
reprocessing <NA>
plant <NA>
in <NA>
Cumbria <LOCATION>
, <NA>
northwest_England <LOCATION>
, <NA>
to <NA>
be <NA>
four <NA>
times <NA>
the <NA>
national <NA>
average. <NA>
``It <NA>
is <NA>
hard <NA>
to <NA>
imagine <NA>
that <NA>
you <NA>
could <NA>
see <NA>
an <NA>
excess <NA>
around <NA>
Dounreay <LOCATION>
and <NA>
an <NA>
excess <NA>
around <NA>
Sellafield <LOCATION>
, <NA>
and <NA>
it <NA>
is <NA>
just <NA>
bad <NA>
luck,'' <NA>
said <NA>
commission <NA>
chairman <NA>
Martin_Bobrow <PERSON>
. <NA>
Scottish <NA>
Health <NA>
Minister <NA>
Michael_Forsyth <PERSON>
said <NA>
the <NA>
government <NA>
had <NA>
accepted <NA>
the <NA>
committee's <NA>
recommendation <NA>
to <NA>
hold <NA>
an <NA>
investigation <NA>
into <NA>
the <NA>
high <NA>
rates, <NA>
despite <NA>
the``small <NA>
number <NA>
of <NA>
cases <NA>
involved. <NA>
'' <NA>
However, <NA>
union <NA>
spokesman <NA>
Bryan_Durrans <PERSON>
of <NA>
the <NA>
Institute_of_Professional_Civil_Servants <ORGANIZATION>
called <NA>
the <NA>
report <NA>
``inconclusive. <NA>
The <NA>
Dounreay <NA>
complex <NA>
employs <NA>
2,100 <NA>
workers <NA>
in <NA>
a <NA>
barren <NA>
area <NA>
of <NA>
Northern_Scotland <LOCATION>
that <NA>
offers <NA>
little <NA>
alternative <NA>
employment. <NA>
The <NA>
environmental <NA>
group <NA>
Friends <NA>
of <NA>
the <NA>
Earth <LOCATION>
lauded <NA>
the <NA>
report <NA>
as <NA>
the <NA>
first <NA>
government <NA>
admission <NA>
of <NA>
a <NA>
link <NA>
between <NA>
leukemia <NA>
and <NA>
nuclear <NA>
emissions, <NA>
and <NA>
called <NA>
for <NA>
an <NA>
immediate <NA>
closure <NA>
of <NA>
both <NA>
the <NA>
Dounreay <ORGANIZATION>
and <NA>
Sellafield <ORGANIZATION>
plants. <NA>
``The <NA>
nuclear <NA>
industry <NA>
has <NA>
finally <NA>
been <NA>
implicated <NA>
in <NA>
causing <NA>
cancers <NA>
_ <NA>
something <NA>
it <NA>
has <NA>
denied <NA>
for <NA>
years,'' <NA>
said <NA>
spokesman <NA>
Stewart_Boyle <PERSON>
. <NA>
Leukemia <NA>
clusters <NA>
_ <NA>
occurrences <NA>
of <NA>
the <NA>
disease <NA>
statistically <NA>
higher <NA>
than <NA>
normal <NA>
_ <NA>
have <NA>
also <NA>
been <NA>
found <NA>
in <NA>
southern <NA>
England <LOCATION>
near <NA>
the <NA>
Atomic_Weapons_Research_Establishment <ORGANIZATION>
, <NA>
the <NA>
Royal_Ordnance_Factory <ORGANIZATION>
and <NA>
the <NA>
SJMN91-06040145 <DOCNO>
John <NA>
Peters <NA>
,_director_of_<ORGANIZATION>USC </PERSON>
's <NA>
occupational <NA>
health <NA>
division <NA>
at <NA>
the <NA>
University_of_Southern_California <ORGANIZATION>
, <NA>
presented <NA>
his <NA>
findings <NA>
Thursday <DATE>
at <NA>
a <NA>
closed <NA>
scientific <NA>
meeting <NA>
in <NA>
Carmel. <LOCATION>
; <NA>
Peters <PERSON>
said, <NA>
through <NA>
a <NA>
spokesman, <NA>
that <NA>
he <NA>
would <NA>
not <NA>
release <NA>
his <NA>
data <NA>
or <NA>
discuss <NA>
his <NA>
findings <NA>
in <NA>
public <NA>
until <NA>
they <NA>
have <NA>
been <NA>
reviewed <NA>
and <NA>
accepted <NA>
for <NA>
publication <NA>
in <NA>
a <NA>
scientific <NA>
journal. <NA>
But <NA>
in <NA>
a <NA>
departure <NA>
from <NA>
usual <NA>
scientific <NA>
procedure, <NA>
summaries <NA>
of <NA>
his <NA>
findings <NA>
were <NA>
distributed <NA>
by <NA>
the <NA>
Electric_Power_Research_Institute <ORGANIZATION>
, <NA>
the <NA>
Palo <NA>
Alto-based <NA>
industry <NA>
group <NA>
that <NA>
financed <NA>
his <NA>
study <NA>
and <NA>
sponsored <NA>
the <NA>
Carmel <LOCATION>
meeting. <NA>
But <NA>
the <NA>
Environmental_Protection_Agency <ORGANIZATION>
, <NA>
in <NA>
a <NA>
recent <NA>
draft <NA>
report, <NA>
concluded <NA>
that <NA>
there <NA>
was <NA>
enough <NA>
evidence <NA>
of <NA>
a <NA>
possible <NA>
link <NA>
to <NA>
warrant <NA>
new <NA>
research. <NA>
; <NA>
In <NA>
the <NA>
USC <ORGANIZATION>
study, <NA>
which <NA>
began <NA>
in <NA>
1986 <DATE>
, <NA>
Peters <PERSON>
examined <NA>
the <NA>
lives <NA>
of <NA>
464 <NA>
children <NA>
under <NA>
the <NA>
age <NA>
of <NA>
10. <NA>
; <NA>
Unlike <NA>
those <NA>
who <NA>
conducted <NA>
earlier <NA>
studies, <NA>
Peters <PERSON>
' <NA>
group <NA>
entered <NA>
homes <NA>
and <NA>
took <NA>
direct <NA>
measurements <NA>
of <NA>
the <NA>
electric <NA>
and <NA>
magnetic <NA>
fields. <NA>
; <NA>
Like <NA>
previous <NA>
researchers, <NA>
Peters <PERSON>
found <NA>
an <NA>
association <NA>
between <NA>
neighborhood <NA>
power <NA>
lines <NA>
and <NA>
the <NA>
risk <NA>
for <NA>
childhood <NA>
leukemia. <NA>
AP900809-0104 <DOCNO>
A <NA>
leukemia <NA>
patient <NA>
received <NA>
her <NA>
mother's <NA>
bone <NA>
marrow <NA>
Thursday <DATE>
, <NA>
after <NA>
doctors <NA>
failed <NA>
to <NA>
find <NA>
a <NA>
perfect <NA>
match <NA>
among <NA>
50,000 <NA>
people <NA>
who <NA>
volunteered <NA>
as <NA>
donors. <NA>
Allison_Atlas <PERSON>
, <NA>
20, <NA>
had <NA>
the <NA>
transplant <NA>
at <NA>
Fred_Hutchison_Cancer_Research_Center <ORGANIZATION>
in <NA>
Seattle <LOCATION>
. <NA>
Her <NA>
mother, <NA>
Arline <PERSON>
, <NA>
54, <NA>
was <NA>
the <NA>
donor. <NA>
The <NA>
plight <NA>
of <NA>
Miss_Atlas <LOCATION>
, <NA>
a <NA>
New_York_University <ORGANIZATION>
student <NA>
from <NA>
Bethesda <LOCATION>
, <NA>
Md. <LOCATION>
, <NA>
prompted <NA>
50,000 <NA>
people <NA>
to <NA>
volunteer <NA>
for <NA>
bone <NA>
marrow <NA>
tests. <NA>
Doctors <NA>
said <NA>
Miss <NA>
Atlas <NA>
would <NA>
have <NA>
had <NA>
a <NA>
60_percent <PERCENT>
chance <NA>
of <NA>
recovery <NA>
if <NA>
the <NA>
donated <NA>
marrow <NA>
was <NA>
a <NA>
perfect <NA>
match. <NA>
Her <NA>
chances <NA>
are <NA>
reduced <NA>
``somewhat'' <NA>
but <NA>
other <NA>
patients <NA>
with <NA>
the <NA>
same <NA>
degree <NA>
of <NA>
mismatch <NA>
have <NA>
recovered, <NA>
said <NA>
hospital <NA>
spokeswoman <NA>
Alice_Burgess <PERSON>
said. <NA>
Without <NA>
the <NA>
transplant, <NA>
she <NA>
would <NA>
live <NA>
less <NA>
than <NA>
a <NA>
year, <NA>
Burgess <PERSON>
said. <NA>
The <NA>
Atlas <PERSON>
family's <NA>
public <NA>
campaign <NA>
last <NA>
fall <NA>
raised <NA>
$3_million <MONEY>
to <NA>
process <NA>
blood <NA>
samples <NA>
from <NA>
the <NA>
50,000 <NA>
people <NA>
in <NA>
the <NA>
United_States <LOCATION>
and <NA>
Israel <LOCATION>
who <NA>
registered <NA>
with <NA>
the <NA>
National_Marrow_Donor_Program <ORGANIZATION>
. <NA>
